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Intellectual disability (ID) and autism spectrum disorders (ASDs) can have a 
devastating impact on an individual’s functioning and quality of life.  Insights from 
pre-clinical models of monogenic forms of ID and ASD are now revealing the 
biochemical pathways and aberrations in cellular and synaptic functioning involved.    
 
One monogenic cause of ID, ASD and epilepsy is SYNGAP1 ID which results from 
mutations in the SYNGAP1 gene on human chromosome 6.  Although a variety of 
symptoms have been reported, many affected individuals have moderate to severe 
intellectual impairment and severe seizure phenotypes.   
 
Previous pre-clinical studies have mainly focussed on the effects of altered SynGAP 
expression in mice.  This thesis is therefore the first to explore altered SynGAP 
expression in a rat model.  It also adds to the body of research exploring the roles of 
SynGAP isoforms in glutamatergic synaptic function. 
 
The SynGAP_GAP deletion rat was engineered to have a deletion encompassing the 
enzymatically active GTPase activating protein (GAP) domain of the protein, via 
which SynGAP regulates multiple biochemical pathways by enhancing the slow 
intrinsic hydrolysis of GTP by GTP-binding proteins.  Syngap
GAP/GAP 
rats appeared 
small and failed to thrive.  As with Syngap
-/-
 mice, this complete loss of WT 
SynGAP proved lethal, whereas Syngap
+/GAP
 rats appeared to develop normally.   
 
The electrophysiological data obtained from this new model reveals a reduction in 
the frequency of miniature excitatory post-synaptic currents (mEPSCs) in 
Syngap
+/GAP 
cultured neurons.  However the exaggerated hippocampal long-term 
depression identified in Syngap
+/-
 mice was not seen in the rats.  There was also no 
evidence of differences in intrinsic cell properties, excitatory and inhibitory currents 
or ratios of AMPAR / GABAAR and AMPAR / NMDAR between WT and 




In addition to the characterisation of the SynGAP_GAP deletion rat, the impact of 
the previously unstudied Eα1 isoform on forebrain neuronal synaptic function was 
examined through mEPSC recordings.  A trend towards lower mEPSC frequency 
was found which supports previous research showing that α1 isoforms reduce 
synaptic strength. 
This body of work therefore adds to published evidence of isoform specific functions 
and provides the first evidence of the impact of SynGAP alterations in rats, the 
results of which show some intriguing differences from previous work in mice.  
 
Lay summary 
Learning disability or ‘Intellectual disability’ (ID) and autism spectrum disorders 
(ASDs) can have a devastating impact on a person’s functioning and quality of life.  
Insights from rodents with deliberate changes (‘mutations’) in specific genes that are 
linked to ID and ASD in humans are now revealing abnormalities in the brain that 
are involved in these conditions.  One cause of ID and ASD in humans, called 
SYNGAP1 Intellectual Disability, results from mutations in a gene called SYNGAP1 
which is the blueprint for cells to produce a protein called SynGAP.  This protein is 
an important regulator of signalling in the brain.  Many affected individuals have 
moderate to severe intellectual impairment, autism spectrum disorder and severe 
forms of epilepsy.   
 
Previous rodent studies have mainly focussed on the effects of altering the amount of 
SynGAP protein in mouse brains.  This thesis is the first to explore the impact of 
SynGAP mutation in rats.  The SynGAP_GAP deletion rat, as the new rat was 
named, was engineered to be missing a portion of the SynGAP protein called the 
GAP domain which normally acts as a brake on particular signalling pathways in the 
brain.  Rats with the mutation in both of their two copies of the gene appeared small 
and failed to thrive.  As had previously been shown in mice, this complete lack of 
normal SynGAP proved lethal, whereas rats with only one copy of the mutation 




For some experiments brain cells from the new rats were grown in dishes (‘cultured’) 
and for others, brain slices were used.  Tiny electrical currents from individual or 
groups of cells were recorded.  Surprisingly, certain findings from published research 
in mice were not reproduced.  In mice with no SynGAP, particular electrical currents 
between brain cells were more frequent, thought to be because the ‘brake’ effect of 
SynGAP had been lost.  However the cells of rats with two mutated copies of 
SynGAP this signalling was no different from rats with no mutation.  Furthermore 
the signalling in rats with one normal and one mutated copy of SynGAP was less 
frequent which was somewhat puzzling.  Research has previously shown that 
application of a drug called DHPG to brain slices from heterozygous SynGAP mice 
(those with only one abnormal copy of SynGAP) results in an exaggerated reduction 
in electrical transmission in the hippocampus, a brain region involved with learning 
and memory.  In the heterozygous rats, this signalling was no different from rats with 
normal SynGAP.  Other recordings were made of the electrical properties of single 
rat brain cells which were less directly comparable to previous work in mice.  These 
were also no different in heterozygous rats compared to rats with normal SynGAP. 
 
In addition to the above, cultured brain cells were manipulated to have extra Ealpha1, 
a previously unstudied type of SynGAP.  A trend towards less frequent occurrence of 
certain currents passing between the cells was found.  This is in keeping with 
previous research showing other alpha1 types of SynGAP reduce the signalling 
between neurons.   
 
This body of work therefore adds to published evidence suggesting that different 
types of SynGAP have specific functions and provides the first evidence of the 
impact of SynGAP alterations in rats, the results of which show some intriguing 
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E/I   Excitation/Inhibition 
ERK    Extracellular signal-regulated kinases  
FXS   Fragile X Syndrome 
GABA(R)  gamma-Aminobutyric acid (receptor) 
GAP   GTPase activating Protein 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GEF   Guanine nucleotide exchange factor  
GFP   Green fluorescent protein 
GTP/GDP   Guanosine triphosphate / guanine diphosphate 
HCN   Hyperpolarization-activated cyclic nucleotide–gated 
ID   Intellectual disability 
(m)IPSC   (miniature) inhibitory post-synaptic current 
(m)IPSP  (miniature) inhibitory post-synaptic potential 





LB   Luria broth 
LEH   Long Evans Hooded 
LTD    Long-term depression  
LTP   Long-term potentiation 
MAPK   Mitogen-activated protein kinases 
mGluR  Metabotropic glutamate receptor 
mPFC   Medial prefrontal cortex 
NMDA(R)   N-methyl-D-aspartate (receptor) 
NSID   Non-syndromal intellectual disability 
P or PND  Postnatal day 
PCR   Polymerase chain reaction 
Pen/Strep   Penicillin / streptomycin 
PH   Pleckstrin homology 
PPF   Paired pulse facilitation 
PSD   Post-synaptic density 
PSD-95   Post-synaptic density 95 
PTX   Picrotoxin 
PV   Parvalbumin 
qPCR   Quantitative polymerase chain reaction 
RasGAP   Ras GTPase activating protein 
RapGAP  Rap GTPase activating protein  
RNA   Ribonucleic acid 
mRNA   Messenger ribonucleic acid 
RT-PCR  Reverse transcription polymerase chain reaction 
siRNA   small interfering RNA 
shRNA  short hairpin RNA 
tRNA   transfer RNA 
SNP   Single nucleotide polymorphism 
SynGAP   Synaptic GTPase activating protein 
SST   Somatostatin 
TTX   Tetrodotoxin 
WT   Wild type 












1 CHAPTER ONE: INTRODUCTION 
 
1.1 Background 
Intellectual disability (ID) and Autism Spectrum Disorders (ASDs) can have a 
devastating impact on an individual’s life expectancy and quality of life (Patja et al. 
2001; Tyrer et al. 2006; Emerson et al. 2010; Dieckmann et al. 2015, Baxter et al. 
2015) and can be associated with multiple physical and mental comorbidities 
throughout the life span (Munir 2016; Cooper & Smiley 2009; Cooper 1999).   
Despite the therefore pressing need to modulate these conditions, at present there are 
no drug therapies to directly target ID or autism spectrum disorder.  However, 
preclinical research is identifying the biochemical pathways and networks that 
underpin the pathology in ID and ASD which will hopefully in time lead to new 
therapies.  Studies into ID and ASD have implicated aberrations in genes associated 
with dendritic spine and synaptic function including in SYNGAP1 gene (Ropers & 
Hamel 2005; Betancur 2011; Pinto et al. 2011; Penzes et al. 2011; Iossifov et al. 
2012; de Ligt et al. 2012; Mefford, Heather C; Batshaw, ML and Hoffman 2012; 
Rauch et al. 2012; Penzes et al. 2013; Fitzgerald et al. 2015; Vissers et al. 2015).   
 
This thesis therefore focusses on the mechanisms underlying SYNGAP1 ID which is 
also associated with ASD and epilepsy and results from mutations in the SYNGAP1 
gene on human chromosome 6.  SYNGAP1 codes for the SynGAP protein which is 
one of the most abundant proteins in the post synaptic density of neurons.  Its 
absence is lethal in mice and various aberrations have been found in the cellular and 
synaptic functioning of Syngap
+/-
 mice.  This thesis details the initial characterisation 
of the first SynGAP rat model which has a deletion encompassing the enzymatic 
GAP domain of the protein, the domain which normally enables it to regulate 
downstream signalling pathways.  Previous work in our laboratory has explored the 





1.2 Intellectual Disability 
In order to appreciate the relevance and importance of pre-clinical work in ID and 
ASD, an understanding of the two conditions is helpful.  There are two main 
international classification systems for mental disorders, the World Health 
Organisation’s International Classification of Disease Version 10 (ICD 10) and the 
fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).  
 
The term Intellectual Disability (ID) is defined in ICD 10 as ‘a condition of arrested 
or incomplete development of the mind, which is especially characterized by 
impairment of skills manifested during the developmental period, skills which 
contribute to the overall level of intelligence, i.e. cognitive, language, motor, and 
social abilities’ (WHO 1992). In order for a diagnosis of Intellectual Disability to be 
made, the onset of the symptoms or impairments must occur before the age of 18 
years.  The severity of ID is defined by Intelligence Quotient (IQ) as follows: 
 Mild (IQ 50 to 69) 
 Moderate (IQ 35 to 49) 
 Severe (IQ 20 to 34) 
 Profound (IQ < 20) 
 
DSM-5 (APA 2013) similarly classifies Intellectual Disability as presenting with 
impairments in general mental abilities that impact adaptive functioning across the 
following domains 
1) Conceptual (e.g. language, reasoning and memory) 
2) Social (e.g. interpersonal communication skills, empathy and social 
judgment) 
3) Practical (e.g. self-management in personal care, money management, job 
responsibilities etc.)   
It also specifies that the impairments must begin during the developmental period 
and in addition to IQ it also classifies the severity of the disorder by the degree of 




In some countries other terms are still used to describe the same disorder.  These 
include ‘Learning Disabilities’, ‘Mental Retardation’, ‘Mental Handicap’, ‘Mental 
Disability’, ‘Developmental Disabilities’, ‘Mental Deficiency’ and ‘Mental 
Subnormalty’ (WHO 2007).  The prevalence of ID is somewhat uncertain, but 
interpretation and comparison of data gave figures of 9-14/1000 in childhood and 3-
8/1000 in adults in high income countries; rates were higher in low-income countries 
(Cooper & Smiley 2009).  A meta-analysis of population based data gave a 
prevalence of 10.37/1000 of the population, but it noted that studies in children and 
adolescents and in developing countries give higher estimates (Maulik et al. 2011).    
 
There are hundreds of environmental causes of ID including perinatal anoxic / 
traumatic brain damage, foetal alcohol syndrome, infections in pregnancy (e.g. 
rubella, cytomegalovirus etc.), heavy metal poisoning etc. (Cooper and Smiley 
2009), but genetic factors play an very important role too.   The genetic mutations 
involved are extremely heterogeneous with more than 700 genes (X-linked, 
autosomal-dominant and autosomal-recessive) now linked to ID (Vissers et al. 2015).  
Forms of ID are defined as syndromic or non-syndromic (NSID) depending on 
whether additional morphological, radiologic or metabolic abnormalities over and 
above the ID itself are observed on physical examination, laboratory investigation 
and brain imaging. (Ropers & Hamel 2005; Dierssen & Ramakers 2006; Rauch et al. 
2012).   
1.3 Autism Spectrum Disorder 
Autism was independently recognised by Leo Kanner and Hans Asperger in the 
1940s.  Kanner described what is thought of as ‘Classical autism’ (Kanner 1943) in a 
case series of 11 children in which he described the key deficit as being the 
children’s “inability to relate themselves in the ordinary way to people and situations 
from the beginning of life”.  Asperger published in German in 1994 and his original 
paper was translated later by Uta Frith (Asperger & Frith 1991).  He described a 
similar disorder albeit with relative preservation of language skills.  It wasn’t until 
1987 that the syndrome named after him was recognised in the third edition of the 
DSM (see Murphy et al. 2016 for a review of the diagnostic classifications of autism 
spectrum disorders). ‘Childhood Autism’ as it is defined in ICD 10 is ‘(a) the 
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presence of abnormal or impaired development that is manifest before the age of 
three years, and (b) the characteristic type of abnormal functioning in all the three 
areas of psychopathology: reciprocal social interaction, communication, and 
restricted, stereotyped, repetitive behaviour’ (WHO 1992). There has been growing 
recognition since the publication of ICD 10 that ‘childhood autism’ is not simply a 
disorder of childhood and that although the associated impairments may improve 
over the lifespan, the diagnostic status remains relatively stable (reviewed in Magiati 
et al. 2014).   
 
DSM-5 re-defined the classification of Autism Spectrum Disorder in 2013 to: 
a) Persistent disorders in  social communication and social interaction across 
contexts, not accounted for by general developmental delays and 
b) Restricted, repetitive patterns of behaviour, interests, or activities  
that must be must be present in early childhood and limit and impair everyday 
functioning (APA 2013).  
 
ASD is more common in those with ID than in individuals of IQ > 70 (Brugha et al. 
2016) and as with ID the proposed causes are multiple.  They include genetic 
disorders, advancing parental age, complications in pregnancy and exposure to 
chemicals (Lai et al. 2014). 
1.4 Single gene disorders associated with ID and ASD 
The aetiological complexity and phenotypic diversity of ID and ASD are challenging 
when trying to identify the underlying mechanisms driving them.  One popular 
approach is therefore to study single gene disorders associated with ID and ASD.  
These include Fragile X Syndrome (FXS), Rett Syndrome and Tuberous Sclerosis 
(TS) all of which have been extensively studied in rodent models.  This thesis 
focusses on SYNGAP1 ID, a single gene disorder that is associated with both ID and 
ASD. 
1.4.1 SYNGAP1 ID 
The human SYNGAP1 gene is located at Chromosome 6p 21.3 and codes for the 
Synaptic GTPase Activating Protein (SynGAP) protein.  This protein been shown in 
preclinical models to be abundant in the post-synaptic density of neurons and to be 
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involved in synaptic signalling by regulating the insertion of excitatory α-amino-3-
hydroxy-5-methyl-4-isoxa-zolepropionic acid (AMPA) receptors into the cell 
membrane (Chen et al. 1998; Kim et al. 1998; Krapivinsky et al. 2004; Rumbaugh et 
al. 2006).  Further detail on the structure and function of SynGAP is presented later. 
 
The first link between mutations in SYNGAP1 and clinical disorders was made by 
researchers in Montreal in 2009.  Due to the known association between intellectual 
disability and disruption of synaptic plasticity pathways, SYNGAP1 was chosen as a 
candidate gene in a screen of de novo mutations in patients with non-syndromic 
intellectual disability (Hamdan et al. 2009).  3 of the 94 patients were identified as 
having de novo mutations in SYNGAP1.  The three were aged between 4 and 11 
years of age and all had global developmental delay, severe language impairment and 
hypotonia; two also had epilepsy.  Since this first study several more papers 
identifying and / or characterising people with SYNGAP1 mutations have followed 
(Table 1).  Some of these individuals have mutations that only affect SynGAP and 
others have mutations encompassing multiple genes including SYNGAP1 (Krepischi 
et al. 2010; Zollino et al. 2011; Writzl & Knegt 2013; Parker et al. 2015).  The 
mutations were de novo in the majority of cases where parental data was available.  
Only one patient has been identified in which the mutation was inherited.  This was a 
Danish patient in whose father the mutation was mosaic (Berryer et al. 2013).  
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Table 1– Timeline of papers identifying or characterising individuals with SYNGAP1 mutations 




New Features Noted 
Hamdan 2009 94 patients with non-syndromic ID 
3 females, 
4-11 years 
Global developmental delay, severe language 
impairments, hypotonia and epilepsy 
Hamdan et al. 2011 95 patients with sporadic NSID 1 female, 2 males  
Krepischi et al. 2010 300 patients with ID studied by 1Mb array-CGH 6 year old male Deletion of 18 known genes including SYNGAP1 
Pinto et al. 2010 Single SNP microarray in 1604 people with ASD 1exonic deletion  
Vissers et al. 2010 Whole exome sequencing ten parent-proband trios 1 female  
Zollino et al. 2011 Case report of a 5 year old girl 1 female 
Deletion of 4 genes including SYNGAP1. Gut 
rotation & pancreas segmentation abnormalities 
noted 
Klitten et al. 2011 Case report of a male child 1 male 
Balanced translocation with a breakpoint 
between exons 5 and 6 of SYNGAP 
de Ligt et al. 2012 Exome sequencing of 100 people with severe ID 1  
Rauch et al. 2012 
51 children from the German Mental Retardation 
Network 
1 female and 1 
male 
 
Berryer et al. 2013 
16 patients with NSID and generalised epilepsy from 
Denmark and a similar cohort of 16 patients from 
Montreal with NSID 
1 Dane & 2 
Canadians 
The Dane’s father was mosaic for the mutation, 
required extra help at school and suffered 
depressive episodes 
Carvill et al. 2013 
Cohort of patients with epileptic encephalopathies 
tested with high throughput targeted sequencing 
2 females, 3 
males 
Range of severe epilepsy phenotypes, early 
developmental delay and subsequent regression 
Writzl & Knegt 
2013 
Case study of a 9 year old boy examined with 
comparative genomic hybridization (CGH) analysis 
1 male 
de novo 50 kb deletion encompassing four genes 
including SYNGAP1(encompassing the same 
genes as in the Zollino paper) 
Redin et al. 2014 
Targeted sequencing of protein-coding exons of 217 
genes associated with ID or ASD in 106 patients with 
ID with or without ASD 
1 male  




Table 1 continued… 
Parker et al. 2015 
7/ 10 identified from the first cohort of patients from 
the Deciphering Developmental Disorders Study which 
recruited >12,000 children across the UK 
8th patient identified via routine testing at a NHS 
paediatric genetics clinic.  Patients 9 and 10 were 
monozygotic twins referred for genetic evaluation 
7 females, 3 
males 
First paper suggesting SYNGAP1 ID is 
syndromic (see main text) 
Stülpnagel et al. 
2015 
Case report of a patient with SYNGAP1 mutation 
identified on next generation sequencing 
A 15 year old 
non-dysmorphic 
girl 
Complete EEG normalisation with eye opening 
Mignot et al. 2016 
SYNGAP1 exome screening (n = 192) or exome 
sequencing (n = 59) in 251 patients with 
neurodevelopmental disorders 
8 females, 9 
males 
Presented data from their own identified 
patients and 11 other patients from other centres 
plus 2 patients previously published (Rauch et 
al. 2012; Stülpnagel et al. 2015) 
Prchalova et al. 2017 Case report of a patient with SYNGAP1 mutation 
A 31 year old 
female 
Variant located in the broader splice donor 
region of intron 10 




It was initially thought that SYNGAP1 ID (also sometimes referred to as ‘autosomal 
dominant intellectual disability type 5’) was non-syndromic (Hamdan et al. 2009), 
but this view was challenged by a paper in 2015 describing syndromic features in 10 
individuals including a pair of monozygotic twins (Parker et al. 2015).  All ten had 
global developmental delay and moderate to severe intellectual disability. Six had a 
diagnosis of autism spectrum disorder and seven had seizures.  The seizures were 
most commonly complex and generalised and included drop attacks, myoclonic 
seizures and absences.  Seven showed generalised hyperexcitability and aggressive 
behaviour and all ten had sleep disturbances.   This work was followed by phenotypic 
analysis of 17 patients with SYNGAP1 mutations (Mignot et al. 2016).  Their main 
clinical features are summarised in Table 2 which demonstrates that the variation in 
phenotypes is marked, but with distinct similarities between patients.  In addition to 
the data in the table, Mignot and colleagues noted that all 16 patients who had 
undergone an EEG had abnormalities at one time or another (3 patients had multiple 
tests), which may suggest major brain network dysfunction.  The most common 
abnormalities were ictal or interictal bursts of spikes, spike and waves or slow waves.   
 
The mutations identified in Mignot’s 17 patients affect most of the 19 exons of the 
protein, only sparing 1, 2, 9, 14, 16, 18 and 19 (Figure 1).  Exons 8 and 15 are the 
largest and have the most mutations along with Exon 5.  However no definite 
correlation was found between the location of the mutation on SYNGAP1 and the 
clinical presentation in either Mignot et al. 2016 or Carvill et al. 2013. 
 
The paper also collated the data of all published mutations in SYNGAP1 to date.  Of 
the 47 individuals reported with SYNGAP1 mutations, three of the mutations were 
each found in two different patients in separate studies.  As a pair of monozygotic 
twins were included in the 47 sample number a total of 43 mutations limited to the 
SYNGAP1 gene have now been identified in published research.  As panel B in 
Figure 1 shows, the vast majority are missense mutations and some of these have 
been shown to result in degradation of the SynGAP protein when transfected into 







Table 2 - Characteristics of Patients with SYNGAP1 mutations from the Mignot et al. 2016 study 








Autism diagnosis 8 of 16 assessed* 
Epilepsy diagnosis 16# 
Seizure categories  
Typical or atypical absences 9 
Massive myoclonic jerks 7 
Eyelid myoclonia 3 
Clonic or tonic clonic 3 
Myoclonic absences 3 
Atonic  2 
Seizure triggers  
Photosensitivity 5 
Fixation-off sensitivity  1 




Gait abnormalities 10 
Truncal hypotonia 10 
Facial hypotonia 4 
Brain MRI 
Normal 13 
Arachnoid cysts 2 
Mild myelination delay 1 
Signal abnormalities 1 








Figure 1 – There is significant diversity in the mutations on the SYNGAP1 gene. 
 
Adapted from Mignot et al. 2016. 
 
 (A) Location of mutations on SYNGAP1.  Mutations in red are the patients from the Mignot study, 
mutations in black correspond to previously published patients and recurrent mutations are underlined 
 
(B) Schematic representation of the mutations (above the protein schematic) and the variants present 
in the Exome Aggregation (ExAc) database (below the schematic) on the longest SYNGAP1 isoform 




1.5 Structure and Function of SynGAP 
SynGAP appears to be an important protein given the severity of symptoms present 
when it is disrupted and the fact that it is highly conserved across species (McMahon 
et al. 2012).  It was first identified in rat forebrain post-synaptic density (PSD) 
isolates where it was found to be one of the most abundant proteins, accounting for 
approximately 1-2% of total PSD protein (Chen et al. 1998).  It is expressed strongly 
in the mouse cortex and hippocampus as well as at lower levels in the thalamus, 
amygdaloid complex, cerebellum, striatum, brainstem and olfactory bulb (Kim et al. 
1998; Komiyama et al. 2002; Tomoda et al. 2004; Porter et al. 2005; Knuesel et al. 
2005; Moon et al. 2008).  Moon and colleagues found that 2 different isoforms of 
SynGAP (α1 and β) were present in all cerebral layers and in neuronal cell bodies 
and primary apical dendrites.   In the hippocampus the highest immunoreactivity for 
both isoforms was in the strata radiatum and oriens of the CA1-CA3 regions and the 
molecular layer of the dentate gyrus; weaker immunoreactivity was evident in the 
stratum lacunosum-moleculare (Moon et al. 2008).   
 
The general development and lamination of the cortex was found to be normal in 
Syngap
+/-
 mice, but Syngap
-/-
 mutants had a small reduction in cortical thickness in 
the posterior medial barrel sub-field and anterior snout region (Barnett et al. 2006).  
The same authors found that SynGAP is necessary for the development of whisker 
related functional modules (‘barrels’) in the somatosensory cortex which each 
receive specific sensory input from one of the animal’s whiskers (Barnett et al. 
2006).  Komiyama and colleagues found no differences in the CA1 hippocampus of 
Syngap
+/-
 mice on Nissl staining with markers of synaptic-terminal or dendrites, nor 
with more detailed analysis of dendritic architecture (Komiyama et al. 2002).  
However an increase in apoptotic cells has been demonstrated in the Syngap
-/-
 mouse 
hippocampus, cortical layers I–VI and the Purkinje cell layers of the cerebellum (an 
area the authors noted to be underdeveloped (Knuesel et al. 2005).  
 
SynGAP protein expression changes during development and rapidly increases in the 
cortex and hippocampus between embryonic day 16 and post-natal day 1 (P1) 
(Knuesel et al. 2005).  Porter and colleagues found the expression in the mouse 
hippocampus peaked around P7 and was then maintained throughout adulthood 
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(Porter et al. 2005).  This is in keeping with Li et al.’s finding that the level of 
SynGAP mRNA in rat forebrain at 1 day and 1 week after birth was as high as the 
adult level (Li et al. 2001).   However Clement et al. found SynGAP mRNA 
transcripts in mice peaked at P14 in the hippocampus (Clement et al. 2012).   In the 
cortex Porter and colleagues found that the SynGAP protein was restricted to specific 
layers, rose to P7, was maintained for the second week of life and then declined in 
adulthood (Porter et al. 2005), but McMahon and colleagues found that its mRNA 
transcripts peaked at P14 (McMahon et al. 2012).  In the barrel cortex SynGAP was 
present in neonatal homogenates and its expression increased into adulthood (Barnett 
et al. 2006).   
 
Double labelling mouse hippocampal neurons with antibodies to SynGAP and the 
synaptic marker protein synaptophysin showed that SynGAP localises to 
hippocampal synapses (Kim et al. 1998).  It also binds to the PDZ domains of NR1 
subunit of the N-methyl-D-aspartate (NMDA) receptor, SAP102 and PSD-95 
scaffolding protein via the QTRV motif on its C terminus which is only present in 
the α1 isoform (see below) (Chen et al. 1998; Kim et al. 1998; Araki et al. 2016).   
1.5.1 SynGAP Structure  
SynGAP is a complex protein which has multiple N terminal (A, B, C and E) and C 
terminal (α1, α2, β and γ) isoforms (McMahon et al. 2012).  Between the N and C 
terminal isoforms there is a ‘core domain’ which is common to all isoforms and 
includes the C2, GAP and SH3 domains (see Figure 2).  
 
SynGAP also has a Pleckstrin Homology (PH) domain which is incomplete in the C 
isoform of the protein.  The different protein isoforms have been shown to impact 
differently on synaptic function, with SynGAP α1 negatively regulating synaptic 
strength to a varying extent depending on which N terminal isoform it is coupled 










1.5.2 Functions of the SynGAP Protein Domains 
Pleckstrin Homology Domain 
Pleckstrin homology (PH) domains are so called because they include a ~100 amino-
acid region of sequence homology that is present twice in pleckstrin (the major 
protein kinase C substrate in platelets).   The exact function of the PH domain in the 
SynGAP is yet to be delineated, but the PH domains of other proteins play a role in 
binding to the cell’s phospholipid membrane and activating lipid secondary 
messengers (Lemmon 2008).  
C2 Domain 
C2 domains are calcium dependent lipid binding domains.  They  have been found 
across a variety of proteins which are involved in diverse processes such as vesicular 
transport, lipid modification, protein phosphorylation and GTPase regulation 
(reviewed by Nalefski & Falke 1996).  They have been shown to play a role in 
membrane binding, mediating protein-protein interactions and small molecule 
binding, as well as the binding of calcium (Ca
2+
) itself.  The Ca
2+
- binding sites of 
different C2 domains are proposed to be specialised to provide optimized Ca
2+
- 
binding parameters, changes in conformation upon Ca
2+
 binding, or docking 
interactions for different biological functions (Nalefski & Falke 1996).  The role of 
the C2 domain in SynGAP has not been explored in relation to calcium binding 
specifically, but it was demonstrated in 2008 to be crucial for the protein’s role as a 
RapGAP (Pena et al. 2008) which is consistent with studies of C2 domains in two 
other RapGAP proteins, GAP1 and RASAL RapGAP (Sot et al. 2010).  This role is 
described in more detail below. 
SH3 Domain 
SH3 domains are small protein interaction modules (Saksela & Permi 2012).  As 
described in a review by Kaneko et al., they are involved in a multitude of cellular 
processes including intracellular signalling and cell-environment communication, 
cytoskeletal rearrangements and cell movement, cell growth and differentiation, 
protein trafficking and degradation and immune responses (Kaneko et al. 2008). 
GAP Domain 
The GAP domain is the enzymatic portion of the SynGAP molecule that defines it as 
a GTP-ase activating protein (GAP) and mediates its function on downstream 
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pathways.  GAPs enhance the slow intrinsic hydrolysis of GTP by GTP-binding 
proteins (Vetter & Wittinghofer 2001; Bernards 2003). These are proteins that can be 
subdivided into several families including Ras, Rap and Rho families and play a role 
in a diverse range of different cellular functions from cytoskeletal dynamics, cellular 
growth and differentiation to transmembrane signal transduction (Bernards 2003; 
Scheffzek & Ahmadian 2005).  The GTP-binding proteins cycle between an ‘on’ 
state (GTP bound) in which downstream signalling is activated and an ‘off’ or 
deactivated state (GDP bound) which enables them to act as molecular switches.  
This mechanism is controlled by the opposing actions of guanine nucleotide 
exchange factors (GEFs) which promote the dissociation of protein bound GDP and 
GAPs. Some GAPs are specific to one subfamily of GTP-binding proteins whereas 
others have dual specificity, in particular for Ras and Rap.   
SynGAP as a Ras and Rap GTPase 
SynGAP has portions of sequence homologous with those previously identified in 
RasGAPs (Chen et al. 1998) and its 3D conformation is similar to that of other Ras 
and Rap GAPs p120GAP, NF1 and also Rap1B (Sot et al. 2010).   In the early 
papers, 2 different assays confirmed its RasGAP activity.  The first involved 
incubating GTP-bound Ras with PSD protein isolates and determining the percentage 
of GDP by thin layer chromatography before adding a mouse antibody against the 
GAP domain of SynGAP which was found to inhibit the GAP activity by 75-78% 
(Chen et al. 1998).  In the second GTPase assay, the detection of radiolabelled 
phosphate in the presence of a GST fusion protein of H-ras was dramatically 
increased when a GST fusion protein of the RasGAP domain of SynGAP was added 
(Kim et al. 1998).   
 
It was only later that SynGAP’s dual Ras and Rap GTPase activity was identified 
(Krapivinsky et al. 2004; Pena et al. 2008; Walkup et al. 2015).  Its stimulation of 
Rap-GTPase activity was shown to be more than 10-fold compared to its 2-fold 
stimulation of Ras-GTPase (Krapivinsky et al. 2004).  Walkup and colleague found 
that the Ras and Rap GAP activity of SynGAP is independently regulated by cyclin-
dependent kinase 5 (CDK5), a kinase involved in neuronal processes such as 
regulation of synaptic plasticity, and Ca
2+
/ calmodulin-dependent protein kinase II 
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(CaMKII), a protein kinase involved in long-term potentiation through signal 
transduction cascades (Herring & Nicoll 2016).  Both increased SynGAP’s Ras and 
Rap GAP activity, but CDK5 phosphorylation preferentially increased the rate of 
SynGAP’s HRas activity over its Rap1 GAP activity and CaMKII phosphorylation 
did the opposite (Walkup et al. 2015).   
 
As mentioned above, other SynGAP protein domains influence the activity of its 
GAP domain.  This is also true of the action of SynGAP phosphorylation by CDK5 
and CaMKII which occurs via a number of phosphorylation sites in the carboxyl 
portion of the protein (Oh et al. 2004; Krapivinsky et al. 2004; Walkup et al. 2015).  
This differential regulation of SynGAP’s GAP activity is further modified by 
neuronal activity as demonstrated by the application of NMDA increasing the rate of 
phosphorylation by CDK-5 only at specific phosphorylation sites on the SynGAP 
protein (Walkup et al. 2015).  Moreover, radiolabelled assays demonstrated a 90% 
reduction in SynGAP phosphorylation following activation of NMDA receptors 
(NMDARs).  SynGAP binds to MUPP1 a large, ubiquitously expressed scaffolding 
protein which also binds to CaMKII and forms a complex.  It is thought that calcium 
flowing in through NMDARs binds to CaMKII causing it to dissociate from the 
complex hence reducing its ability to phosphorylate SynGAP (Krapivinsky et al. 
2004). 
 
The importance of the GAP domain in normal development has been demonstrated 
by the fact that a SynGAP construct with mutations in the GAP domain that 
markedly reduce its function could not rescue dendritic spine abnormalities seen in 
Syngap
-/-
 mouse hippocampal cultures (Vazquez et al. 2004).  Moreover, 
overexpression of a SynGAP construct with a mutated (inhibited) GAP domain had 
no effect on frequency or amplitude of miniature excitatory post-synaptic currents 
(mEPSCs) in cultured neurons in contrast to the decreased frequency and amplitude 




1.6 Synaptic Plasticity 
Neuronal synaptic plasticity is defined as the capability of synapses to modify their 
function, to be replaced, and to increase or decrease in number when required 
(Cotman & Nieto Sampedro 1984).  The Synaptic Plasticity and Memory Hypothesis 
theorises that this ability for synapse efficacy to change, underlies learning through 
the storage of information (reviewed by Takeuchi et al. 2014).   
1.6.1 Synaptic plasticity pathways 
The trafficking of AMPAR receptors is key to this as long-term potentiation (LTP) of 
synaptic strength is associated with increased AMPARs at the cell surface and long-
term depression (LTD) by a reduction in AMPARs (reviewed by Malinow & 
Malenka 2002).  The trafficking of AMPARs is known to involve the small GTP 
binding proteins Ras and Rap (Zhu et al. 2002; Zhu et al. 2005; Derkach et al. 2007) 
and the mitogen activated protein kinase (MAPK) pathway, downstream of Ras 
(Figure 3).  The pathway is triggered by calcium influx through NMDA receptor or 
voltage-gated calcium channels which leads to an increase in Ras and in turn to 
activation of Raf, mitogen- activated protein kinase / ERK kinase (MEK) and ERK 





Figure 3 – Activation of extracellular signal-regulated kinase (ERK) by synaptic signalling and 
downstream targets. 
 
(A) Adapted from (Thomas & Huganir 2004) Calcium influx, either through NMDA (N-methyl-D- 
aspartate)-type glutamate receptors or voltage-gated calcium channels triggers an increase in the levels 
of Ras–GTP. This leads to the activation of Raf, mitogen- activated protein kinase (MAPK)/ERK 
kinase (MEK) and ERK. 
 





1.6.2 The importance of AMPA receptor structure in synaptic plasticity 
AMPARs have four sub-units GluR1-4 and those with long cytoplasmic tails 
(GluR1-, GluR2L- or GluR4) are involved in the delivery of AMPARs to the 
membrane during synaptic potentiation via Ras pathways (Zhu et al. 2002; Stornetta 
& Zhu 2011).  Those with short tails (GluR2, GluR3 and GluR4c) play a role in 
synaptic AMPA-R removal during synaptic depression and also in the one to one 
recycling of AMPARs from the membrane (Zhu et al. 2002; Stornetta & Zhu 2011).   
1.6.3 The role of ERK MAPKinase pathways and synaptic plasticity 
The MAPKinase cascades are complicated and ERK 1/2 is only one of the four 
(Figure 3).  Zhu and colleagues observed that the active phosphorylated form of 
ERK1/2 (also known as p42/44 MAPK), was enhanced in tissue expressing 
constitutively active Ras and decreased in tissue expressing dominant negative Ras. 
However constitutively active Rap resulted in increased levels of phosphorylated p38 
MAPK and when p38 MAPK was blocked, the synaptic depression initiated by Rap 
was also blocked (Zhu et al. 2002).  AMPA mediated transmission was potentiated 
by ~80% in cells expressing the constitutively active form of Ras, but those 
expressing the constitutively active form of Rap showed ~50% depression in AMPA 
mediated currents (Zhu et al. 2002).  This therefore suggests that ERK1/2 potentiates 
AMPAR insertion into the cell membrane and p38 MAPK reduces it.  Opposing 
effects of ERK1/2 and p38 MAPK have also been identified in other cell types and 
even inhibition of one over the other (Oh et al. 2000; Westermarck et al. 2001; 
Heffron & Mandell 2005).   
1.6.4 SynGAP’s role in synaptic plasticity 
In 2000 Platenik et al. postulated that SynGAP might be a link between NMDA 
receptor activation and regulation of the ERK1/2 MAPKinase downstream signalling 
pathway through its action on Ras (Pláteník et al. 2000 and Figure 4).  NMDA 
activation leads to influx of calcium which phosphorylates CaMKII in turn leading to 
phosphorylation of SynGAP (Krapivinsky et al. 2004; Walkup et al. 2015; Walkup et 











Figure 4 – Proposed model of MAP kinase cascade activation involving SynGAP. 
 
Adapted from (Pláteník et al. 2000). 
 
SynGAP is physically associated with the NMDA receptor through PSD-95 and under resting 
conditions prevents activation of Ras by other signalling pathways. This brake is released when 







As would be expected from SynGAP’s role as a RasGAP, increased levels of Ras 
have been observed in conditions of SynGAP haploinsufficiency (Carlisle et al. 
2008; Araki et al. 2015).  Increased basal levels of phosphorylated (activated) ERK 
have also been shown in Syngap
-/-
 cultures (Rumbaugh et al. 2006) and Syngap
+/-
 
adult mice (Komiyama et al. 2002; Ozkan et al. 2014).  This level of activated ERK 
increased on stimulation of NMDA receptors (Komiyama et al. 2002; Rumbaugh et 
al. 2006), but not following theta burst stimulation (Ozkan et al. 2014).  Furthermore, 
Ozkan et al. demonstrated deficits in LTP which is in keeping with other work in 
Syngap
+/-
 mice in which LTP was stimulated with high frequency stimulation or 
theta burst activity (Komiyama et al. 2002; Kim et al. 2003; Ozkan et al. 2014).  
Berryer and colleagues explored the effects of mutations found in human SYNGAP1 
patients.  They found that transfection of neurons in organotypic slice culture with 
WT SYNGAP1 reduced the detectable level of phosphorylated (activated) ERK, 
whereas transfection with certain mutations found in human patients with SYNGAP1 
mutations resulted in no difference in phosphorylated ERK in comparison with 
untransfected or GFP transfected cells (Berryer et al. 2013).   
 
Komiyama went on to investigate the mechanisms underlying LTP, specifically the 
idea that SynGAP haploinsufficiency results in increased Ras. Somewhat 
surprisingly, H-Ras
-/-
 mice showed enhanced AMPAR transmission following an 
LTP stimulation paradigm despite their lack of H-Ras.  This could indicate that it is 
not the H-Ras form of Ras that mediates AMPAR trafficking, but doesn’t preclude 
the involvement of other forms of Ras in this process.  There is evidence that the 
level of Ras and Rap signalling needs to be maintained in a ‘happy medium’ to 
mediate downstream signalling and balance AMPAR trafficking (Zhu et al. 2002; 
McCormack et al. 2006; Stornetta & Zhu 2011).  Therefore it is also possible that 
other forms of Ras are up-regulated in H-Ras mice to compensate for the genetic 
deficiency, but this wasn’t investigated. 
 
In keeping with the proposed pathway from Ras to ERK signalling (Figure 3) and the 
papers cited above showing opposing actions of ERK and p38 MAPK, Rumbaugh 
and colleagues showed that when NMDA activation occurred in rat cultured neurons 
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overexpressing SynGAP, there was a suppression of ERK activation and an increase 
in p38 MAPK activity.  They also demonstrated that in knockout mouse neuronal 
cultures and when SynGAP was acutely knockdown with siRNA in rat neuronal 
cultures, there was increased ERK activation. Furthermore, basal p38 MAPK activity 
was significantly decreased in mouse KO neurons.  Both the effect on ERK and p38 
MAPK was found to be mediated by the protein’s GAP domain.   
 
In contrast, Krapivinsky and colleagues showed that mimicking activation of NMDA 
receptor by using TAT-blocking peptides that disrupted the SynGAP-MUPP1 
interaction, significantly reduced the downstream activity of p38 MAPK with no 
associated change in ERK activity (Krapivinsky et al. 2004).   To further complicate 
matters, it is possible that SynGAP may be regulating pathways that are Ras 
dependent but ERK independent as not all LTP induction paradigms require ERK to 
be successful (Watabe et al. 2000; Winder et al. 1999).  However this needs further 
exploration. 
 
Therefore the complexities of signalling downstream of SynGAP are still to be fully 
delineated, however the schematic presented by Jeyabalan et al. gives a reasonable 
overview of the processes involved (Figure 5).   
1.6.5 The link between SynGAP and AMPAR trafficking 
In addition to discrepancies in ERK MAPKinase activation in the Rumbaugh and 
Krapivinsky papers, Rumbaugh et al. found a reduction in the surface GluR1 
AMPAR sub-unit signal which indicated fewer AMPARs on the surface in 
conditions of SynGAP overexpression in neuronal cultures, whereas Krapivinsky et 
al. found a reduction in GluR1 (as well as GluR2 and GluR3 signal) when SynGAP 
was knocked down.  However, in agreement with Rumbaugh’s findings, papers have 
found that GluR1 synaptic clusters are more numerous and bigger in Syngap
-/-
 mice 
plus dendritic spines are larger and levels of AMPARs are concentrated (Kim et al. 
2003; Vazquez et al. 2004; Carlisle et al. 2008; Araki et al. 2015).  Larger GluR1 
clusters and also a specific increase in the number of small clusters were also seen in 
adult mice in whom SynGAP was acutely knocked down using a Cre-LoxP system 



























Figure 5 - Signalling mechanism upon phosphorylation of SYNGAP1. 
 
Adapted from Jeyabalan et al. 2016. 
 
Schematic model of the cellular events that link CaMKII activity to phosphorylation of SYNGAP1 
and its regulation of downstream molecules. Upon NMDAR activation, Ca2+ enters the postsynaptic 
cytosol, triggering phosphorylation of CaMKII, which in turn phosphorylates SYNGAP1 
(pSYNGAP1). pSYNGAP1 regulates Ras-GTPases controlling AMPAR insertion into the 
postsynaptic membrane. In Syngap1 heterozygous mutation, the inhibition of Ras activation by 
SYNGAP1 (shown as #) is lost, which increases Ras activity, thereby increasing AMPAR exocytosis 
to the postsynaptic membrane. Phosphorylation of SYNGAP1 by cyclin-dependent kinase 5 (CDK5) 
activates Rap1 that increases endocytosis of AMPAR. It is not clear how pSYNGAP1 regulates other 
SYNGAP1-associated proteins such as Cdc42, Rac1 (dotted orange lines), which are yet to be studied. 
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It is important to note that, in contrast with the other studies, Krapivinsky used a 
SynGAP–α construct throughout their experiments.  Therefore they may have 
uncovered an isoform specific effect which perhaps also explains their observed 
reduction in p38 MAPK without ERK activation.  Rumbaugh and colleagues did also 
mutate the SynGAP α1 isoform in addition to their disruption of all SynGAP 
isoforms and when doing this they no longer saw a reduction in GluR1 signal.  This 
suggests α1 plays an important role in the AMPAR trafficking process, although it 
has been shown to have no direct effect on dendritic spine density or morphology 
(McMahon et al. 2012).  Perhaps therefore, Krapivinsky’s SynGAP-α was 
specifically α2 as this lacks the QRTE binding motif which facilitates binding to 
PDZ domains of other proteins, possibly meaning that α2 can’t mediate AMPAR 
trafficking in the same way.  Additional experiments are required to confirm this and 
to try to understand if this explains the different ERK MAPKinase effects seen in the 
Krapivinsky paper. 
 
Further evidence for SynGAP’s role in AMPAR trafficking comes from its 
preferential association with the NR2B subunit of NMDARs in adult brain which 
were shown to play a role in the removal of AMPARs containing the GluR1 subunit 
from the cell surface and deactivating Ras-ERK signalling (Kim et al. 2005).  GluR1 
AMPA subunit surface expression was ~33% lower in cells transfected with 
SynGAP and when SynGAP expression was blocked with RNAi, ERK expression 
following NMDAR activation became sustained rather than transient.   
 
1.6.6 Other evidence linking SynGAP to synaptic plasticity 
Araki et al demonstrated that following chemically induced LTP, SynGAP moved 
out of dendritic spines in cultured neurons in a process dependent on CaMKII 
activation.  This dispersion still occurred during the inhibition of Ras and Rap 
suggesting it was upstream of SynGAP’s activation of small G proteins.  They noted 
that LTP induction resulted in increases in the size of dendritic spines as expected 
(Matsuzaki et al. 2004), but this increase was not maintained when CaMKII was 
inhibited or when the phosphorylation sites on SynGAP were mutated. This work 
needs further investigation though as using phospho-mutants resulted in changes in 
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basal function of synapses that may have influenced their ability to respond to 
chemical LTP induction.   
 
Walkup et al. recently observed that phosphorylation of SynGAP α1 by CaMKII 
reduces its affinity for the PSD-95 protein resulting in re-organisation of the synaptic 
proteins as they have more opportunity to bind with PSD-95.  This includes proteins 
such as transmembrane AMPAR regulatory proteins (TARPs) and Leucine Rich 
Repeat TransMembrane proteins (LRRTM) which have previously associated with 
glutamatergic synapse development and AMPAR trafficking (Tomita et al. 2005; 
Siddiqui et al. 2010; Opazo et al. 2012; Walkup et al. 2016).   
 
Hence there are many lines of inquiry that are demonstrating the importance of 
SynGAP in synaptic function and in the next section, the relevance of this to animal 
behaviour will be explored. 
 
1.7 Behavioural changes in SynGAP haploinsufficiency 
Various studies have now linked reductions in SynGAP levels with behavioural 
deficits.  Similar patterns have been shown in mice regardless of whether the studies 
use genetic knockout models (Komiyama et al. 2002; Muhia et al. 2009; Muhia et al. 
2010; Clement et al. 2012; Ozkan et al. 2014; Berryer et al. 2016) or manipulate 
SynGAP at specific ages and in specific brain areas (Muhia et al. 2012; Ozkan et al. 
2014; Berryer et al. 2016).   
1.7.1 Locomotion 
Once of the most prevalent findings in the literature is that of hyperactivity in 
Syngap
+/- 
mice in comparison to WT animals (Guo et al. 2009; Muhia et al. 2009; 
Muhia et al. 2010; Muhia et al. 2012; Clement et al. 2012; Berryer et al. 2016).  
Berryer et al. also observed that this phenotype was not present in mice in which the 
SYNGAP1 gene was conditionally deleted in only the GABAergic interneurons of the 
cortical, hypothalamic and mesencephalic areas (Berryer et al. 2016).  Ozkan and 
colleagues however did  observe hyperactivity in their mouse in which SYNGAP was 
conditionally knocked out in forebrain glutamatergic neurons (Ozkan et al. 2014) 
perhaps suggesting this is a phenotype linked more to alterations in excitatory than 
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inhibitory function.  The picture is complicated though as they went on to show that 
the animals remained hyperactive in a ‘rescue model’ of this forebrain glutamatergic 
SynGAP deficient mouse (Ozkan et al. 2014), but didn’t observe hyperactivity in 
their adult induced SynGAP global haploinsufficiency model. 
1.7.2 Measures of anxiety 
Several studies have demonstrated a reduced level of anxiety in Syngap
+/- 
mice as 
shown by increased time in the open arms of the elevated plus maze and increased 
exploration of the centre area of an open field test (Guo et al. 2009; Muhia et al. 
2010; Clement et al. 2012; Ozkan et al. 2014; Berryer et al. 2016).  Once again this 
reduced anxiety was absent in Berryer’s GABAergic conditional knockout mouse, 
but present in Ozkan’s forebrain glutamatergic knockout model (Ozkan et al. 2014; 
Berryer et al. 2016).  Furthermore, the phenotype was ameliorated by rescue of the 
forebrain glutamatergic model (Ozkan et al. 2014).  Perhaps surprisingly a trend 
towards increased anxiety was seen in adult knockdown of SYNGAP1 (Muhia et al. 
2012), whereas the induction of SynGAP haploinsufficiency in adult mice by Ozkan 
and colleagues had no appreciable effect on the animals’ performance in the elevated 
plus maze (Ozkan et al. 2014). 
1.7.3 Learning and Memory 
Komiyama et al. saw that Syngap
+/-
 mice had a slower rate of spatial learning than 
WT control mice as demonstrated by more diffuse searching for a submerged 
platform in the Morris water maze after the platform was moved from its original 
location (Komiyama et al. 2002).  However after extra training they were better able 
to locate the platform.  Muhia and colleagues also observed some differences in the 
Morris water maze between Syngap
+/-
 mice and WTs.  Specifically, on removal of 
the platform Syngap
+/-
 mutants showed a relative lack of target quadrant preference 
in the first 15 seconds, but thereafter there was no difference between genotypes  
(Muhia et al. 2010).  Extinction of learning was largely no different between 
genotypes in either study (Komiyama et al. 2002; Muhia et al. 2010).  Adult 
knockdown of Syngap also resulted in deficits in the water maze when the platform 
was removed (Muhia et al. 2012). 
In other experiments Syngap
+/-
 mice were observed to have significantly reduced 
alternation in the spontaneous alternation test in the T-maze reflecting deficits in 
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working memory (Deacon & Rawlins 2006; Muhia et al. 2010).  This was also seen 
in mice in which SYNGAP1 haploinsufficiency was induced in the first week of life 
and the phenotype was not modified by rescue of the genetic defect in adult mice 
(Clement et al. 2012).  Berryer and colleagues confirmed this finding in Syngap
+/- 
mice and in contrast with measures of hyperactivity and anxiety, also observed it in 
their GABAergic conditional knockout model, suggesting it may be due to deficits in 
inhibitory function.  However, it was also noted by Ozkan and colleagues in their 
conditional knock out mouse in which SynGAP is lacking in excitatory forebrain 
glutamatergic neurons (Ozkan et al. 2014).  Spontaneous alternation was 
indistinguishable from that of control animals in the forebrain glutamatergic rescue 





 mice have also been shown to be unable to discriminate between similar 
contexts after a fear conditioning paradigm which the authors felt was consistent 
with functional deficits in the dentate gyrus (Guo et al. 2009; Clement et al. 2012).  
Ozkan et al. also found Syngap
+/-
 mice and their conditional forebrain glutamatergic 
neuron knockout model froze less than WTs in a remote fear paradigm suggesting 
deficits in fear memory circuitry.  The phenotype was absent in the rescue model of 
the forebrain glutamatergic knockout mouse and it also was not seen in their mouse 




 mice were observed to make more working memory errors in 
radial arm maze experiments which test spatial learning and memory and failed to 
improve over the course of training unlike WT mice (Muhia et al. 2010).  
1.7.4 Social function 
When presented with a stranger mouse, WT and Syngap
+/-
 mice both spend more 
time exploring the stranger than an inanimate object (Guo et al. 2009; Berryer et al. 
2016).  However if the object is then replaced with a second stranger mouse, WT 
mice spend significantly more time with the new mouse, but Syngap
+/-
 mice do not 
(Guo et al. 2009; Berryer et al. 2016).  This was also true of Berryer’s GABAergic 
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conditional knockout mouse.  The implication is that Syngap
+/- 
mice are unable to 
distinguish the second stranger from the first and so don’t recognise it as novel. 
1.7.5 Other behavioural findings 
Guo and colleagues found that Syngap
+/-
 mice had increased startle responses 
compared to WT mice and there was a suggestion that they also had a preference for 
social isolation (Guo et al. 2009).   
 
Therefore the literature exploring the effects of altered SynGAP expression on mouse 
behaviour is complicated by the age at which the expression is altered and in which 
brain areas.  However it seems clear that it often results in hyperactivity and deficits 
in learning and memory. 
1.8 Altered SynGAP expression and epilepsy in mice 
As well as the behavioural data presented above, there is evidence that Syngap
+/-
 
mice have widespread and frequent cortical epileptiform discharges on EEG (Ozkan 
et al. 2014) and a reduced seizure threshold compared to WT mice (Clement et al. 
2012; Ozkan et al. 2014) which can be rescued on reversal of global SynGAP 
haploinsufficiency (Ozkan et al. 2014).  A reduction in seizure threshold was also 
seen in Ozkan’s forebrain glutamatergic neuron knockout mouse as well as their 
rescue model for this forebrain glutamatergic construct, but not in the mice in which 
global SynGAP haploinsufficiency was induced in adulthood.  Once again this 
illustrates the role of age in the presence of certain phenotypes. 
 
1.9 The advantages of rat models over mouse models 
Although a number of SynGAP mouse models are already in existence, rats offer 
several advantages in furthering our understanding of SynGAP protein function and 
its relationship to human disorders.  They are more intelligent and sociable (editorial 
by Iannaccone & Jacob 2009; Kummer et al. 2014) and quicker to complete water 
maze tasks with less variability in performance than mice (Whishaw 1995).  This is 
advantageous when considering ID and ASD which affect cognition and social 
behaviour.  There is also better spatial resolution on fMRI of a rat brain compared to 
a mouse brain (Ellenbroek & Youn 2016) and is it much easier to acquire 
reproducible brain activation upon stimulation in rats than mice (Jonckers et al. 
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2015).  Therefore the chances of identifying disorder specific biomarkers on 
scanning that translate to humans may be higher in rats.   
 
Hence, this thesis charts the initial characterisation of SynGAP_GAP deletion rat 
which is an exciting new tool in SynGAP research.   
 
1.10 Mechanistic convergence between genetic causes of ID and ASD 
The relevance of the work undertaken in this thesis will hopefully extend beyond the 
field of SynGAP specific research as there is increasing evidence of convergence of 
mechanisms underlying the genetic disorders associated with ID and ASD (Figure 6). 
  
Due to SynGAP’s link to the Ras/MAPKinase biochemical signalling pathways.  
SYNGAP1 associated intellectual disability has now been recognised as one of a 
wider group of conditions known as RASopathies (Tidyman & Rauen 2016).  These 
are medical genetics syndromes that are caused by germ-line mutations in proteins 
affecting the Ras/MAPKinase pathways.   Several other genetic causes of ID fall into 
this group including Neurofibromatosis 1 (NF1 gene), Costello Syndrome (HRAS 
gene) and Noonan Syndrome (PTPN11 and RAF1). 
 
There is also a growing body of research pointing towards similarities in cellular 
processes and molecular pathways, particularly those involved in synaptic function, 
in different genetic causes of ID and ASD (Auerbach et al. 2012; Zoghbi & Bear 
2012; Costa-Mattioli & Monteggia 2013; Krumm et al. 2014; Pinto et al. 2014; De 
Rubeis et al. 2014).  Auerbach et al. 2012 proposed that the mechanisms underlying 
FXS and TS and are on a continuum.  This was based on their finding that 
aberrations in LTD lay in opposite directions in the two syndromes and that by either 
manipulating mGluR5 signalling in opposite directions or by producing double 
mutant mice, these aberrations could be ameliorated.  Recently Barnes et al. 2015 
demonstrated convergence in exaggerated protein synthesis dependent LTD between 
mouse models of Fragile X Syndrome and SynGAP.  Double mutants in this study 
however showed no significant differences from either single mutant model 
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suggesting that a common pathophysiological mechanism is at work in both FXS and 
SynGAP.   
 
Therefore identification of phenotypes and understanding of cellular and synaptic 
deficits in the SynGAP_GAP deletion rats will be of value on several levels.  Firstly 
it will add to the body of research investigating the function of the SynGAP protein.  
Secondly it will contribute to our understanding of the mechanisms underlying the 
deficits seen in SYNGAP1 ID and thirdly the information gathered may be applicable 










Figure 6 - The proteins disrupted by de novo mutations in autism spectrum disorder (ASD) and 
intellectual disability (ID) fall into similar categories of function.    
 
Adapted from (Krumm et al. 2014). 
 
Proteins corresponding to genes with de novo truncating mutations (red nodes) or selected missense 
mutations (blue nodes) in four ASD exome studies and two ID exome studies are connected using 
experimentally derived protein–protein interaction (PPI) data. Peripheral nodes (lighter shades) 
represent genes with additional truncating de novo mutations, which are separated from the central 






1.11 Aims of this thesis 
 
The broad aims of this thesis were therefore to  
1) Conduct an initial characterisation of what is believed to be the world’s first 
SynGAP rat model with particular focus on confirming its SynGAP genetic 
sequence and expression 
2) Use electrophysiological recordings to examine measures of hippocampal and 
cortical function including long-term depression, intrinsic cell properties and 
excitatory and inhibitory currents 
3) Expand on previous work suggestive of differential physiological roles of 
SynGAP isoforms by 
a. Examining the role of SynGAP Eα1 isoform on synaptic strength 
through mEPSC recordings from neurons transfected with Eα1 
b. Investigating the relative abundance of SynGAP isoforms and 





2 CHAPTER TWO: METHODS 
 
2.1 Animal maintenance and termination 
The rodents used in this thesis were group housed and bred in accordance with the 
United Kingdom’s Animals (Scientific Procedures) Act 1986 (ASPA 1986).   They 
were maintained in a facility that was kept on a 12:12 hour light: dark cycle with 
food and drink ad libitem.   
 
For the preparation of rat brain slices, the rats were anaesthetised using isoflurane 
and decapitated either with sharp scissors or a guillotine in accordance with the 
Animal (Scientific Procedures) Act 1986 under the authority of Project Licence 
number 60/4290.  Cultures were prepared from embryos which are not subject to 
procedures under ASPA 1986 and their mothers were decapitated by cervical 
dislocation, a Schedule 1 technique under ASPA 1986. 
 
2.2 Creation of the SynGAP_GAP deletion Rat 
The SynGAP_GAP deletion rat was designed in the Centre for Integrative 
Physiology, University of Edinburgh, but engineered in the USA by Sigma 
Advanced Genetic Engineering (SAGE) Laboratories, St Louis, USA (now Horizon 
Discovery).  SAGE employed zinc-finger endonuclease technology following the 
brief agreed with the researchers from Edinburgh and created a 3584bp deletion in 
the Syngap gene encompassing the GAP domain of the protein.  Briefly, using 
Sigma’s CompoZr
TM
 Zinc-finger nuclease (ZFN) Technology and SAGEspeed™ 
animal Knockout production processes, ZFNs were designed to target the Syngap 
gene sequence above and below the GAP domain (Figure 7).  These were then 
incorporated into a plasmid with the nuclease of the Fok-1 restriction enzyme which 
provides DNA cleavage activity (Figure 7).   The ZFNs are endonucleases that bind 
to specific DNA sequences, thus by pairing them with Fok-1 activity specific DNA 
sites can be targeted and cleaved.  The ZFNs were microinjected into the pronucleus 
of fertilised, one cell embryos.  The cleavage of the DNA stimulated homologous 
recombination repair pathways to re-join the DNA creating mutant embryos that 
were germline transmissible.  Genotyping was carried out on the pups after birth to 
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identify founder animals carrying the mutation, which were then bred with WT Long 
Evans Hooded rats to generate heterozygous F1 rats.  Selection of appropriate F1 
animals based on genotyping and sequencing was then carried out before further 
mating pairs were set up. 
 
The founder animal for the SynGAP_GAP deletion colony used in this body of work 
was shown by SAGE to have a 3584 bp deletion and a 3 bp (‘CAC’) insertion 
predicted to be at NCBI coordinates 14889-18472.   F2 animals were shipped to the 
University of Edinburgh and were inspected regularly.  For a subset of litters, a 
digital photograph of the pups was taken as soon as it was possible to see their 
unique black and white markings.  The pups were then weighed thrice weekly 
(Monday, Wednesday and Friday) from P1 to P23 (the exact ages depended on the 
day of the week on which the litter was born) using the photograph to identify each 


















Figure 7 – Genetic engineering of the SynGAP_GAP deletion rat. 
 
(A) Schematic of strategy to delete the GAP domain from the rat SynGAP gene. 
 
(B) pZFN plasmid map. 
 
Both images taken from project document entitled Generation of SynGAP1 Knockout Rat Model: 








Tails/ear clips were digested in 500 µl tail buffer (100 mM Tris pH 8.5, 200mM 
NaCl, 0.2% SDS, 5 mM EDTA) and 5 µl proteinase K (20 mg/ ml). The Tris, NaCl 
and EDTA were obtained from Sigma Aldrich and the SDS from 2BScientific Ltd.  
Digested tails were shaken vigorously by hand, then put in a 55˚C water bath for >12 
hours.  The debris was pelleted by spinning at 13,000 x g in a microfuge for 10 
minutes.  400 μl of the supernatant from each sample was added to 400 μl of 
isopropanol and shaken vigorously by hand, before being centrifuged for a further 10 
minutes at 13,000 x g.  The supernatant was poured off and the pellet rinsed with 1 
ml 70% ethanol.  150 µl double distilled water (ddH20) was added for ear clips or 
500 µl ddH20 for 0.5 cm tail.  Once re-suspended the samples were left over night 
with the caps open to allow any excess ethanol to evaporate.  
 
PCR Reactions 
The genotyping protocol was designed with two assays (Figure 8).  Assay 1 
confirmed the absence of the deletion (i.e. identified WT alleles) because in WTs the 
distance between the primers is too long to amplify and so a positive result is only 
achieved in heterozygotes and homozygotes.  As the primers for Assay 2 are both 
within the deletion, this assay is positive in WTs and heterozygotes, but negative in 









Figure 8 – Schematic of the genotyping assays for the SynGAP_GAP deletion rat.   
 
In the absence of the deletion, the distance between the Assay 1 primers is too long to amplify.  
Therefore Assay 1 is only positive in heterozygotes and homozygotes.  As the primers for Assay 2 are 
both within the deletion, this assay is positive in WTs and heterozygotes, but negative in 
homozygotes. 
  
UPSTREAM  DOWNSTREAM  DELETION 
Assay 1 
Expected mutation 
band 595 bp 
Founder5 Assay1 del down 
Cel1-R (Reverse Primer) 
Founder5 Assay1 Up Lg F1 
(Forward Primer)  
Founder5 Assay2 up Cel1-R 
(Reverse Primer) 
Founder5 Assay2 up Cel1-F 
(Forward Primer)  
Assay 2 
Expected wild type 






Table 3 - Primers for Genotyping the SynGAP_GAP deletion rat and confirming the deletion 
 
The following PCR reaction was carried out for both assays 
 
For each 20 µl reaction 
 DNA template       0.5 µl 
 Forward primer (final concentration 0.5 µM)   0.25 µl 
 Reverse primer (final concentration 0.5 µM)   0.25 µl 
 TAQ DNA polymerase (Qiagen #201203)   0.2 µl (1 unit) 
 dNTP Mix, PCR Grade (Qiagen # 201901)   0.4 µl 
 10x Coral buffer from TAQ DNA Polymerase kit  2.0 µl 
 ddH20           16.4 µl 
 Total volume       20 µl 
 
Thermocycling conditions: 
1. 95°C for 5 minutes 
2. 95°C for 30 seconds 
3. 60°C for 30 seconds 
4. 68°C for 1 minute 
5. Go to step 2, 35 times 
6. 68°C for 5 minutes 
7. 10°C forever    
8. END 
Genotyping 
Assay 1  
For Founder5 Assay 1 Up Lg F1 GGCACCTTCCCCAAGTAAGT 
Rev Founder5 Assay1 del down Cel1-R TCACTTGGTGAGTGAGTGCC 
Assay 2 
For Founder5 Assay2 up Cel1-F ACTGCGAGTTATGCCTGGAC 
Rev Founder5 Assay2 up Cel1-R CTCATTGTCTGGTAACGGGC 
Confirming the deletion 
For SynGAP Rat cDNA FWD2 GACTCCATTATCAAGCCAGTACA 
Rev SynGAP Rat Exon 14 Set 3 CGAGCCATGAAGGACTGAA 
57 
 
The products were run on a 1% agarose gel with the Promega™ G2101 DNA ladder 
from Thermo Fisher Scientific.  Images were cropped for presentation, but full gel 
images prior to cropping are shown in Appendix 1. 
 
Genotyping of the rats was initially carried out in house but the results of assay 2 
were unreliable so all experimental animal genotyping was outsourced to Transnetyx, 
Cordova, TN, USA which uses a real-time PCR method of genotyping.   
 
2.2.2 mRNA deletion confirmation 
In order to determine the exact nature of the deletion in the SynGAP_GAP rat, 
mRNA was extracted from whole brain tissue using the Qiagen RNeasy Mini Kit 
(#74104/74106).  Whole brain tissue was taken from 1 adult WT and 1 adult 
Syngap
+/GAP 
rat then dissected, flash frozen on dry ice and kept at -80ºC until 
required.  The tissue was thawed on ice and the Qiagen RNeasy Mini Kit instructions 
followed.  Briefly, approximately 30 mg of tissue was homogenised in a glass 
homogeniser in 600 μl Buffer RLT containing 6 μl β-mercaptoethanol.  The lysate 
was centrifuged at full speed for 3 minutes and 1 volume of 70% ethanol added to 
the supernatant in a separate tube.  The mix was added to an RNeasy Spin Column 
and centrifuged again at ≥8,000 x g for 15 seconds. 10 μl DNase I stock solution 
mixed with 70 μl Buffer RDD was added to the column membrane, and left at room 
temperature for 15 min.  The column was washed twice with 350 μl Buffer RW1, 
centrifuging for 15 seconds between each.  Two further wash steps with 
centrifugation were performed with 500 µl Buffer RPE containing 100% ethanol.  
RNA was then eluted using 25 μl RNase-free water. 
cDNA was then made from the mRNA using the Invitrogen SuperScript III First-
Strand Synthesis SuperMix for qRT-PCR (ThermoFisher Scientific Catalogue no. 
11752-050).  The following reagents were gently mixed: 
 2X RT Reaction Mix  10 µl 
 RT Enzyme Mix  2 µl 
 RNA (up to 1ug) 
 DEPC treated water  to 20 µl  
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and incubated at 25ºC for 10 minutes, then at 50ºC for 30 minutes.  The reaction was 
terminated by 5 minutes at 85ºC and then chilled on ice.  1ul (2U) of E.coli RNase H 
was added and the mix was incubated at 37C for 20 minutes. 
Polymerase-chain reaction (PCR) was used to amplify the cDNA using the Taq DNA 
Polymerase (250 U) kit (Qiagen #201203).  The mix for one tube was: 
 cDNA      0.5 µl 
 SynGAP Rat cDNA FWD2 (Table 3)  100 nM  
 SynGAP Rat Exon14 Set 3 (Table 3)  100 nM 
 Coral Buffer (10X)    2.0 µl 
 dNTP      0.4 µl 
 TAQ polymerase (1 unit)   0.2 µl 
 ddH2O      12.9 µl 
The PCR protocol used was: 
1. 94ºC for 3 minutes 
2. 94ºC for 30 seconds 
3. 52ºC for 30 seconds 
4. 72ºC for 2 minutes 
5. 72ºC for 10 minutes 
It was run for 25 cycles and the PCR products were run on a 1% agarose gel at 60 
mV alongside a 1 kb DNA ladder (New England Biolabs #N3232S) to confirm the 
success of the PCR. 
 
Extraction and Re-amplification of DNA  
As no clear band was seen in WT neocortex cDNA, from this point on WT 
hippocampus and heterozygous whole brain were used.  The Macherey-Nagel 
NucleoSpin
®
 Gel and PCR Clean-up Kit (Fisher Scientific #12303368) was used.  
Briefly 1 volume of PCR sample was mixed with 2 volumes of buffer NTI and added 
to a NucleoSpin
®
 Gel and PCR Clean-up column for centrifuging at 11,000 x g for 
30 seconds.  Two wash steps using 700 μl buffer NT3 with 30 second centrifugation 
between each.  The membrane was dried by centrifuging for 1 minute with no buffer.  
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The column was incubated at 70ºC for 5 minutes to remove excess ethanol.  Elution 
buffer was heated to 70ºC, added to the column and left for 5 minutes to increase the 
yield before centrifuging for one minute at 11,000 x g.  Two elution steps were used, 
the first with 20 µl and the second with 15 μl of elution buffer.   
 
The extracted products were then subjected to PCR again using the same protocol to 
further amplify the cDNA fragment.  The products were run on a 1% gel at 65 mV 




 Gel and PCR Clean-up Kit was again used to 
purify the PCR products.  The original sample (15 µL) was made up to 50 µl with 
ddH20 at the start and once again two elution steps were used twice (first with 20 µl 
and then with 15 µl).  The rest of the protocol proceeded as detailed above. 
 
The purified PCR products were sent to Edinburgh Genomics for Sanger Sequencing 
using SynGAP Rat cDNA Seq For (CGTACAAAGTCACAACCCAAACC) and 
SynGAP Rat cDNA Seq Rev primers (TGCCAGGTTGGAAACACTAC).  Using 
Geneious R7 (Biomatters Ltd) software, the sequence of the deletion was determined 
by comparison with the SynGAP rat 1308 bp transcript numbered 






2.2.3 Western Blotting 
 
Tissue preparation 
Following decapitation as described in section 2.1, the skin was cut along the midline 
and the skull was peeled back using forceps to allow access to the brain.  A spatula 
was used to remove the brain from the skull cavity and the appropriate brain regions 
dissected in ice cold cutting aCSF or PBS.  The tissue was then snap frozen on 
aluminium foil laid over dry ice.  If not being homogenised immediately, it was 
stored at -80˚C. 
 
Tissue homogenisation 
Lysis buffer was prepared by mixing protease inhibitor tablets (cOmplete™, Mini, 
EDTA-free Protease Inhibitor Cocktail, Sigma Aldrich), RIPA buffer (Reagents from 
Sigma Aldrich except when noted: 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-
100, 0,5% sodium deoxycholate, 0.1% sodium dodecylsulphate (2BScientific Ltd), 1 
mM EDTA) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail Sets II and 
IV, Merck Millipore) on ice.  Plastic homogenisation sticks or a mortar and pestle 
were used to homogenise the tissues in lysis buffer.  Approximately 9 μl lysis buffer 
was used per 1 mg of tissue.  If necessary, samples were then vortexed to complete 
homogenization, before a small proportion of the sample was reserved separately for 
the protein concentration assay.  Laemlli buffer (Sigma Aldrich) was added to the 
remaining sample to break the disulphide bonds in the proteins and coat them in a 
negative charge to facilitate the western blotting.  These samples were then boiled for 
five minutes to denature any proteases. 
 
Protein level determination  
The Pierce
TM
 BCA Protein Assay Kit from Thermo Fisher Scientific (#23227) was 
used as per the kit instructions to measure the protein level in each of the samples 
reserved without laemlli buffer.  Diluted albumin standards were prepared from the 
kit and the protein samples were diluted 5 or 10 fold to ensure the quantity present 
would fall within the range of the kit’s standard sample curve.  BCA working reagent 
was prepared by mixing Reagent A with Reagent B (50:1) and 200 μl was added to 
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10 μl of each albumin standard and each diluted protein sample in a 96 well plate.  
The plate was incubated for 30 minutes at 37°C and a FluoStar Optima plate reader 
(BMG Labtech) was used to read the plate at an absorbance of 570 nm.  The curve 
plotted from the values of the BCA Protein Assay Kit standard samples was used to 
calculate the protein concentration of each tissue sample using Graphpad Prism for 
Windows (GraphPad Software) and Microsoft Excel (Microsoft) software.   
 
Running the western blot 
Before loading 12 μl of each sample into 10% Mini-PROTEAN
®
 TGX™ Gels (Bio-
Rad), they were boiled again for five minutes and briefly spun down.  5 μl of protein 
ladder was also loaded to each gel (SeeBlue® Plus2 Pre-stained Protein Standard or 
Fermentas PageRulerPlus Prestained Protein Ladder, Thermo Scientific Pierce).  The 
gels were run at a constant current of 10 to 20 mA per gel in running buffer 
consisting of ddH20 plus the following reagents (from Sigma Aldrich unless 
otherwise stated: 25mM Tris, 190mM glycine and 0.1% Sodium dodecylsulphate 
(2BScientific Ltd)).   
 
Transfer steps 
The samples were transferred to nitrocellulose membrane (Bio-Rad) in transfer 
buffer consisting of ddH20, 25mM Tris (Sigma Aldrich), 190mM glycine (Sigma 




The nitrocellulose membranes were rinsed three times with PBS and blocked with 
equal quantities of Odyssey Blocking Buffer and PBS (Sigma Aldrich) plus 0.5% 
Triton X-100 (Sigma Aldrich) for 10-15 minutes.  Primary antibody and β-actin 
antibody (Table 4) were then added to the solution and left overnight at 4 °C or for 4 
hours at room temperature.  The membranes were then washed three times with PBS 
mixed with 0.5% Triton X-100 and incubated in the dark in secondary antibody 




Imaging and quantification of the samples 
The membranes were imaged using Li-COR Odyssey Version 5 Software and 
analysed using Image J Software.  Densiometry of the protein bands was conducted 
using the gel analysis functions within the software and values from SynGAP bands 
were normalised to their corresponding β-actin band.  The images were cropped for 
presentation, but the full gel images prior to cropping are shown in Appendix 1. 
 
Western blot analysis 
β-actin normalised values for heterozygous and homozygous SynGAP bands on each 
blot (as applicable) were compared to the mean WT values from the same membrane 
and expressed as a percentage ± SEM in arbitrary units.  The statistical tests used are 
detailed in the relevant figure legends.  Parametric tests were used for data that 
passed a d’Agostino Pearson normality test, otherwise non- parametric analyses were 
used. 
 
Table 4 – Antibodies used for western blotting 
Antibodies Supplier Catalogue  No. Dilution SynGAP Isoform 
Primary Antibodies     














06-900 1:2000 SynGAP alpha1 
Anti-SynGAP 
[EPR2883Y] 
Abcam ab77235-100 1:2000 SynGAP alpha2 
Anti-beta Actin Abcam ab8227 1:2000 n/a 
Secondary Antibodies     
IRDye® 800CW 
Goat anti-Rabbit IgG 
(H + L), 0.5mg 
Li-COR 926-32211 1:5000 n/a 
Goat anti-Mouse IgG 









2.3 SynGAP Isoform Experiments 
These experiments were conceived and carried out in collaboration with Dr Owen 
Dando who mapped the mRNA-seq reads, Dr Paul Skehel with whom I ran PCR 
reactions and cleaned and further amplified the product before sequencing and 
Shinjini Basu who conducted the RT_PCR experiments (Centre for Integrative 
Physiology, University of Edinburgh). 
2.3.1 SynGAP isoform construction 
Owen Dando mapped mRNA-seq read sets comprising data from  
1. Cortical-patterned neurons derived from human embryonic stem cells and  
from cultured mouse primary cortical neurons (Qiu et al. 2016)  
2. Mouse and human frontal cortex tissue (Lister et al. 2013) 
to their respective genomes using TopHat2, a splicing-aware read mapper (Kim et al. 
2013).  He then examined for novel splice junctions at the SynGAP locus and so 
identified putative new SynGAP 5' variant forms A1 and G  in addition to the known 
N terminal (A, B, C, E) and C terminal (alpha1, alpha2, beta and gamma) isoforms.   
Previous work in the laboratory produced constructs of the different SynGAP 
isoforms (McMahon et al. 2012).  This involved constructing full length SynGAP 
constructs and ligating them into a CMV backbone from the eGFP-C1 vector 
(Clontech, accession number U55763) from which the eGFP gene had been removed 










Figure 9 – eGFP-C1 vector map. 




In this current new body of work PCR was used to amplify the SynGAP N terminal 
using McMahon’s existing SynGAP Aα2 and Bα1 vectors.  The rationale laid out in 
Figure 10 was followed. The PCR products were run on a 70% agarose gel to 
evaluate the result.   
 
Reaction Mixture 
 1/20 dilution of SynGAP template      1 µl 
 10mM dNTP (Qiagen #201900)       1 µl 
 Each primer (Table 5)       0.25 µg 
 Phusion® HF Reaction buffer (New England Biolabs #B0518S) 10 µl  
 Phusion® High-Fidelity DNA Polymerase (NEB #M0530S)  0.5µl (5 units) 
 De-ionised water        37 µl 
 Total volume        50 µl 
 
Thermocycling Conditions 
1. 96°C for 2 minutes 
2. 96°C for 30 seconds 
3. 58°C for 10 seconds 
4. 72°C for 10 minutes 
The protocol was run with 2 holds and 20 cycles 
 
Table 5 – SynGAP isoform construction primers 
SYNGAP N AND C TERMINAL PCR PRIMERS 
Primer Name Sequence 
SynGAP N terminal forward 
SynGAP N terminal reverse 
GCTTCAAGGAGTCACATTCCCAC 
TTCTTCCTGGGACAGCAACCTC 
SynGAP C terminal forward 
SynGAP C terminal reverse 
AAAAAACCTCCCACACCTCCCC 
TCAATGGGGCGGAGTTGTTAC 
SYNGAP SEQUENCING PRIMERS 
Primer Name Sequence 
Mouse SynGAP Core Region Forward  5'-3' 



























Mouse SynGAP Core 
Region Forward 5'-3' 
Mouse SynGAP Core 





2.3.2 PCR purification and clean up 
The PCR products were then purified using the Macherey-Nagel NucleoSpin® Gel 
and PCR Clean-up kit using the same protocol described above. 
 
Gene block fragments of all N and C terminal isoforms based on the sequences 
identified by Owen Dando and containing T7 promoter regions were ordered from 
Integrated DNA Technologies.  In-fusion cloning (In-Fusion® HD Cloning Kit, 
Clontech Laboratories Catalogue Number 638909) was then used to generate A1α1, 
Eα1, Gα1, A1α2, Eα2 and Gα2 SynGAP isoforms.  The reagents used for the cloning 
were: 
 1µl linearized vector (PCR product) 
 1µl (1µg) gene block fragment 
 0.5µl 5X In-fusion HD Enzyme Premix provided with the kit 
 
The mix was incubated at 37°C for 15 minutes and then transformed by mixing with 
33 µl chemically competent cells, keeping the mix on ice for 30 minutes and then 
heat shocking it for 45 seconds at 42°C.  It was next placed on ice for two minutes 
before 250 µl SOC medium was added and the cells were placed in a shaker at 150 
rpm at 37°C for 45-60 minutes.  The cells were plated on Kanamycin Luria Broth 
(LB) agar plates and incubated overnight at 37°C.  3 or 4 colonies from each plate 
were then picked and grown on in LB kanamycin broth overnight before being 
centrifuged at ~17900 x g for 30 seconds.  The DNA in the recovered pellet was 
purified using the Qiagen QIAprep Spin Miniprep Kit (#27104) as per the kit 
instructions as follows.  The supernatant was removed and the pellet re-suspended in 
250 μl Buffer P1.  250 μl Buffer P2 was added before mixing thoroughly until the 
solution was a clear blue colour.  350 μl Buffer N3 was added and mixed 
immediately until the solution became colourless.  The mix was centrifuged for 10 
minutes at ~17900 x g before the supernatant was aspirated with a vacuum manifold.  
Washes with 500 μl Buffer PB and 750 μl Buffer PE containing ethanol were carried 
out with vacuum aspiration between each.  The samples were centrifuged for 1 
minute ~17900 x g to remove residual wash buffer and the DNA was eluted using 50 
μl Buffer EB. 
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2.3.3 Restriction enzyme digestion 
Restriction Enzyme Digestion to confirm the insertion of the isoform using KPN 
enzyme was conducted using the following mix which was incubated at 37°C for at 
least 2 hours before being run on an agarose gel: 
 2 µl DNA 
 5 units enzyme KPN 1 (New England Biolabs #R0142S) 
 1.5 µl New England Biolabs Buffer 1 (10X concentration, #B7001S) 
 Water to make up to 15 µl 
 
Following this confirmation, 5.8 µl of each purified DNA sample was mixed 
separately with forward and reverse SynGAP sequencing primers (Table 3) and was 
sent for Sanger Sequencing carried out by Edinburgh Genomics, The University of 
Edinburgh.  The sequences were analysed and confirmed using Geneious R7 
(Biomatters Ltd) software.  Larger quantities of each isoform were then made from 
colonies grown on overnight as before using the Qiagen QIAprep Spin Maxiprep Kit.  
Briefly the DNA pellet obtained from centrifuging at ≥15,000 g for 5 minutes was re-
suspended in 10 ml Buffer P1 solution and then mixed with 10 ml Buffer P2.  10 ml 
of chilled Buffer P3 was added and the solution mixed until a smooth suspension was 
achieved.  It was then poured into a QIAfilter cartridge and left at room temperature 
for 20 minutes, before being filtered into a clean falcon tube. 2.5ml of Buffer ER was 
added to the filtered lysate and after mixing it was incubated on ice for 30 minutes.  
A QIAGEN-tip 500 was equilibrated by filling it with Buffer QBT and allowing the 
column to empty by gravity flow before the filtered lysate was applied to the 
QIAGEN-tip 500.  The QIAGEN-tip 500 was then washed twice by filling it with 
Buffer QC and the DNA was eluted with 15 ml Buffer QN.  10.5 ml of room 
temperature isopropanol was added to precipitate the DNA before centrifugation at 
≥15,000 g for 30 minutes.  The supernatant was decanted and 2 ml endofree water 
with ethanol was used to remove the rest of the isopropanol.  The supernatant was 
aspirated and the pellet left to air dry for 5-10 minutes before being re-suspended in 




2.3.4 Real time reverse transcriptase and quantitative PCR experiments 
The protocol for these experiments was as follows. 
2.3.4.1 Tissue preparation 
Litters of mice from SynGAP heterozygous parents were anaesthetised at P0 with 
inhaled isofluorane and then decapitated with sharp scissors in accordance with the 
Animal (Scientific Procedures) Act 1986 under project licence number 60/4290.  The 
skin was cut along the midline and the skull was peeled back using forceps to allow 
access to the brain.  A spatula was used to remove the brain from the skull cavity and 
the neocortex was dissected in ice cold cutting aCSF or PBS.  The tissue was then 
snap frozen on aluminium foil laid over dry ice before being stored at -80˚C.  Tail 
samples were taken for genotyping allowing total RNA extraction to be carried out 
on Syngap
-/-
 mice only for the current experiments.  Total RNA was extracted using 
the RNeasy mini-kit (Qiagen) and RNase-Free DNase set (Qiagen) and following the 
kit instructions. Briefly, approximately 30 mg of tissue was homogenised with a 
needle and syringe in 600 μl buffer RLT containing 6 μl β-mercaptoethanol.  The 
lysate was centrifuged for 15 seconds at 16,000 x g and the supernatant transferred to 
a new microcentrifuge tube. 1 volume of 70% ethanol was added and mixed by 
pipetting before being transferred to an RNeasy spin column in a collection tube and 
centrifuged again for 15 seconds.  70 μl DNase I stock solution (15000 Kunitz units) 
mixed with 10 μl Buffer RDD was added to the column membrane, and left at room 
temperature for 15 min.  The column was washed twice with 350 μl Buffer RW1 and 
twice with 500 μl buffer RPE with 15 second centrifugation between the washes.  
RNA was eluted in RNase free water.  Total RNA concentration was measured 
spectrophotometricly using the Nanodrop 1000 (Thermo Scientific).   
2.3.4.2 Synthetic mRNA production 
Transcripts were generated from the specific plasmids made in using the mMessage 
mRNA kit.  Briefly, the plasmids were linearised by restriction enzyme digest.  The 
reagents for this were  
 1µg DNA 
 1µl (2000 U) EcoR1 enzyme, [# R0101S New England Biolabs, (NEB)] 
 1µl NEB4 10 x buffer (# B7004S NEB) 
  H20 to make up to 10µl.   
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The mix was incubated at 37°C for 2 hours.  
 
The reaction volume was made up to 100 µl with H20 and an equal volume of 
phenochloroform isoamyl alcohol (25:24:1 v/v) was added.  The mix was vortexed 
for 30 secs to extract protein and was then centrifuged at 4°C at maximum speed for 
5 minutes to separate the phases.  The upper aqueous layer was separated into a new 
tube and further extracted with an equal volume of chloroform, and the aqueous 
phase recovered into another new tube.  1/10
th
 or 10 l volume of 3M acid sodium 
acetate was added and the DNA precipitated by the addition of 200μl of 100% 
ethanol, and recovered by centrifuged at 4°C at maximum speed for 20mins.  The 
supernatant was vacuum aspirated and the pellet washed in 200μl 70% ethanol.  It 
was centrifuged again at 4°C for 5 minutes and the supernatant aspirated.  The pellet 
was allowed to air dry for 5 minutes and then re-suspended in 11µl RNAse free H20. 
 
The mMESSAGE mMACHINE® Kit (Thermo Fisher Scientific #AM 1344) was 
used to transcribe the DNA into RNA as follows.  The transcription reaction was 
assembled at room temperature as follows and incubated at 37°C for 1 – 2 hours. 
 
Reaction mix 
 2X NTP/CAP   10µl 
 10X Reaction buffer  2µl 
 Linear template DNA  0.2 µg 
 Enzyme mix   2µl 
 Nuclease-free water  To 20μl 
 
The quality and integrity of the mRNA made was determined using Agilent 




2.3.4.3 Primer design 
In designing the primers, the following parameters were used as a framework in an 
attempt to ensure the primers would work in a comparable manner under the same 
experimental conditions to allow for comparisons to be made of the abundance of the 
different SynGAP isoforms. 
 Primer length 17 – 23 bp 
 Melting temperature 59 – 62.9°C 
 Difference in melting temperatures of no more than 1°C 
 Primer end is a cytosine or guanine 
 Primers span an exon boundary 
 Product (amplicon) length of 150 -250 bp    
 Primers don’t form hetero dimers, primer dimers, or have a secondary structure  
2.3.4.4 Primer validation 
Primers were designed for each of the SynGAP N terminal isoforms and for 
GADPH, a control gene (Table 6).  A three step validation process was carried out 
for each primer as follows: 
1. When designing the primers, any giving secondary products < 1 kb in length 
were discarded to minimise the amplification of non-specific products 
2. One-step RT PCR was carried out for each primer using 1 µg of SynGAP 
isoform synthetic RNA and the products were run on a 0.7% agarose gel to 
confirm the amplification of just one specific product 
3. Melt curve analysis was conducted at the end of each run between 55°C and 
90°C.  A single melting peak was taken as demonstrating one specific 
product.  Any samples with multiple peaks were discarded from the analysis.  
 
Table 6 – SynGAP isoform qPCR primers 
SynGAP Isoform Forward Primer Reverse Primer 
A CGAGTCCAGCCGAAACAAAC GGGACTCAGCAGGGACTC 
A1 CGATGTCCTATGCCCCCTTC GGGACTCAGCAGGGACTC 
B GCTCTTCTTGCTGCTTTCCG GGGACTCAGCAGGGACTC 
C AAGTGCTGACCATGACCG GGGACTCAGCAGGGACTC 
E TTCTCGCTGCATCTTCCGAG GGGACTCAGCAGGGACTC 
G CGGTGCGAGATGGAGGC GGGACTCAGCAGGGACTC 
Pan Syngap CGAAGTGCTGACCATGAC CGGCTGTTGTCCTTGTTG 
GADPH (control)  GGGTGTGAACCACGAGAAAT CCTTCCACAATGCCAAAGTT 
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2.3.4.5 One-step RT PCR 
The OneStep RT PCR kit (Qiagen) was used in the primer validation process.   The 
following reagents were mixed on ice: 
Reaction mix 
 H20    13.5 µl 
 5x buffer   5 µl 
 dNTPs    1 µl 
 Enzyme mix   1 µl 
 10 µM forward primer 1.5 µl 
 10 µM reverse primer  1.5 µl 
1 µg of template RNA was added to each tube.   
 
Thermocycling conditions 
 50°C for 30 minutes 
 25 cycles of  
 95°C for 15 minutes 
 94°C for 45 seconds 
 59°C for 45 seconds 
 72°C for 1 minute 
 Followed by 72°C for 10 minutes.   
 
The reaction was then held at 4°C.  The product was run on a 0.7% agarose gel.  As with 
genotyping and western blotting, the images were cropped for presentation, but full gel 
images are shown in Appendix 1.  
 
2.3.5 “Spike-in” and qPCR experiments 
So called ‘pan Syngap’ primers (Table 6) which were previously used to amplify all 
known SynGAP isoforms (McMahon et al. 2012), were used in RT-PCR to check for 
the absence of SynGAP in the P0 homozygous mouse neocortex.  Known amounts of 
the synthetically made mRNA of SynGAP N terminal isoforms A, B, C, E and G on 
the α2 c-terminal backbone were then added or ‘spiked’ into the total mRNA 
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extracted from P0 Syngap
-/-
 mouse neocortex.  qPCR was then carried out in 
triplicate with different quantities of each synthetic isoform.  This was to establish 
the relative efficiencies of each primer combination and the accuracy of the qRT-
PCR across the triplicates.  Each synthetic isoform was also added individually 
ranging from 0.1 pg - 100 pg in an attempt to determine the physiological levels of 
isoform expression by comparing the Ct value at which the gene was detected in 
Syngap
-/-
 mice versus their wild type littermates.  The Ct values were all normalised 
to the housekeeping gene GAPDH.   
 
First strand synthesis was performed using the First strand cDNA synthesis for RT-
PCR kit (Roche).  Typical reaction and reverse transcription thermal cycling 
conditions for these experiments were as follows: 
 
Reaction Mix                   Final Concentration 
 2 µl RNA (mouse brain RNA plus 1 µl synthetic RNA)    Varied by experiment 
 1 µl Oligo [dT] primers (50 pmol/µl)    2.5 µM  
 2 µl Random Primers (600 pmol/µl)    60 µM   
 H20         To total 13 µl  
Followed by adding 
 4 µl 10x reaction buffer including 8mM final concentration of  MgCl2  
 0.5 µl Reverse Transcriptase (20 U/µl)   10 U   
 2 µl Deoxynucleotides (10 mM each)   1 mM each 
 0.5 µl RNase inhibitor (40 U/µl)     20 U  
 
Total volume was 20 µl 
 
Thermocycling Conditions: 
 25°C for 10 minutes 
 55°C for 30 minutes 
 85°C for 5 minutes 




Real time RT-PCR was performed using an MJ research DNA Engine Opticon and 
an Applied Biosystems 7500 Real-Time PCR system with Quantitect SYBR Green 
PCR kit (Qiagen).  A typical PCR reaction and thermal cycling conditions are shown 
below.  15 μl total reaction volume was used for all reactions carried out on the 
Applied Biosystems machine whilst 20–25 μl total reaction volumes were for 
reactions in the Opticon machine as the machine sensitivities varied.   
 
Reaction Mix 
 2x QuantiTect SYBR Green PCR Mix (including Rox) 12.5 µl 
 Forward Primer (300 nM final concentration)  0.75 µl 
 Reverse Primer (300 nM final concentration)  0.75 µl 
 H20         10 µl 
 cDNA (of appropriate concentrations)   1 µl 
 Total volume       25 µl 
 
Thermocycling 
Step 1: 95°C for 10 minutes 
Step 2: 40 cycles of 
1. 95°C for 30 seconds  
2. 60°C for 40 seconds 
3. 72°C for 1 minute 
Step 3: Dissociation Curve 
1. 95°C for 1 minute 
2. 55°C for 30 seconds 
3. 95°C for 30 seconds  
Readings were taken at every 0.5°C temperature increase 
2.3.5.1 Quality control measures 
Known amounts of control cDNA from ~P90 WT mouse neocortex were used to 
construct a standard curve in triplicate for each SynGAP N terminal isoform primer 
pair and the GAPDH control primer pair.  Furthermore water blank and minus 
reverse transcriptase controls were performed for each isoform on every run.  If 
product was amplified in either of these controls, the corresponding experimental 
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data was discarded.  Opticon Monitor analysis (version 1.01) or Applied Biosystems 
software were used to compare amplification during the log-linear phase from the 
dilution series of control cDNA to ensure there was similar amplification of the 
cDNA for each replicate sample.  
2.3.5.2 Data analysis 
The primer pair efficiencies were calculated using the online ThermoFisher 
Scientific qPCR primer efficiency calculator 
https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-





values for the primer pairs were calculated from the 
standard curve data in GraphPad Prism for Windows (GraphPad Software).  The 
Opticon Monitor analysis (version 1.01) or Applied Biosystems software 
automatically calculated Ct values and plotted melt curves and amplification plots.  
2.4 Tissue culture 
2.4.1 Preparation of SynGAP_GAP rat primary hippocampal cultured 
neurons  
Heterozygous-heterozygous timed matings of SynGAP_GAP Long Evans Hooded 
rats were set up so that primary hippocampal cultures could be prepared from WT, 
heterozygous and homozygous embryos at embryonic day 18.  The primary cultures 
were kindly prepared by Katherine Bonnycastle, Centre for Integrative Physiology, 
University of Edinburgh.    Her protocol for this was as follows.   
 
Preparation 
Coverslips were coated with a mixture of 50 ml autoclaved Boric acid (100 mM, pH 
8.5) and 500 µg pol-D-lysine (Sigma Aldrich, stock 5 mg / ml in water) and left 
overnight on a rotator.  They were then washed with autoclaved pure water twice and 
left for 1-2 hours on the rotator before being dried on a paper towel sterilised with 
ethanol.  One 13 mm coverslip was placed in each well of a 24 well plate.  50 μl of 
laminin (Sigma Aldrich) was added to 5 ml of neurobasal medium (ThermoFisher 
Scientific) and kept on ice.  50 µl of this mix was then pipetted on each coverslip and 
the plates were placed in a 37°C/ 5% CO2 incubator.  Papain powder (Worthington 
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Biochemical Corporation) was pre-diluted 10 units / ml and 200 μl was put straight 
into a 15 ml Falcon tube.  One tube was used for each embryo head.  The tubes were 
pre-warmed in the water bath at 37°C.  Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12 – ThermoFisher Scientific) was supplemented 
with 1% penicillin/streptomycin solution and 10% Foetal Bovine Serum.  This 
preparation was then aliquoted to give 500 µl per papain tube and 2 ml per papain 
tube to top up volume before centrifuging.  Neurobasal medium was supplemented 
with 10 ml B27 (ThermoFisher Scientific), 0.5 mM (1.25 ml) L-glutamine (Sigma 
Aldrich) and 1% penicillin/streptomycin solution (ThermoFisher Scientific).  This 
was then aliquoted so that 100 μl was available per head dissected plus 1 ml for 
every well.  The aliquots of supplemented DMEM/F12 and neurobasal medium were 
pre-warmed in the 37°C/ 5% CO2 incubator to let the CO2 equilibrate.   
 
Dissection 
After the pregnant females were culled, the abdomen was sprayed thoroughly with 
ethanol to minimise the spread of animal dander.  The skin and underlying fascia was 
cut around and upwards to avoid getting dander inside the abdominal cavity.  The 
uterine horns were dissected and transferred to a petri dish.  The embryos were 
removed from their amniotic fluid sacs and decapitated with scissors.  The head and 
body were transferred to the same well of a 6 well plate. 
 
The hippocampi from the chosen heads were dissected by using sharp forceps to 
remove the skin before gently removing the skull.  The brain was scooped out using 
a spatula, the brainstem and cerebellum were removed and the hemispheres 
separated.  The meninges were torn away and the hippocampus removed.  To try and 
ensure cells were healthy, the total dissection time were restricted to no more than 75 
minutes from the point of uterine horn extraction. 
 
Tissue Digestion 
Both hippocampi from each head were placed in one of the pre-warmed tubes 
containing 200 µl of papain and left at 37°C in a water bath for 20 minutes to digest 
the tissue.  The excess papain was then discarded and 500 μl of the pre-warmed 
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DMEM/F12 was added to each tube to saturate the enzyme.  The tissue was pipetted 
up and down approximately 25 times until it disaggregated into a single-cell 
suspension.  The cell suspension was topped up to 2.5 ml using the rest of the pre-
warmed DMEM/F12 and the tube was centrifuged at ≥15000 x g for 5 minutes.  The 
supernatant was discarded and each tube of cells re-suspended in 100 µl of the pre-
warmed neurobasal medium.  10 µl of the suspension was placed on each side of a 
haemocytometer and a cell count performed so that 50,000 cells/well could be plated 
onto the laminin spot on each pre-prepared coverslip.  The cells were then left to 
settle for one hour before 1 ml of pre-warmed neurobasal medium was added.  The 
plates were then kept in the 37°C/ 5% CO2 incubator.  On day 3, neurobasal medium 
was added to the wells with cytosine β-D-arabinofuranoside (Ara-C, Sigma Aldrich) 
to give a final concentration of 1 µM to stop the proliferation of glia.   
 
Electrophysiological recordings were made at days in vitro 13-15.  The analysis of 
the recordings was carried out whilst blind to genotype. 
 
2.4.2 WT hippocampal tissue cultures for transfection with SynGAP 
isoform Eα1 
Autoclaved glass coverslips were placed in 24 well culture plates and coated for 2 
hours with 200 µl of poly-L-lysine (Sigma Aldrich) stock solution (10 mg / ml) per 
40 ml of distilled H20.  They were coated for a further hour in 1 ml of Fibronectin 
(Thermo Fisher Scientific) stock solution (1 mg / 10 ml) per 10 ml of distilled H20.  
Timed matings of Sprague-Dawley WT rats were set up and at day 20.5, pregnant 
females were culled.  The mother’s abdomen was sprayed with ethanol and the 
abdominal wall cut to enable removal of the embryos which were then decapitated 
with sharp scissors and placed in basal medium eagle solution (BME, Thermo Fisher 
Scientific) on ice.   
 
Each pup brain was removed from the skull and hemisected before the hippocampi 
were dissected out in filtered HBSS (Thermo Fisher Scientific) / HEPES (Sigma 
Aldrich) Solution (500 ml of Hank’s Based Salt Solution and 1.19 g HEPES with pH 
adjusted to 7.3).  The hippocampi were incubated at 37°C in 2 ml Hanks / HEPES 
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Solution with 200 µl Trypsin (Worthington) and 20 µl DNase (Sigma Aldrich).  The 
solution was removed and the tissue washed twice in solution that was 90% BME 
with 10% horse serum (Thermo Fisher Scientific) before being triturated with a fire 
polished pipette.  The cells were counted with a haemocytometer and plated on the 
coverslips after the fibronectin had been washed off with BME.  The following day 
the old media was removed and replaced with fresh serum free medium.  Thereafter 
the cells were fed twice weekly, removing half of the old medium and replacing it 
with fresh serum free medium made up in 500 ml batches consisting of 500 ml BME, 
8 ml of a 32.5% glucose solution (in double distilled water), 5 ml sodium pyruvate 
100 mM solution (Thermo Fisher Scientific), 5 ml N2 supplement (Thermo Fisher 
Scientific) and 10 ml B27 supplement (Thermo Fisher Scientific).  Initially 5 ml 
penicillin-streptomycin solution (Thermo Fisher Scientific) was also added, but in 
later cultures this changed to 5 ml Antibiotic-Antimycotic 1x (Thermo Fisher 
Scientific) due to persistent fungal contamination. 
 
Initially the density of cultures was low and variable and it was hypothesised that 
this was contributing to the cells appearing unhealthy visually and on 
electrophysiological recording.  The density of plated cells was therefore 
standardised to 1500 cells / mm
2
.   
 
2.4.3 WT cortical primary tissue cultures for transfection with SynGAP 
isoform Eα1 
These cultures were kindly prepared by members of the Hardingham Laboratory, 
Centre for Integrative Physiology, University of Edinburgh.  Their protocol was as 
follows: 
The coverslip coating mix was prepared using 1 mg poly-lysine (BD Biosciences) 
and 0.375 mg laminin (Sigma Aldrich) for 75 ml.  0.4 ml coating mix was used per 
well in a 24 well plate and the plate was left in the 37°C incubator for ~2 hours.  
Dissection solution (reagents from Sigma Aldrich) was prepared by mixing 36 ml of 
Dissociation Medium [Na2SO4 1 M, MgCl2 2 M, CaCl2 1 M, HEPES 1 M, phenol 
red, glucose 2.5 M (45%)] in a 100 ml sterile bottle with 4 ml of 10X kynurenate 
magnesium (made from H2O, phenol red, 1 M NaOH, 1 M HEPES and 2 M MgCl2).  
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The pH of the solution was adjusted by adding drops of 0.2 M NaOH, stirring 
constantly. The pH was correct when the colour changed from orange (or yellow) to 
a rose shade of red. 9 ml of this solution was then placed in two small plastic Petri 
dishes (to place the cortices in after dissection).  Growth medium and papain were 
pre-warmed in a 37°C water bath before starting dissections. 
 
Sprague-Dawley WT rat pairings were set up in timed matings so that the pups could 
be dissected at embryonic day (E) 21.   The mother rat was culled and ethanol 
sprayed on her abdomen.  The abdominal wall and underlying fascia was cut and the 
embryonic pups removed and decapitated with sharp scissors.  The number of pups 
required was calculated by expecting to need 1/7 cortex per 2 ml and 0.5 ml of 
solution per well.  The brains were dissected and incisions made in the cortices to 
increase the surface area that interacted with the papain enzyme.  The cortices were 
transferred to a plastic tube and as much of the dissection solution as possible was 
removed.  A drop of 0.2 M NaOH was added to the enzyme to make it pink rather 
than yellow if necessary.  1 ml of papain was added to the cortices and incubated at 
37°C in the water bath, stirring every 5 minutes.  The coated plates were then 
prepared by removing the excess coating mix with a vacuum pump.  They were 
washed once with sterile water which was then aspirated. The plates were stacked in 
the incubator to dry completely.  All the papain was removed from the cortices tube 
and the tube was washed with remaining 2 ml Dissociation Medium mixed with 
kynurenate magnesium. The tube was washed twice with 2 ml 1% NBA growth 
medium (NeuroBasal A, Thermo Fisher Scientific), rat serum 1% (Harlan SeraLab 
Ltd), Antibiotic-Antimycotic 1x (Thermo Fisher Scientific), B-27 1x (Thermo Fisher 
Scientific), glutamine 1mM (Sigma Aldrich) and gently shaken to mix.  2 ml of 1% 
NBA was then added to the tube and the mix was pipetted up and down quickly 50-
60 times to mix.  A further 2 ml 1% NBA was then added and it was left for 5 
minutes for all the debris to settle.  The medium was gently aspirated without 
disturbing the tissue at the bottom and another 2 ml of growth medium was added to 
the tube.  Again it was mixed by pipetting up and down 50 times and 2 ml more 
medium was added before resting for a further 5 minutes.  This step was repeated 
until a total of 10 ml of growth medium had been used.  The mix was diluted with 
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pre-warmed OptiMEM+ (Thermo Fisher Scientific), to achieve the required 
concentration of 1/7 cortex/ 2 ml. (0.0625 cortex / ml) and homogenised by further 
mixing with a pipette.  0.5 ml of the cell mix was plated per well of a 24-well plate 
and incubated for 2.5 hours at 37°C.  The diluted medium was aspirated from each 
well and 1 ml of pre-warmed growth medium (1% NBA) was added to the wall of 
the well.  Cells were left in the 37°C incubator to grow. 
 
Culture maintenance: 
On Days in Vitro (DIV) 4, 1 ml / well of fresh pre-warmed medium mixed with 
1.2mM Cytosine β-D-arabino-furanoside hydrochloride (AraC) (Sigma Aldrich) was 
added to block DNA replication and stop glial cells dividing.  Thereafter the cells 
were fed twice weekly, removing half of the old medium and replacing it with fresh 
serum free growth medium made up in 500 ml BME, 8 ml of a 32.5% glucose 
solution (in water, sterile), 5 ml sodium pyruvate 100 mM solution, 5 ml N2 
supplement and 10 ml B27 supplement.  As with hippocampal cultures, initially 5 ml 
penicillin-streptomycin solution (Thermo Fisher Scientific) was also added to the 
medium, but this was later changed to 5 ml Antibiotic-Antimycotic 1x (Thermo 
Fisher Scientific) due to persistent fungal contamination. 
 
2.5 Transfection for electrophysiological recording for mEPSCs 
SynGAP isoforms were transfected into the cultured WT Sprague-Dawley cortical 
and hippocampal cells on Days in Vitro (DIV) 8-10 using lipofectamine.  Equal 
amounts of SynGAP Eα1 isoform DNA and eGFP plasmid (2 µg of each per well in 
a 6 well plate or 0.65 µg of each per well of a 24 well plate) were added to Opti-
MEM (Thermo Fisher Scientific) (50 µl/well in a 6 well plate or 33µl/well in a 24 
well plate).  The eGFP was kindly provided by Katie Marwick, Hardingham 
Laboratory, Centre for Integrative Physiology, University of Edinburgh.  
Lipofectamine 2000 (ThermoFisher Scientific) was separately mixed with Opti-
MEM.  Initially 4µl of Lipofectamine in 50µl Opti-MEM was used for one well in a 
6 well plate or 2.33µl in 33µl for one well in a 24 well plate.  This was gradually 
reduced over successive transfections due to poor cell health.  The final 
lipofectamine concentration used was 0.8 µl in 33µl (for one well in a 24 well plate).  
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Both mixtures were left on ice for 5 minutes then mixed and vortexed briefly before 
being left on the bench for 20 minutes.  A proportion of the medium from each well 
of the culture plate to be transfected was removed  (0.5 ml / well for a 6 well plate 
and 0.25 ml / well for a 24 well plate), pooled and made up to 2 ml / well for a 6 well 
plate or 0.5 ml / well for a 24 well plate. The Opti-MEM, DNA and lipofectamine 
mix was then pipetted onto the top of the well and the plate was incubated for 2 
hours at 37ºC.  All the media was removed from the transfected wells and replaced 
with the media reserved earlier.  Electrophysiological recordings of miniature 
excitatory post-synaptic currents (mEPSCs) were made from them 16 to 25 hours 
later.   
2.6 Preparation of Acute Hippocampal Brain Slices 
The rats were anaesthetised and decapitated as described in section 2.1.  The skin 
was cut along the midline and the skull was peeled back using forceps to allow 
access to the brain.  A spatula was used to remove the brain from the skull cavity and 
400 μm thick horizontal hippocampal brain slices were cut on a Leica VT1200S 
vibratome in ice-cold ‘cutting’ artificial cerebral spinal fluid.  This was made from 
the following reagents (all from Sigma Aldrich and expressed in mM) and was 
carbogenated with 95% O2 and 5% CO2: NaCl 86, NaH2PO4 1.2, KCl 2.5, NaHCO3 
25, glucose 20, sucrose 75, CaCl2 0.5, MgCl2 7.  For long-term depression 
recordings, AMPAR / GABAR and AMDAR / NMDAR recordings, a cut was made 
through CA3 to prevent recurrent electrical activity from CA3 distorting the 
recordings.   
 
Slices were allowed to recover for 30 minutes at 35°C in external recording solution 
containing the following reagents (Sigma Aldrich) in mM: NaCl 124, NaH2PO4 1.2, 
KCl 2.5, NaHCO3 25, glucose 20, CaCl2 2, MgCl2 1.  Slices were then maintained at 
room temperature (20 - 22ºC) for a minimum of 30 minutes before recordings were 
made.  Recordings were made from CA1 pyramidal neurons identified by their 
characteristic shape.  The composition of the external recording solution remained as 
above except for the addition of certain pharmacological compounds as described 
below for each individual experiment.  The perfusion flow rate was maintained at 3 - 




For acute brain slice recordings, WT and heterozygous littermates were used and 
animals were chosen either at random or by another experimenter to ensure the main 
experimenter remained blind to genotype.  The genotype was not revealed until after 
data analysis. 
 
2.7 Electrophysiological methods 
2.7.1 Electrophysiology recording equipment 
Recording electrodes (Premium Standard Wall Borosilicate Capillary Glass with 
Filament, OD 1.5 mm, ID 0.86 mm) were pulled on either a Sutter P95 or P97 
Micropipette Puller) to give a pipette resistance between 2 to 7 MΩ.  Bipolar 
stimulating electrodes were made from nickel / chromium (80% / 20%) wire.  Pulses 
were delivered by a DS3 Isolated Constant Current Stimulator (Digitimer Ltd).  
 
For field potential experiments, recordings were acquired using WinLTP Version 2.1 
(The University of Bristol), amplified 1000 times (initially with NPI electronics 
amplifier and then an Axoclamp-2b amplifier from Axon Instruments), filtered at 4 
kHz and digitised (National Instruments BNC-2090A) at 20 kHz.   
 
For whole cell patch-clamp recordings from acute brain slices, recordings were made 
using a MultiClamp 700B amplifier and a Digidata series 1440a digitiser (Molecular 
Devices CA 94089 USA).  The samples were digitised at 20 kHz and low pass 
filtered at 2 kHz.  The acquisition software was Clampex Version 10 software 
(Molecular Devices).  For recordings from primary cultures the data acquisition 
software was WinEDR Version 3.4.3 software.  The data was digitised using a 
National Instruments (NIDAQ-MX) Card and amplified with an AxoPatch 200B.  
The recordings were digitized at 10 kHz and low pass filtered at 2 kHz.  Reagents 
used for electrophysiological experiments were sourced from Sigma Aldrich unless 
otherwise stated. 
2.7.2 Extracellular field recordings 
To measure long-term depression (LTD) in the hippocampus pairs of 200 µs current 
pulses 50 ms apart were delivered every 30 seconds to the Schaffer collateral axons 
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in post-natal day (P) 26 - 30 rats.  The recording electrodes were filled with the 
standard external recording solution detailed above.  The stimulus intensity was 
adjusted to give approximately 50% of the amplitude which elicited a population 
spike.  Recordings were discarded if a stable 20 minute baseline could not be 
achieved.  In those in which this stable baseline was achieved, 100 µM (R, S)-3, 5-
Dihydroxyphenylglycine (DHPG) (Abcam) was bath applied to the slice for five 
minutes.  The recording then continued for a further 60 minutes.  For a subset of 
slices, 100 μM the protein synthesis inhibitor cycloheximide (CHX) (Abcam) was 
bath applied at least 30 minutes before application of DHPG and kept in the solution 
throughout the recording to evaluate whether new protein synthesis was required for 
LTD. 
2.7.3 Intracellular recordings from hippocampal brain slices 
2.7.3.1 Intrinsic cell properties 
In order to examine CA1 pyramidal cell intrinsic properties, the following protocols 
were run after whole cell recording was established in P13 - 15 and P26 - 30 male 
and female rats.  The recording electrodes were filled with potassium gluconate 
internal solution comprising (in mM) K gluconate 120, KCl 20, HEPES 10, NaCl 4, 
Mg ATP 4, Na3GTP 0.3, sodium phosphocreatine 10.  Firstly, 1 minute of gap-free 
recording was made in I=0 mode.  The recording was switched to current clamp and 
the bridge balance was adjusted.  Next a -250 pA hyperpolarising step was applied in 
triplicate in current clamp in order to calculate the sag, followed by a series of 25 pA 
current steps from -100 pA to +400 pA again in triplicate to investigate action 




2.7.3.2 Excitatory and inhibitory current recordings 
In order to examine the excitatory – inhibitory balance in hippocampal pyramidal 
CA1 neurons, spontaneous and miniature post synaptic currents were recorded from 
male and female P13-15 and P26-30 rats as follows.   
 
The recording electrodes were filled with caesium gluconate internal solution 
comprising (in mM) Caesium gluconate 140, CsCl 8, HEPES 10, EGTA 0.2, Na 
ATP 2, Mg ATP 2, Na3GTP 0.3.  Following the establishment of whole cell 
recording, the cell was initially held at -70 mV and recordings of spontaneous 
excitatory post-synaptic currents (sEPSCs) were made for 4 minutes.  The access 
resistance was monitored throughout using a hyperpolarising step every 1 minute.  
The holding potential was then changed to 0 mV and the cell was left for 4 minutes 
to adapt to this.  Spontaneous inhibitory postsynaptic currents (sIPSCs) were then 
recorded for 4 minutes.   
 
0.3 µM tetrodotoxin (TTX, supplied by Tocris) was added to the external recording 
solution to unmask miniature currents and the holding potential was returned to -70 
mV.  After 5 minutes stabilisation time, 4 minutes of miniature excitatory post-
synaptic currents (mEPSCs) were recorded.  The holding potential was then once 
again adjusted to 0 mV and after 4 minutes of adjustment time, 4 minutes of 
miniature inhibitory post-synaptic currents (mIPSCs) were recorded. 
 
The receptors mediating each part of the recordings were established by the abolition 
of the current with the addition of 10 μM 1,2,3,4-Tetrahydro-7-nitro-2,3-
dioxoquinoxaline-6-carbonitrile disodium (CNQX, Abcam), an AMPA/Kainate 
receptor antagonist to excitatory recordings and 100 µM picrotoxin (PTX, GABA-A 
receptor antagonist consisting of a 1:1 mixture of picrotoxinin and picrotin from 
Abcam or Hello Bio) to inhibitory recordings.  
2.7.3.3 AMPAR / GABAR and AMPAR / NMDAR ratios 
In P26-30 male and female rats, single 0.1 Hz current pulses were delivered every 6 
seconds to the Schaffer collateral axons using a DS3 Isolated Constant Current 
Stimulator (Digitimer Ltd) and a bipolar electrode made from nickel / chromium 
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(80%/ 20%) wire.  The recording electrodes were filled with caesium gluconate 
internal solution comprising (in mM) Cs gluconate 140, CsCl 3, HEPES 10, EGTA 
0.2, Na ATP 2, MgATP 2, Na3GTP 0.3 and QX-314 5 (Abcam).  QX-314 is a Na
+
 
channel blocker added to the internal to improve the voltage space clamp.  The 
stimulation required to produce a reliable current response of a minimum of 
approximately 100 pA amplitude at 0 mV was identified using steps of increasing 
stimulation (typically in the region of 40 μA to 1 mA).   This was because prior to 
doing this, several cells were successfully recorded from at -70 mV, but when the 
holding potential was changed to 0 mV there was insufficient response to record 
inhibitory post-synaptic currents (IPSCs).  The chloride reversal potential was 
identified by recording excitatory post-synaptic currents (EPSCs) with gradually 
more positive holding potentials from -70mV until clean, monosynaptic events were 
seen.  The chloride in the internal solution was restricted to 8 mM and using the 
Nernst equation, the predicted chloride reversal potential at 32°C was -73.21 mV.  
The measured chloride reversal potential ranged from -58 mV to -68 mV.   Once it 
had been identified, 30 consecutive EPSCs were then recorded at the chloride 
reversal potential.  This ensured that all negative deflecting events were α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor mediated. 
 
The AMPA reversal potential was then identified using gradually more positive 
holding potentials from -10 mV until a clean monosynaptic response was identified.  
30 IPSCs were then recorded.  75 - 100 µM PTX was then applied and this abolished 
the current demonstrating these responses were γ-Aminobutyric acid receptor 
(GABAR) mediated.   
 
The cell was then held at +40 mV and 30 EPSCs were recorded.  In a subset of 
recordings this current was altered by the application of 10 μM CNQX, an AMPA / 
Kainate receptor antagonist and / or 50 μM D-(-)-2-Amino-5-phosphonopentanoic 
acid (D-AP5, Abcam), a selective NMDA receptor antagonist.  The application of 
both drugs together abolished the current.  The holding potential was changed to -70 
mV and a further 30 AMPAR mediated EPSCs were recorded.  These responses 
were abolished when CNQX was applied to a subset of cells.  Throughout the 
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recordings, the access resistance was monitored using a hyperpolarising step just 
before each 0.1 Hz pulse.   
 
2.7.4 Intracellular recordings from cultured neurons 
Once removed from the 37°C incubator at the time of recording, coverslips were 
continuously perfused at a flow rate of 3 - 5 ml / minute with external recording 
solution of the following composition (in mM) at room temperature (20-22°C): NaCl 
150, KCl 3, HEPES 10, CaCl2 2.5, MgCl2 1.3, glucose 10, glycine 0.05 plus 
tetrodotoxin 300 nM, picrotoxin 50 μM.  Magnesium was present in the external 
solution to ensure the voltage sensitive NMDA receptors were blocked so that any 




hippocampal recordings were made from DIV 13 to 15.  Recordings from cortical 
and hippocampal cultured Sprague-Dawley rat neurons transfected with SynGAP 
Isoform Eα1 were made from DIV 9 to 11 along with recordings from neighbouring 
control cells and cells from untransfected coverslips.  The internal solution was 
composed of (in mM) Cs Gluconate 130, CsCl 10, HEPES 10, EGTA 0.1, glucose 
10, sodium phosphocreatine 10, Mg ATP 4 and Na3GTP 0.5.  Its pH was adjusted to 
7.3 using CsOH; aiming for an osmolarity of 285 - 295 mOsm. 10 minute mEPSC 
recordings were made from cells with a typical pyramidal shape in voltage clamp at -
70 mV.  During the recordings, the perfusion was turned off to minimise the artefact 
from the perfusion which could mask mEPSCs.  Hyperpolarising steps were 
programmed every minute to monitor the access resistance.  A maximum of 3 cells 
were recorded from on each coverslip and typically coverslips were discarded after 
being out of the incubator for recording for 45 minutes.  The number of cultures used 




Table 7 – Number of cultures that mEPSCs were recorded from  
Experiment Brain Region Number of Cultures 













2.8 Power calculations 
In general the experiments carried out in this thesis were exploratory being the first 
of their kind to compare WT to genetic mutants in a model of SynGAP mutation in a 
rat.  Even those experiments investigating parameters previously measured in mouse 
models of SynGAP haploinsufficiency were generally not direct replicates in the rat.   
Therefore using published data for power calculations wasn’t possible.  The 
exceptions were the LTD experiments and the SynGAP isoform mEPSC recording 
experiments.   
 
In the LTD experiments data from Barnes and colleagues Syngap
+/-
 mouse 
experiments was used for power calculation as very similar experimental procedures 
were employed (Barnes et al. 2015).  Taking Barnes’ data and aiming for an effect 
size of 0.05 and power of 0.8, 13 animals were found to be needed per group for 
standard LTD experiments.  For experiments comparing the effect of protein 
synthesis inhibition between genotypes 6 animals were found to be required per 
genotype group.   
 
For the SynGAP Eα1 isoform mEPSC recordings, there was no previously published 
Eα1 data to refer to.  Therefore power calculations were based on data from the 
unpublished thesis of Aoife McMahon, Centre for Integrative Physiology, University 
of Edinburgh (McMahon 2010).  This thesis formed the basis for McMahon’s 
subsequent paper which examined the influence of SynGAP isoforms Aα1, Bα1, 
Cα1, Aα2, Bα2 and Cα2 on mEPSC amplitude and frequency (McMahon et al. 
2012).  The most applicable data for the power calculations comes from cells 
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transfected with SynGAP isoforms Aα1, Bα1 and Cα1 as they have the same C 
terminal as those used in the current thesis (α1).  If McMahon’s SynGAP Aα1 data 
which showed the largest difference from the eGFP control is used, a group size of 
23 cells is predicted to be required in order to achieve an effect size of 0.05 and 
power of 0.8 in the Eα1 experiments.  However using her Cα1 data (which showed 
the smallest difference from eGFP controls), 127 per group would be required.  
These calculations are based on mEPSC amplitude data as McMahon presented log 
transformed data for mEPSC frequency and the raw values to make the calculation 
with weren’t available. 
 
The Biomath online power calculator was used for all the calculations described 
above (http://biomath.info/power/ttest.htm).   
 
2.9 Data analysis 
For all data sets, D’Agostino & Pearson normality tests were carried out.  If, for two 
group comparisons, both groups in the analysis passed the normality test (p value of 
> 0.05), parametric tests were used.  If not, non-parametric analysis was used.  
Following this rule, for the comparison of two data groups, either an unpaired t-test 
or Mann-Whitney test was used unless otherwise stated.  The tests used to compare 
more than two groups are detailed under the appropriate section below.   Significance 
was defined as p < 0.05 throughout and all analyses, example traces and graphs were 
carried out or constructed using Graphpad Prism for Windows software (GraphPad 
Software).  Full details of the statistical tests and results are presented in the figure 
legends rather than the main text of this thesis.  In electrophysiological recordings 
where more than one cell or slice was recorded from per animal/ pup, the data has 
been collated by both cell/ slice and animal/ pup. 
2.9.1 Field recording analysis 
The acquired data was exported to Microsoft Excel 2010 and plotted in Graphpad 
Prism for Windows (GraphPad Software).  Traces in which there had been an 
identifiable technical issue were discarded.  Mean long-term depression was 
calculated as the mean slope (mV / ms) value of the characteristic field potential of 
the first of the paired pulses, every thirty seconds for the last 10 minutes of the trace.  
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Slope was used as a measure rather than amplitude so that the measurement wasn’t 
contaminated by population spikes. 
2.9.2 Intrinsic cell properties analysis 
Recordings were examined post-hoc and discarded if the resting membrane potential 
was more positive than -50 mV, or if the appearance of the action potential spikes 
was either indicative of a non-pyramidal cell type (e.g. fast spiking interneuron) or of 
the series resistance being too high (i.e. spikes with a notably short amplitude). 
 
The following properties were analysed in Clampfit Version 10.6.2.2 (Molecular 
Devices LLC): 
 Cells had mistakenly been held at -70 pA rather than -70 mV and so baseline 
voltage was calculated from the first 5 current steps (all sub-threshold).  All cells 
with a baseline voltage more positive than -64 mV or more negative than -76 mV 
were excluded to improve the homogeneity of the data   
 Resting membrane potential was calculated by taking the mean amplitude of the 
one minute gap-free recording   
 Input resistance was calculated from the first 5 current steps (all sub-threshold) 
by comparing the mean voltage recorded during the baseline 200 ms and 200 ms 
of each step.  This was then plotted and linear regression of the slope was 
performed.  
 Membrane time constant was measured from the +25 pA step of the protocol as 
the cleanest curve fitting was achieved at this current injection.  A standard 
exponential curve was fitted by eye to the rising current and tau was 
automatically calculated by GraphPad Prism 
 Capacitance was calculated as membrane time constant divided by input 
resistance 
 Sag was calculated from the -250 pA steps by calculating the difference between 
the peak deflection and the steady state of the step 
 Action potential properties were calculated at the first step at or after rheobase 
(i.e. the first current step with any action potentials).  The first action potential 
generated was used for analysis and its trace was differentiated to give the change 
in voltage over the change in time (dV / dt).  The point at which dV / dt exceeded 
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10 mV / ms was therefore identifiable and taken as the start of the action 
potential.  Action potential threshold was measured here and the other action 
potential properties that were then calculated by the software were peak 
amplitude, half-width, maximum rise slope and  maximum decay slope 
 Action potentials per step were counted for each current step 
 
2.9.3 Analysis of mEPSC recordings from SynGAP_GAP deletion rat 
cultures 
The access resistance (Ra) was examined and portions of the trace with Ra > 30 MΩ 
or a > 20% variation in Ra were discarded.  If at least 4 minutes of consecutive trace 
remained, further analysis was completed.  The traces were analysed using the 
template detection setting in Clampfit Version 10.6.2.2 (Molecular Devices LLC).  
An initial template was constructed by identifying the first fifteen exemplar events of 
the recording.  This was then used to detect events throughout the trace.  The final 
minute of the recording was then visually examined and true events were identified 
as those with a fast rise time and asymmetric appearance.  The Template Match 
Threshold of the template detection was adjusted to ensure true events were being 
captured whilst still avoiding false-positives.  Data was gathered from 3 separate 
cultures for these experiments and for the second two, as the experimenter, I was 
blind to genotype during recording.  For all three cultures I was blind to genotype 
whilst analysing the files.   
 
The recordings for the three genotypes (WT, heterozygous and homozygous) did not 
all pass a Shapiro-Wilk Normality Test and so were analysed using a Kruskal-Wallis 
test.  Significance was defined as p < 0.05.  
2.9.4 Excitatory-inhibitory balance analysis 
The access resistance (Ra) was examined and portions of the trace with Ra > 30 MΩ 
or a > 30% variation in Ra were discarded.  If at least 3 minutes of consecutive trace 
remained, further analysis was completed.  The traces were analysed posthoc using 
the template detection setting in Clampfit Version 10.6.2.2 (Molecular Devices LLC) 




2.9.5 AMPAR / GABAR and AMPAR / NMDAR ratio analysis 
The traces were analysed posthoc using Clampfit Version 10.6.2.2 (Molecular 
Devices LLC).  Cells were discarded if the access resistance was >30 MΩ or if it 
varied by more than 20% during the recording.  The 30 EPSCs or IPSCs in each 
recording were averaged and the baseline for the average trace adjusted.    For 
AMPAR / GABAR ratios each average event was integrated to give the total charge 
transfer.  The AMPA charge transfer was then divided by the GABA charge transfer 
in Microsoft Excel 2010.  For AMPAR / NMDAR ratios, the peak of the traces 
recorded at -70 mV was divided by the average amplitude from 80-85 ms post 
stimulus of the traces recorded at +40 mV.  80 – 85 ms post stimulus was chosen as 
by this time in the -70 mV recordings, all the AMPA traces had decayed to < 3% of 
their peak amplitude, so the contribution of the AMPA receptors to the response at 
80 - 85 ms post stimulus in the +40mV traces was minimal.   
2.9.6 SynGAP isoform Culture mEPSC recording analysis 
The access resistance (Ra) was examined and portions of the trace with Ra > 30 MΩ 
or a > 20% variation in Ra were discarded.  Further analysis was completed using 
Minianalysis Version 6 Software (Synaptosoft Inc.). Root mean squared (RMS) 
noise was analysed and portions of the trace with noise > 4 RMS were excluded.  If 
at least 5 minutes of consecutive trace remained, for the majority of files the 
software’s in built AMPA EPSC detection template was used to identify mEPSCs, 
for the remainder settings were manually adjusted to try and capture true events 
whilst excluding false positives.  The extracted events were then manually reviewed 
to ensure they were fast rising and asymmetric.  Any anomalous events were 
discarded and missed events added and the final pool of identified events was filtered 







3 CHAPTER THREE: GENERATION OF THE 
SYNGAP_GAP DELETION RAT 
 
3.1 Key findings 
 Exons 8 to 12 inclusive are deleted in the Syngap gene in the SynGAP_GAP 
deletion rat model.  This is predicted to encompasses the C2 and GAP 
domains of the protein 
 SyngapGAP/GAP rats are smaller than their littermates and homozygosity of the 
mutant SynGAP allele is fatal in the first few days of life 
 Hippocampal WT SynGAP protein expression in the SynGAP_GAP deletion 
rat colony increases from P7 to P28, whereas mutant protein increases from 
P7 to P14 before stabilising by P28 
 WT and mutant SynGAP protein are both expressed in visual and 
hippocampal brain tissue at P20 and can be detected with all four existing 
SynGAP isoform antibodies 
 
3.2 Introduction 
Although there are several mouse models of SynGAP haploinsufficiency in 
existence, the greater intelligence and sociability of the rat (editorial by Iannaccone 
& Jacob 2009; Kummer et al. 2014) is advantageous when conducting research 
related to ID and ASD, as explained in the introduction to this thesis.  On this 
premise, the SynGAP_GAP deletion rat was engineered and this chapter pertains to 
its generation using Zinc Finger Technology and confirmation of the mutation using 
genotyping, mRNA analysis and western blotting.  The rationale for deleting the 
GAP domain of the SynGAP protein comes from the multitude of studies that have 
linked the GAP domain function to SynGAP’s ability to regulate downstream 
signalling events (Chen et al. 1998; Kim et al. 1998; Krapivinsky et al. 2004; 
Vazquez et al. 2004; Rumbaugh et al. 2006; Pena et al. 2008; Walkup et al. 2015).   
Confirmation of the genetic abnormality in the rats was the first priority as 
understanding exactly what the disruption to the SynGAP protein was formed the 
basis for the interpretation of all other findings in this thesis.  Thereafter, assessment 
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of the general characteristics of the SynGAP_GAP deletion rat pups was important 





mice.   
3.2.1 SynGAP mouse models 
The first SynGAP mutant mice were generated by Komiyama et al. 2002 by 
disrupting the C2 and GAP domains of the protein in C57BL/6 mice with a vector 
comprised of a hemagglutinin (HA) epitope tag, internal ribosomal entry site, lacZ 
gene and polyA tail.  Kim et al. 2003 also generated a SynGAP mouse line by 
disrupting exons 7 and 8 (part of the PH and part of the C2 domain) with a neo
R
 
cassette again in C57BL/6 mice.  This site was chosen as it is the first common 
methionine site in the shortest SynGAP isoform (SynGAP C) and the resulting mice 
have low levels of SynGAP remaining at approximately 120 kDa on immunoblotting 
whereas the other mouse models have no SynGAP remaining.  Vazquez et al. 2004 
inserted a Neo cassette flanked by LoxP sites into intron 3 of the SynGAP gene and 
an additional downstream LoxP site within intron 9.  Therefore expression of Cre 
recombinase results in deletion of SynGAP exons 4 to 9 (part of the PH domain, the 
C2 domain and a portion of the GAP domain) in this model which was backcrossed 
onto a C57BL/6 background.  The design of the SynGAP_GAP deletion rat was such 
that the C2 and GAP domains of the protein would be lost, similar to the Komiyama 
mouse model. 
 
 From a breeding and development point of view, the inheritance of their SynGAP 
mouse lines was found by Komiyama et al. 2002 and Kim et al. 2003 to follow a 
Mendelian pattern and heterozygotes were fertile and developed without overt signs 
of abnormality.  However Syngap
-/- 
pups died, mostly within 48 hours of life 
(Komiyama et al. 2002; Kim et al. 2003; Vazquez et al. 2004; Porter et al. 2005; 
Knuesel et al. 2005).  Vazquez et al. 2004 observed them to be initially smaller in 
size at P0 than their littermates and to appear to fail to thrive in comparison with 
their heterozygous and WT littermates.  They were noted to weaken and to display 
impaired motor skills and trembling before death.  In contrast, homozygous cultured 





It is predicted that deleting a portion of the SynGAP protein in rats will lead to death 
in homozygotes.  It is also predicted that the mutant SynGAP will be present in 
various brain regions including the hippocampus and will be found to be comprised 
of multiple SynGAP isoforms when examined by western blotting. 
 
3.4 Results 
3.4.1.1 Confirmation of the mutation 
Genotyping of heterozygous SynGAP_GAP deletion rats revealed bands of the 
predicted size, namely ~600 bp for assay 1 (to detect the absence of the deletion) and 
~400 bp for assay 2 (to detect a WT band) (Figure 11).  mRNA extracted from an 
adult heterozygous SynGAP_GAP deletion rat was converted to cDNA and 
amplified with PCR.  As Figure 12 shows, the resultant band was faint and 
sequencing of it was unsuccessful.  The PCR product was therefore re-amplified 
before being cleaned up and sent for Sanger sequencing at Edinburgh Genomics. The 
sequence confirmed that the SynGAP_GAP deletion mutant rats have a deletion 
encompassing exons 8 to 12 of the Syngap gene resulting in a truncated protein, 















Figure 11- Genotyping of SynGAP_GAP deletion rats. 
 
Syngap+/GAP (left) and WT (WT) (right) rat genotyping with assays 1 and 2 for each. 
 
In the absence of the deletion, the distance between the Assay 1 primers is too long to amplify.  
Therefore Assay 1 is only positive in heterozygotes and homozygotes.  As the primers for Assay 2 are 
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Figure 12 – The amino acid deletion in the Syngap
+/GAP
 rats encompasses exons 8 to 12 of the 
SynGAP protein. 
 
(A) Bands show successful amplification of WT hippocampal and Syngap+/GAP whole brain samples. 
(B) Bands show successful re-amplification of the WT and Syngap+/GAP samples from panel (A) 
following further PCR amplification. 
(C) Amino acid sequence of the Syngap deletion in the Syngap+/GAP.  This corresponds to exons 8-12 
inclusive which is a deletion of 451 amino acids. 
(D) Schematic of the rat SynGAP protein.  The black line indicates the deletion in the SynGAP_GAP  
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3.4.2 Colony characterisation 
Of the first 120 pups born from WT (WT) – Syngap
+/GAP 
pairings, 56 were WT and 
64 were Syngap
+/GAP






 pairings were born, 
but 4 of these had one or more pups missing (presumed cannibalised) before samples 
could be taken for genotyping.  Of the 4 litters where the genotype for all pups was 
known, there were 9 WT, 17 Syngap
+/GAP
 and 11 Syngap
GAP/GAP
.  Therefore the 
breeding appears to follow a Mendelian pattern.  WT and Syngap
+/GAP
 pups were 
indistinguishable clinically with specifically no noticeable difference in activity 
levels in their home cages (although this wasn’t formally tested) in contrast to 
Syngap
+/- 
mice which are consistently noted to be hyperactive in comparison to WT 
mice (Guo et al. 2009; Muhia et al. 2009; Muhia et al. 2010; Muhia et al. 2012; 








 litter was closely observed due to the lethality of 
homozygosity in Syngap
-/-
 mice.  1 pup appeared ill (smaller and markedly less 
mobile than its littermates) at P2 and so it was culled along with an unaffected 
littermate for comparison.  The ill pup proved to be heterozygous and the littermate 
was WT.  All 9 remaining pups still appeared well at P10 when they were taken for 
western blot samples.  However, despite moving normally and apparently eating well 
(an abdominal milk spot was evident) 4 of the remaining 9 were much smaller than 







 litter proved to be somewhat of an anomaly as 






 pairings appeared to 
become ill or die in the first few days of life.  This is depicted in the survival plot in 
Figure 13. 
 
In accordance with the conditions of the UK government project licence granted 
under Animals (Scientific Procedures) Act 1986 that these animals were bred under, 
any ill animals had to be culled as soon as possible.  Therefore the survival plot 
includes animals that were culled because they looked as if they were ill or dying.  
Typically they had reduced head and limb movements, and no longer had a visible 
milk spot.  Furthermore, it wasn’t possible to capture the information about pups that 
were found to be missing (presumed cannabilised) as they had not yet been 
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genotyped.  The apparent death of animals at P10 is artificial as they were taken for 
experiments as described.   
 
89 pups from 10 litters were longitudinally weighed thrice weekly (Monday, 
Wednesday and Friday) from P1 to P23 (depending on which day of the week they 
were born).  The weights of heterozygote animals paralleled that of WTs in both 
genders.  When comparing all three genotypes at P10 (the point at which there was 
the most data for homozygous pups), a significant difference was found on a 1 way 




 rats (WT = 18.91 ± 0.57g, 
Syngap
+/GAP
 = 16.27 ± 0.53g and Syngap
GAP/GAP
 = 8.50 ± 0.29g; Figure 13).   
Although the numbers of homozygous pups was too small to pass a normality test, 
ANOVA was used rather than the non-parametric Kruskal-Wallis test as weight is 
well established as a normally distributed variable.   
 
As the genders of the one litter with P10 homozygous pups was not established, it 
wasn’t possible to determine definitively if this is due to sex differences.  However 
on comparing the P10 WT and Syngap
+/GAP
 rats for which gender was recorded, 
there was a significant difference due to genotype, but not gender on 2 way ANOVA 
analysis.  By P22 this effect had disappeared and there was no significant difference 
on a 2 way ANOVA test at this age between genotype nor gender (Animals from 3 
litters: WT males = 32.75 ± 6.047 g n = 4, WT females = 41.5 ± 2.446 g n = 6, 
Syngap
+/GAP
 males = 31.8 ± 5.285 g n = 5, Syngap
+/GAP
 females = 36.2 ± 1.535 g n = 
9; 2 way ANOVA with post hoc Bonferroni corrections for multiple comparisons, 
gender effect: F(1, 20)  = 0.3541, p < 0.0745; genotype effect: F(1, 20) = 0.7915, p = 
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Figure 13 – Syngap
GAP/GAP 
rats are smaller than their littermates and die in the first few days 
of life.  
 
(A) Survival plot showing mutant Syngap homozygosity was lethal in the first few days of life.  
One litter with 4 homozygotes survived until P10 at which point it was taken for experiments. 
   
(B) Male and (C) Female WT and Syngap+/GAP rats grow at a similar rate, but SyngapGAP/GAP 
littermates are smaller. 
 
 (D) The weights of pups from 6 litters at P10 were significantly different between genotypes (WT 
= 18.91 ± 0.573 g n = 22, Syngap+/GAP = 16.27 ± 0.53 g n = 26, SyngapGAP/GAP = 8.5 ± 0.29 g n = 4; 







3.4.3 Western blotting results 





P10 rats revealed two protein bands in heterozygotes corresponding to one WT allele 
at ~140 kDa (which is correct for WT SynGAP) and a mutant allele at ~ 90 kDa 
(Figure 14). The Bioinformatics Protein Molecular Weight Calculator 
(http://www.bioinformatics.org/sms/prot_mw.html) predicts the molecular weight of 
the deleted portion of amino acid sequence to be 40.27 kDa which is therefore in 
keeping with the difference in allele size on western blotting.  Crucially, no mutant 
SynGAP was detected in WT animals and no WT SynGAP in homozygotes.  
 
These blots also revealed the presence of SynGAP in both the neocortex and 
hippocampus in WT and heterozygous animals (Figure 14).  This is in keeping with 
studies showing that SynGAP is expressed strongly in the mouse cortex and 
hippocampus as well as at lower levels in the thalamus, amygdaloid complex, 
cerebellum, striatum, brainstem and olfactory bulb (Kim et al. 1998; Komiyama et al. 
2002; Tomoda et al. 2004; Porter et al. 2005; Moon et al. 2008).  
 
Furthermore, although the mutant allele band appeared less intense that that of the 
WT band in the mutant, it was not statistically hypomorphic as its intensity was not 
significantly different from the 50% normalised intensity which would be expected 
for one allele in a WT animal or 100% expected in homozygotes (Figure 14).  In 
hippocampal blots, the mutant band in Syngap
+/GAP
 animals was 19.73 ± 2.69% of 
WT and in Syngap
GAP/GAP
 it was 37.02 ± 3.39%.  The beta actin loading control was 
not significantly different between genotypes (WT = 5350.8 ± 48.4 n = 2, 
Syngap
+/GAP
 = 3839.8 ± 405.1 n = 3, Syngap
GAP/GAP
 = 4873.4 ± 294.4 n = 4, Kruskal- 
Wallis test p = 0.1556). 
 
In neocortex samples, the mutant was again not significantly different from the 50% 
intensity which would be expected for one allele in a WT animal (Figure 14).  As 
before, the beta actin loading control was not significantly different between 
genotypes (WT = 2399.4 ± 686.8 n = 2, Syngap
+/GAP
 = 2810.1 ± 233.5 n = 3, 
Syngap
GAP/GAP
 = 1890.2 ± 91.9 n = 4, Kruskal- Wallis test p = 0.1683). 
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Hippocampal SynGAP expression changed over the course of the first 28 days of 
life.  WT rat protein increased in abundance from P0 to P28, whereas Syngap
+/GAP
 rat 
mutant protein appeared to increase from P0 to P14 and then decrease somewhat by 
P28 (Figure 15).  However, closer inspection of the data and the original blot 
(Appendix 1) revealed that one heterozygous rat had markedly higher normalised 
protein levels at P14 due to having a considerably lower intensity β actin band.  
There was no obvious experimental error to account for this.  If this rat is excluded 
from the analysis, the levels of WT and mutant SynGAP in heterozygotes rise from 
P0 to P14 and are then maintained at a comparable level at P28 (with outlier 
excluded, P14: Syngap
+/GAP 
WT band = 27.7 ± 0.9% n = 2, Syngap
+/GAP 
mutant band 
= 17.5 ± 1.0% n = 2, At P28: WT = 100.0 ± 8.5% n = 3, Syngap
+/GAP 
WT band = 
23.5 ± 1.8% n = 3, Syngap
+/GAP 
mutant band = 16.7 ± 0.8% n = 3).  This data and the 
fact that the WT levels continued to rise at P28, suggests that SynGAP expression 
levels may peak later in the SynGAP_GAP deletion rats than in mice.  Porter et al. 
2005 found the expression of SynGAP in the mouse hippocampus peaked around 
post-natal day seven (P7) using X-gal staining to identify the β-galactosidase reporter 
gene which was introduced in this mouse model to monitor the cellular expression 
pattern of the SynGAP gene.  Porter’s study showed that SynGAP levels were then 
maintained throughout adulthood.  SynGAP mRNA transcripts in mice have been 
found to peak at P14 in both the hippocampus (Clement et al. 2012) and cortex  























Figure 14 – WT and mutant bands are seen on western blotting of the Syngap
+/GAP
 rat 
hippocampus and neocortex at P10.  
 
(A) Western blot labelled with pan SynGAP antibody which labels all SynGAP isoforms and 
normalised to the WT mean. WT band ~135-140 kDa and heterozygous band ~95-100 kDa. 
Hippocampus (WT band in WT = 100 ± 16.81% n = 2, WT band in Syngap+/GAP = 42.87 ± 6.14% 
n = 3, Mutant band in Syngap+/GAP = 19.73 ± 2.69% n = 3, Mutant band in SyngapGAP/GAP = 37.02 
± 3.39% n = 4; Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, 
actual median = 43.06, p = 0.5, Mutant band in Syngap+/GAP theoretical median = 50, actual 
median = 21.27, p = 0.25, Mutant band in SyngapGAP/GAP theoretical median = 100, actual median 
= 35.35, p = 0.1250). 
 
(B) Neocortex (WT band in WT = 100 ± 1.88% n = 2, WT band in Syngap+/GAP = 28.93± 3.90% n = 
3, Mutant band in Syngap+/GAP = 7.18 ± 1.11% n = 3, Mutant band in SyngapGAP/GAP = 22.65 ± 
1.87% n = 4; Wilcoxon Signed Rank Test: WT band in Syngap+/GAP theoretical median = 50, 
actual median = 30.33, p = 0.25, Mutant band in Syngap+/GAP theoretical median = 50, actual 
median = 6,79, p = 0.25, Mutant band in SyngapGAP/GAP theoretical median = 100, actual median = 
22.62, p = 0.1250). 
 
W T S y n g a p
+ /G A P
S y n g a p















































  W T   + /G A P   G A P /
                       G A P
W T
M u ta n t
W T S y n g a p
+ /G A P
S y n g a p














































W T  B a n d
M u ta n t B a n d
B
W T
M u ta n t
     W T   + /G A P  G A P /



























































W T  b a n d  in  W T
W T  b a n d  in S y n g a p
+ /G A P
M u ta n t B a n d  in S y n g a p
+ /G A P
P 0    P 7    P 1 4    P 2 8
W T
M utan t
Figure 15 – Hippocampal SynGAP protein levels in Syngap
+/GAP
 rats rise from P0 to P14 and then 
decrease by P28. 
 
Representative image shown is from heterozygous animals.  Western blot was labelled with pan SynGAP 
antibody which labels all SynGAP isoforms and values were normalised to WT at P28. WT bands ~135-
140 kDa and heterozygous band ~95-100 kDa. 
 
P0: WT = 12.6 ± 6.2% n = 2, Syngap+/GAP WT band = 8.0 ± 1.4% n = 3, Syngap+/GAP mutant band = 2.3 ± 
0.8% n = 3.  P7: WT = 39.8 ± 4.6% n = 3, Syngap+/GAP WT band = 16.0 ± 2.3% n = 3, Syngap+/GAP mutant 
band = 16.1 ± 6.6% n = 3.  P14: WT = 52.5 ± 6.1% n = 3, Syngap+/GAP WT band = 48.1 ± 20.4% n = 3, 
Syngap+/GAP mutant band = 30.1 ± 12.6% n = 3.  P28: WT = 100.0 ± 8.5% n = 3, Syngap+/GAP WT band = 





SynGAP expression at P20 was explored in the hippocampus and visual cortex using 
4 SynGAP antibodies which label different SynGAP isoforms - SynGAP A, SynGAP 
α1, SynGAP α2 and the antibody referred to as ‘pan SynGAP’ as it labels all known 
isoforms. 
 
All 4 antibodies labelled SynGAP in both the hippocampus (Figure 16) and visual 
cortex (Figure 17) confirming the presence of multiple SynGAP isoforms in the 
SynGAP_GAP deletion rat at P20.  The pattern of expression was similar throughout 
and at this age, the expression of the mutant allele was again not found to be 
statistically hypomorphic.  Several of the alleles in these blots show multiple bands 
which are indicative of different SynGAP isoforms.  No antibodies exist for SynGAP 
N terminal isoforms so exploring this further by western blotting is not possible at 
this time. 
 
Once again, there was no significant difference in β actin intensity across genotypes 
for any of the four antibodies (Table 8). 
 
Table 8 – Beta actin intensities for P20 hippocampus and visual cortex western blots 
Isoform 
Labelled 





Mann-Whitney test (P 
value) 
Hippocampus 




6460.4 ± 287.8 n = 3 5252.8 ± 929.4 n = 5 0.5714 
SynGAP 
alpha1 
7775.6 ± 321.7 n = 3 7325.6 ± 621.6 n = 5 0.3929 
SynGAP 
alpha2 
5898.2 ± 193.3 n = 3 6304.0 ± 619.1 n =  5 >0.9999 
Visual Cortex 




3660.2 ± 737.7 n = 3 2117.1 ± 539.8 n = 5 0.2500 
SynGAP 
alpha1 
2315.3 ± 16.1 n = 3 2240.1 ± 293.9 n = 5 0.7857 
SynGAP 
alpha2 




Figure 16 – The Syngap
+/GAP
 WT and mutant alleles include SynGAP A, α1 and α2 isoforms in 
the hippocampus at P20.  
 
All data is normalised to the mean WT value of that western blot.  WT bands ~135-140 kDa and 
heterozygous band ~95-100 kDa. 
 
(A) Schematic of the SynGAP protein with black line depicting the deletion in SynGAP_GAP 
deletion rat and labels showing the location of different antibody epitopes on the protein. 
 
(B) SynGAP A isoform N terminal antibody (WT band in WT = 100 ± 10.67% n = 3, WT band 
in Syngap+/GAP = 44.49 ± 7.91% n = 5, Mutant band in Syngap+/GAP = 30.8 ± 4.04% n = 5, 
Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual median = 
35.52, p = 0.4375, Mutant band in Syngap+/GAP theoretical median = 50, actual median = 
26.37, p = 0.0625). 
 
Legend continued overleaf… 
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Figure 16 legend continued… 
 
(C) Pan SynGAP antibody which labels all isoforms (WT band in WT = 100 ± 6.99% n = 3, WT 
band in Syngap+/GAP = 64.13 ± 2.06% n = 5, Mutant band in Syngap+/GAP = 46.87 ± 3.89% n 
= 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual 
median = 61.14, p = 0.0625, Mutant band in Syngap+/GAP theoretical median = 50, actual 
median =44.89, p = 0.6250). 
 
(D) SynGAP alpha1 isoform C terminal antibody (WT band in WT = 100 ± 10.30% n = 3, WT 
band in Syngap+/GAP = 49.77 ± 5.55% n = 5, Mutant band in Syngap+/GAP = 60.93 ± 5.87% n 
= 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual 
median = 51.77, p > 0.9999, Mutant band in Syngap+/GAP theoretical median = 50, actual 
median = 67.28, p = 0.3125). 
 
(E) SynGAP alpha2 isoform C terminal antibody (WT band in WT = 100 ± 7.21% n = 3, WT 
band in Syngap+/GAP = 58.97 ± 2.83% n = 5, Mutant band in Syngap+/GAP = 62.03 ± 4.32% n 
= 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual 
median = 57.02, p > 0.0625, Mutant band in Syngap+/GAP theoretical median = 50, actual 

















Figure 17 - The Syngap
+/GAP
 WT and mutant alleles include SynGAP A, α1 and α2 isoforms in 
the visual cortex at P20. 
 
All data is normalised to the mean WT value of that western blot.  WT bands ~135-140 kDa and 
heterozygous band ~95-100 kDa. 
 
(A) Schematic of the SynGAP protein with black line depicting the deletion in SynGAP_GAP 
deletion rat and labels showing the location of different antibody epitopes on the protein. 
 
(B) SynGAP A isoform N terminal antibody (WT band in WT = 100 ± 21.83% n = 3, WT band 
in Syngap+/GAP = 79.59 ± 27.53% n = 5, Mutant band in Syngap+/GAP = 60.44 ± 16.59% n = 5, 
Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual median = 
61.82, p = 0.4375, Mutant band in Syngap+/GAP theoretical median = 50, actual median = 
41.68, p > 0.999). 
 
Legend continued overleaf… 
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Figure 17 legend continued… 
 
(C) Note example image has been flipped horizontally to show WT on the left and Syngap+/GAP 
on the right. Pan SynGAP antibody which labels all isoforms (WT band in WT = 100 ± 
11.82% n = 3, WT band in Syngap+/GAP = 49.05 ± 7.71% n = 5, Mutant band in Syngap+/GAP 
= 22.85 ± 3.99% n = 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical 
median = 50, actual median = 40.97, p > 0.9999, Mutant band in Syngap+/GAP theoretical 
median = 50, actual median = 22.15, p = 0.0625). 
 
(D) SynGAP alpha1 isoform C terminal antibody (WT band in WT = 100 ± 13.46% n = 3, WT 
band in Syngap+/GAP = 41.39 ± 12.02% n = 5, Mutant band in Syngap+/GAP = 19.73 ± 7.04% n 
= 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual 
median = 33.21, p = 0.6250, Mutant band in Syngap+/GAP theoretical median = 50, actual 
median = 13.81, p = 0.0625). 
 
(E) SynGAP alpha2 isoform C terminal antibody (WT band in WT = 100 ± 12.69% n = 3, WT 
band in Syngap+/GAP = 42.08 ± 2.47% n = 5, Mutant band in Syngap+/GAP = 15.98 ± 0.90% n 
= 5, Wilcoxon signed rank test: WT band in Syngap+/GAP theoretical median = 50, actual 
median = 43.52, p > 0.0625, Mutant band in Syngap+/GAP theoretical median = 50, actual 









This chapter details basic characteristics of the SynGAP_GAP deletion rat.  The 
sequence of the deleted amino acids in the SynGAP protein was confirmed by 
extracting mRNA from homogenised brain tissue, converting it to cDNA and 
sequencing it using Sanger Sequencing.  This is a reliable method and the results 
were in keeping with the western blot experiments as the predicted molecular weight 
of the missing portion of protein corresponded with the difference in protein weight 
(kDa) between WT and mutant bands on western blotting.  The exons deleted 
correspond with the C2 and GAP domains of the protein, but it should be 
acknowledged that no formal testing was carried out to confirm the loss of these 
regions.  A GTPase assay in particular would be valuable to confirm that the 
enzymatic activity of the mutant SynGAP is lost in these rats. 
The general characterisation of the SynGAP_GAP deletion rat colony is in keeping 
with previous reports indicating that the development of Syngap
+/-
 mice is grossly 
similar to that of WT mice whereas homozygous mice do not develop well and die 
prematurely (Komiyama et al. 2002; Kim et al. 2003; Vazquez et al. 2004; Porter et 
al. 2005; Knuesel et al. 2005).  However, the details of the data in this current 
chapter raise a number of points of discussion as follows. 
3.5.1 Validity of the SynGAP_GAP deletion rat  
Engineering the SynGAP rats to have a deletion encompassing the C2 and GAP 
domains has construct validity in terms of investigating the role of different parts of 
the protein in the regulation of downstream signalling cascades.  However, does it 
have face validity for using the model to make inferences about human SYNGAP1 
ID?  The vast majority of people with mutations in SYNGAP1 have missense 
mutations rather than deletions in the protein (Mignot et al. 2016) and these are often 
found to result in truncation of the SynGAP protein (Hamdan et al. 2009; Hamdan et 
al. 2011; Berryer et al. 2013).  Only one person with a deletion limited to SynGAP 
(rather than encompassing other genes too) has been identified and has a deletion of 
Exons 1 to 9 (Mignot et al. 2016).  Therefore, the SynGAP_GAP deletion rat is 
likely to be more useful for assessing the function of the protein rather than as a 
direct comparison to human SYNGAP1 ID. 
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3.5.2 Why did the first litter of SyngapGAP/GAP pups live apparently healthily 
until P10 when later homozygous pups died earlier? 
As the first homozygous pups lived healthily for longer than those in subsequent 
litters they may have been anomalous.  In keeping with homozygotes from later 
litters they were noticeably smaller than their WT and heterozygous littermates 
(Figure 13) suggesting a detrimental effect of the mutation, but otherwise appeared 
well until they were taken for experiments at P10 unlike subsequent homozygous 
pups which sickened before this time.   It is possible that the SynGAP_GAP Deletion 
mutation was not present in every cell (i.e. they were mosaic for the mutation) of the 
first litter containing homozygotes, but this was not formally confirmed. 
 
3.5.3 Why was it not possible to be more specific about the age at which 
Syngap
GAP/GAP
 rats naturally die? 
As this was a newly genetically modified rat line, all litters that could include 
homozygous rat pups were monitored on a daily basis for any signs of pain, suffering 
or distress in light of the lethality of SynGAP homozygosity in mice.  In accordance 
with Animals (Scientific Procedures) Act 1986 licence conditions, pups were culled 
as soon as possible if these signs (typically identified by reduced limb or head 





 litter (later found on genotyping to include 4 
homozygotes) appeared healthy with no signs of distress.  They were therefore 
allowed to live until they were taken for western blot experiments at P10.  However, 
homozygous pups from subsequent litters became ill and died earlier than this 
(Figure 13).   
 
3.5.4 Limitations of the colony characteristics data 
Although it seems clear from the graphs in Figure 13  that there was little difference 
between WT and heterozygous pup weights, but homozygotes were smaller, it is 
acknowledged that using the ANOVA statistical test to compare the weights of pups 
from different genotypes is crude.  It does not take into account other variables that 
may influence pup weight such as the identity of the mother, how well she nursed her 
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pups, what the litter size was, whether any pups were lost early in life giving others 
access to proportionately more milk etc.  More in depth analysis of the pup 
characteristics could be carried out in the future using a Generalised Linear Mixed 
Model which could take these other factors into account.  However it is reassuring 
that similar to the pattern shown in the rats, Knuesel and colleagues found that 
Syngap
+/- 
conditional knock out mice in which the level of SynGAP was 40-50% of 
standard heterozygotes, were smaller than their littermates and also died prematurely 
(Knuesel et al. 2005). 
3.5.5 Limitations of the western blot data 
Western blotting of SynGAP_GAP deletion rat brain tissue repeatedly revealed two 
separate bands in the heterozygous rats which corresponded with the weight of the 
WT SynGAP protein (~135-140 kDa) and the predicted weight of the mutant 
SynGAP allele (~95–98 kDa).  Careful attempts were made to control the 
experimental conditions to allow semi-quantitative assessment of the amount of 
protein present in difference genotypes.  Firstly the mass of total protein in each 
sample was measured using a bicinchoninic acid assay (BCA) Protein Assay.  This is 
a colorimetric assay which enables measurement of protein concentration in samples 
using a spectrophotometer.  This meant that the volume of sample required to load 10 
μg of protein into each lane could be calculated.  Secondly, a loading control protein 
was measured (β-actin).  The utility of a loading control is two fold 
1) It confirms the presence of protein in that lane 
2) It allows the abundance of the protein of interest to be normalised to the loading 
control which is believed to be relatively constantly expressed.  This enables 
comparisons of protein quantity to be made between different samples which 
may have been subject to differential loading errors or differential blot transfer 
(Aldridge et al. 2008) 
β-actin was the loading control chosen for the SynGAP_GAP deletion rat western 
blots and is one of the most commonly used (Li & Shen 2013).  The intensity of β-
actin signal was compared between WT and heterozygous rat samples to ensure that 
it did not vary between experimental conditions as some doubt has been cast on the 
premise that β-actin and other ‘housekeeping’ genes are constantly expressed in 
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different conditions (Dittmer & Dittmer 2006; Li & Shen 2013).  No significant 
difference was found between the intensity of β-actin in WT, heterozygous or 
homozygous rats which was reassuring.  However as β-actin is a high-abundance 
protein whereas the protein of interest (in this case SynGAP) is often less abundant, 
it may not be possible to detect variations in β-actin between samples in the small 
protein concentrations used in western blotting.  Therefore, it is not possible to be 
completely certain that the β-actin remained unchanged between genotypes.  
Furthermore, there appeared to be an anomalous data point in a heterozygous rat at 
P14 due to a considerably lower intensity β actin band as discussed in paragraph 
3.4.3 .     
 
Hence consideration should be given to repeating the western blots with larger 
numbers of samples (so that individual anomalies have less impact on the mean data) 
and using other methods of assessing the consistency of protein levels in each lane 
e.g. normalising to total protein concentration (Aldridge et al. 2008).   
 
The western blot data also reveals that at least 1 SynGAP N terminal isoform (A) and 
2 C terminal isoforms (α1 and α2) expressed in the hippocampus and visual cortex at 
P20  (Figure 16 and Figure 17).  Unfortunately further examination of N terminal 
isoforms is not possible using western blots as no antibodies exist to probe for them.   
 
3.6 Chapter summary 
Zinc finger techniques were used to modify the SynGAP gene in Long-Evans 
Hooded rats resulting in a deletion of 5 exons, including the portion of the gene that 
codes for the C2 and enzymatic GAP domains of the protein.  This results in 
homozygous rats that are smaller than their littermates and die in the first few days of 
life.  Western blotting revealed that the mutant SynGAP protein is present in the 
hippocampus, neocortex and visual cortex and is comprised of at least one N 
terminal and two C terminal isoforms (A, α1 and α2).  This model is likely to be 








4 CHAPTER FOUR: SYNGAP_GAP DELETION RAT 
ELECTROPHYSIOLOGICAL EXPERIMENTS 
 
4.1 Key findings 
 There is no significant difference in long-term depression between WT and 
Syngap
+/GAP
 rats including when new protein synthesis is inhibited 
 There is no significant difference in paired-pulse ratio in hippocampal fEPSP 
recordings between WT and Syngap
+/GAP
 rats 
 There is no significant difference in intrinsic properties at P13-15 or P26-30  
 There is a reduction in the frequency of mEPSCs in Syngap+/GAP hippocampal 
cultured neurons 
 At P13-15 sEPSCs and mEPSCs from Syngap+/GAP rats tended to be larger 
amplitude and higher frequency events 
 At P26-30 sEPSCs and mEPSCs from Syngap+/GAP rats tended to be of larger 
amplitude, but were less frequent than in WTs 
 At P26-30 there were no significant differences between AMPAR / GABAAR 
and AMPAR / NMDAR ratios in Syngap
+/GAP
 rats compared to WT rats 
4.2 Introduction 
Electrophysiology has revealed differences in hippocampal long-term depression 
(LTD) and excitatory-inhibitory balance in previous models of SynGAP 
haploinsufficiency and the experiments in this chapter explore these in the 
SynGAP_GAP deletion rats.   
4.2.1 Long-term depression, SynGAP and intellectual disability 
The link between LTD and neuropsychiatric disorders came with the observation that 
hippocampal mGluR LTD was exaggerated and independent of new protein 
synthesis in a mouse model of Fragile X Syndrome (FXS), a single gene cause of ID 
and ASD in humans (Huber et al. 2002).  This led to the mGluR Theory of FXS 
(Bear et al. 2004) which described Fragile X Mental Retardation Protein (FMRP), 
the protein missing in FXS, as normally functioning as ‘a brake’ on the synthesis of 
new synaptic proteins  which stabilise LTD following stimulation of Group 1 
mGluRs; therefore in its absence LTD was exaggerated.   
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Aberrations in mGluR mediated hippocampal plasticity have now been identified in 
other rodent models of neurodevelopmental disorders that lead to ID, ASD and 
epilepsy phenotypes in humans including Tuberous Sclerosis and Rett Syndrome 
(reviewed by Senter et al. 2016).  Most topically for this thesis, exaggerated mGluR 
dependent LTD has been identified in the CA1 of the hippocampus in Syngap
+/-
 mice 
between the ages of P26-P32 (Barnes et al. 2015).  This is felt to phenocopy the 
exaggerated LTD in FXS as Syngap
+/-
, like FMRP acts on the ERK/MAPK 
biochemical pathways.  This mGluR dependent form of LTD was not seen in adult 
Syngap
+/-
 mice (Komiyama et al. 2002; Kim et al. 2003), but impairments in NMDA 
induced LTD were identified in 6 to 12 week old Syngap
+/-
  mice (Carlisle et al. 
2008). 
 
It is well established that new protein synthesis is required for the successful 
maintenance of mGluR hippocampal LTD in WT animals (Huber et al. 2000).  
However this new protein synthesis was not required for LTD maintenance in a 
mouse model of Fragile X Syndrome (Nosyreva et al. 2006), nor in Syngap
+/-
 mice 
(Barnes et al. 2015).  It is therefore postulated that dysregulation of metabotropic 
glutamate/ ERK dependent protein synthesis may be a common feature of a subset of 
neurodevelopmental disorders (Barnes et al. 2015). 
4.2.2 Excitatory Inhibitory Balance in SynGAP 
It has been proposed that ASD in humans could result from an increased ratio of 
excitation/inhibition (E/I) in various systems in the brain (reviewed by Rubenstein & 
Merzenich 2003).  This would also help to explain the overlap between ASD and 
epilepsy which is thought to arise due to a relative excess of excitation over 
inhibition.  As SynGAP haploinsufficiency in humans is associated with ASD and 
epilepsy and SynGAP is known to regulate excitatory pathways (e.g. ERK/MAPK), 
this theory is of relevance and interest when investigating pre-clinical models of 
SynGAP mutations.  There is mounting evidence of exaggerated excitation in 
SynGAP haploinsufficiency from the whole organism level down to specific cellular 
functions.  Syngap
+/-
 mice, both those that are globally haploinsufficient and a model 
in which SynGAP is knocked down only in forebrain excitatory glutamatergic 
neurons have been shown to have reduced seizure threshold (Clement et al. 2012; 
117 
 
Ozkan et al. 2014).  At a network level, photostimulated signals from the dentate 
gyrus have been shown to be progressively attenuated in WT animals, but not in 
Syngap
+/- 
mice (Clement et al. 2012) and signals from Syngap
+/- 
mice were 
significantly larger than those from WT mice on fast voltage-sensitive dye imaging 




 mouse cultures increased hippocampal and forebrain mEPSC frequency 
(Vazquez et al. 2004; Rumbaugh et al. 2006) and hippocampal mEPSC amplitude 
(Vazquez et al. 2004) have been shown.  In Syngap
+/-
 mice, an increased AMPA / 
NMDA ratio has been found in thalamocortical slices at P5 and in mPFC slices at P8 
(Clement et al. 2013) and increases in mEPSC amplitude and frequency in Syngap
+/- 
mice > 9 weeks of age (but not at P14) in layer 2/3 pyramidal neurons of the mPFC 
have been observed (Ozkan et al. 2014).  When SynGAP haploinsufficiency was 
induced in adult mice using a Cre-LoxP system the amplitude of spontaneous EPSCs 
was shown to be smaller, but their frequency increased (Muhia et al. 2012). 
 
Ozkan et al. also found that mPFC layer 2/3 neurons were hyperexcitable in response 
to evoked neurotransmitter release in Syngap
+/-
 mice and that the excitatory / 
inhibitory balance was shifted towards excitation when isolated excitatory and 
inhibitory currents were measured.  Moreover they examined the inhibitory function 
and found a decrease in mIPSC amplitude in adult Syngap
+/- 
mice and significantly 
decreased firing rate of parvalbumin positive (PV+) cells at 6 weeks (but not P14 or 
9 weeks) of age.   
 
Clement et al. 2012 examined hippocampal function in Syngap
+/- 
mice and found that 
at ~P14 there were increases synaptic transmission (as measured by medial perforant 
path field EPSPs), the ratio of AMPA / NMDA currents in dentate gyrus granule 
neurons (and the AMPA / NMDA current ratio in a Cre LoxP model of induced 
haploinsufficiency) and in mEPSC amplitude and frequency at P14 all of which 
normalised by P21.  They also identified a significant increase in mIPSC frequency 
and amplitude at P14 and felt this might be a compensatory response to the increase 
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in excitation.  Furthermore the intrinsic excitability of dentate gyrus neurons was 
increased in heterozygotes at P8-9 but had resolved by P14. 
 
With regards to inhibitory function, mice with SynGAP haploinsufficiency 
selectively in inhibitory cells originating from the medial ganglionic eminence [PV+ 
and Somatostatin+ (SST+) cells], have significantly longer mIPSC mean inter-event 
intervals in layer 2-3 pyramidal cells in the somatosensory cortex and hippocampal 
CA1 pyramidal cells (Berryer et al. 2016).  Targeted expression of the light sensitive 
Channel rhodopsin-2 via Cre also revealed reduced amplitude of evoked IPSCs in 
Layer 5 pyramidal cells.  Both findings are suggestive of a shift towards excitation.  
However in contrast to these mice, there was no significant difference in mIPSC 
inter-event interval in germ-line deletion of SynGAP (i.e. in Syngap
+/-
 mice), which 
the authors felt could be due to compensatory developmental changes. 
 
Manipulation of SynGAP expression in cultured neurons also lends support to the 
hypothesis that there is a shift towards excitation in conditions of reduced SynGAP 
expression.  A significant increase in mEPSC amplitude was recorded following 
knockdown of alpha SynGAP in DIV 11-16 cultured cortical neurons which could be 
rescued by co-expression of WT SynGAP (Wang et al. 2013).  Overexpression of 
GFP-tagged SynGAP (Cα1isoform) resulted in a marked decrease in both amplitude 
and frequency of AMPAR mediated mEPSCs (Rumbaugh et al. 2006).  However 
deletion of the C terminal portion of SynGAP including the PDZ binding domain and 
also separate mutation of the GAP domain resulted in no difference in amplitude and 
frequency from untransfected neurons.  This therefore implies the need for a 
functioning GAP domain and the ability to interact via its PDZ binding domain for 
SynGAP to influence mEPSC frequency and therefore excitatory function. 
The data presented here from the SynGAP_GAP deletion rats mainly focusses on 





Taken together, the research presented above leads to the hypothesis that in 
Syngap
GAP/GAP
 rats there will be an increase in mEPSC amplitude and frequency.  In 
Syngap
+/GAP
 rats, there will be exaggerated protein synthesis independent mGluR 
mediated hippocampal LTD and changes in cellular and synaptic function indicative 
of increased excitability.   
4.3 Results 
4.3.1 Long-term depression recordings in acute hippocampal slices 
mGluR LTD in the CA1 of the hippocampus of SynGAP_GAP deletion rats was 
induced between P26-30 by bath application of the mGluR agonist DHPG (100 μM) 
to horizontal hippocampal slices for 5 minutes.  For some animals results were 
available for more than one slice, but no significant difference was found between 
WT and Syngap
+/GAP 
slices regardless of whether the unit of analysis was ‘animal’ 
(WT = 78.7 ± 3.1% n = 12, Syngap
+/GAP
 = 73.5 ± 3.3% - Figure 18) or ‘slice’ (WT = 
78.9 ± 3.3% n = 14, Syngap
+/GAP
 = 75 ± 3.4% - Figure 19).  The requirement for new 
protein synthesis for LTD maintenance was then examined by applying 100 µM 
cycloheximide (CHX) prior to the induction of LTD.  As was shown in Syngap
+/-
 
mice (Barnes et al. 2015) there was no significant difference in LTD between 
Syngap
+/GAP 
rats exposed to CHX and those that weren’t (Syngap
+/GAP
 = 72.8 ± 4.0%, 
Syngap
+/GAP
 CHX 72.7 ± 9.1% - Figure 20) this implies LTD in these rats is 
independent of new protein synthesis.  However, unexpectedly there was also no 
significant difference between WT rat slices with and without cycloheximide (WT 
82.4 ± 2.3%, WT CHX 89.9 ± 4.8% - Figure 20) and therefore between the WT rats 
and Syngap
+/GAP
 rat slices exposed to CHX (WT CHX 89.9 ± 4.8%, Syngap
+/GAP
 
CHX 72.7 ± 9.1% - Figure 20).  This appears to be because WT rat LTD was also 
independent of new protein synthesis.  This significant confounder unfortunately 
prevents interpretation of the effect of the SynGAP mutation.    
 
Paired pulse facilitation was calculated from the pairs of fEPSPs stimulated 
throughout the LTD experiments.  No differences were seen between WT and 
Syngap
+/GAP
 rats (at baseline: WT = 1.5 ± 0.05, Syngap
+/GAP
 = 1.6 ± 0.04; after LTD: 
WT = 1.6 ± 0.05, Syngap
+/GAP
 = 1.7 ± 0.05, 2 way ANOVA with post hoc Bonferroni 
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corrections, LTD x genotype interaction: F(1, 28) = 1.234, p = 0.2760).  This is 
consistent with published findings in Syngap
+/-
 mouse hippocampal recordings at 
P14 (Clement et al. 2012) and in adulthood (Komiyama et al. 2002; Kim et al. 2003; 
Ozkan et al. 2014).  As alterations in PPF are indicative of pre-synaptic changes 
(Zucker 1973), this suggests there is no measurable difference in pre-synaptic 










Figure 18 – There is no significant difference in hippocampal mGluR LTD or PPR between P26-
33 WT and Syngap
+/GAP
 rats when the data is collated by animal. 
 
(A) WT and (B) Syngap
+/GAP
 example traces.  
(C) and (D) There is no significant difference in LTD induced with 100 µM DHPG between WT and 
Syngap+/GAP rats.  LTD was measured as the mean value between 70 and 80 minutes. (WT = 78.7 
±3.1% n = 12, Syngap+/GAP = 73.5 ± 3.3% n = 19, Mann-Whitney test p = 0.3889). 
 (E) and (F) Paired pulse ratio is facilitated after LTD, but there is no significant difference between 
WT and Syngap+/GAP rats.  (At baseline WT = 1.5 ± 0.05 n = 12, Syngap+/GAP = 1.6 ± 0.04 n = 18, after 
LTD WT = 1.6 ± 0.05 n = 12, Syngap+/GAP = 1.7 ± 0.05 n = 18, 2 way ANOVA with post hoc 
Bonferroni corrections for multiple comparisons, LTD effect: F(1, 28)  = 12.46, p < 0.0015; genotype 
effect: F(1, 28) = 1.289, p = 0.2659; LTD x genotype interaction: F(1, 28) = 1.234, p = 0.2760). 
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Figure 19 – There is no significant difference in hippocampal mGluR LTD or PPR between P26-
33 WT and Syngap
+/GAP
 rats when the data is collated by slice. 
 
 (A) WT and (B) Syngap+/GAP example traces. 
(C) and (D) There is no significant difference in LTD induced with 100 µM DHPG between WT and 
Syngap+/GAP rats.  LTD was measured as the mean value between 70 and 80 minutes. (WT = 78.9 ± 
3.3% n = 14, Syngap+/GAP = 75 ± 3.4% n = 24, Unpaired t test p = 0.4457).  
(E) and (F) Paired pulse ratio is facilitated after LTD, but there is no significant difference between 
WT and Syngap+/GAP rats.  (At baseline WT = 1.5 ± 0.05 n = 12, Syngap+/GAP = 1.6 ± 0.03 n = 23, after 
LTD WT = 1.6 ± 0.05 n = 12, Syngap+/GAP = 1.7 ± 0.04 n = 23, 2 way ANOVA with post hoc 
Bonferroni corrections for multiple comparisons, LTD effect: F(1, 33)  = 10.61, p < 0.0026; genotype 
effect: F(1, 33) = 0.8964, p = 0.3506; LTD x genotype interaction: F(1, 33) = 0.4712, p = 0.4972). 
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Figure 20 - There is no significant difference in LTD between Syngap
+/GAP
 and WT recordings 
when new protein synthesis is inhibited. 
 (A) WT and (B) Syngap+/GAP example traces in the presence of 100 µM CHX. 
(C) and (D) There is no significant difference in LTD between WT recordings with and without CHX 
(WT = 82.4 ± 2.3% n = 8, WT CHX 89.9 ± 4.8% n = 8, paired t-test  p = 0.1472). 
 (E) and (F) There is no significant difference in LTD between Syngap+/GAP recordings with and 
without CHX (Syngap+/GAP = 72.8 ± 4.0% n = 7, Syngap+/GAP CHX 72.7 ± 9.1% n = 7, Wilcoxon 
matched-pairs signed rank test = 0.8125). 
(G) and (H) There is no significant difference in LTD between WT and Syngap+/GAP recordings with 
CHX (WT CHX 89.9 ± 4.8% n = 8, Syngap+/GAP CHX 72.7 ± 9.1% n = 7, Mann-Whitney test p = 
0.1520).  
LTD was measured as the mean value between 70 and 80 minutes.  Data was collected from one drug 
free and one CHX slice per animal.   
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4.3.2 Intrinsic cell property recordings in acute hippocampal slices 
Intrinsic cell properties were examined by injecting a series of 25 pA current steps 
from -100 to +400 pA during CA1 pyramidal cell whole cell recordings in current 
clamp. 
 
There was no significant difference in resting membrane potential, membrane time 
constant, input resistance, or capacitance between WT and Syngap+/GAP recordings 
at P13-15 and P26-30 when the unit of analysis was ‘animal’ (Figure 21 and Figure 
25). Furthermore there was no significant difference in action potential properties or 
firing rate when the unit of analysis was ‘animal’ at either age (Figure 22, Figure 23, 
Figure 26 and Figure 27).  There was however a trend towards a higher input 
resistance in Syngap+/GAP recordings at P26-30 (Figure 25).  Perhaps with a larger 
sample size this would have become statistically significant.   Physiologically, with 
higher input resistance less current is required to elicit the same depolarisation of a 
neuron.  This would therefore represent a shift towards excitation.   
 
However, certain statistically significant differences were seen when the data was 
analysed with n = cell.  An increase in rheobase (WT = 125 ± 12.09 pA, 
Syngap+/GAP = 160.1 ± 7.674 pA, unpaired t test p = 0.0186) , maximum rise rate 
(WT = 226.7 ± 19.19 mV / ms, Syngap+/GAP =  316.9 ± 25.61 mV / ms, Mann-
Whitney test p = 0.0124) and maximum decay rate (WT = -65.49 ± 3.982 mV / ms, 
Syngap+/GAP  = -75.17 ± 3.164 mV / ms, Mann-Whitney test p = 0.0480) were 
observed in Syngap+/GAP rats at P13-15 (Figure 22).  At P26-30 an increase in 
membrane time constant (Figure 25 - WT = 12.83 ± 1.03 ms, n = 24, Syngap+/GAP 
= 14.29 ± 0.70 ms, unpaired t test p = 0.0481) and action potential half width (WT = 
0.94 ± 0.04 ms, Syngap+/GAP = 1.09 ± 0.05 ms, Unpaired t test p = 0.0135) and a 
decrease in action potential maximum decay rate (WT = -108.50 ± 4.11 mV / ms, 
Syngap+/GAP = -91.92 ± 4.78 mV / ms, unpaired t test p = 0.0119) (Figure 26) were 
seen in Syngap+/GAP rats.  This is likely to be a pseudo-replication effect as there is 
no significant difference when the unit of analysis is ‘animal’.  This means that the 
statistical interpretation of the data is inflated to significance because the use of n = 
cell fails to take into account the increased similarity and the lack of independence 
between cells from the same animal which introduces bias into the analysis (Lazic 
126 
 
2010; Sikkel et al. 2013).  I therefore believe the correct results are those analysed by 
n = animal.  Furthermore, the ‘significant’ differences seen when the unit of analysis 
is ‘cell’ are in the direction of inhibition over excitation as they would result in fewer 
action potentials in a given period of time (except for the increase in maximum rise 
rate at P13-15 and increase in maximum decay rate at P26-30) which is not in 
keeping with the published literature on SynGAP mutations.  Whilst clearly this is 
not a reason in itself to doubt the result, when considered alongside the lack of 
independence of multiple cells from individual animals this strikes me as a further 
illustration of the unhelpful effects of pseudo-replication. 
 
Hyperpolarising (-250 pA) current steps were injected into each cell in order to 
measure the ‘sag’ in current produced by the opening of hyperpolarisation-activated 
cyclic nucleotide-gated (HCN) channels.  This is of interest because HCN channels 
open in response to membrane hyperpolarisation and have roles in the maintenance 
of resting membrane potential, input resistance, dampening of synaptic potentials, 
neural oscillations and temporal dendritic summation (reviewed by Benarroch 2013; 
He et al. 2014). CaMKII and p38-MAPK pathways and glutamatergic signalling via 
both AMPA and NMDA receptors have been postulated as modulators of HCN 
channel expression and HCN channel dysfunction has been implicated in epilepsy 
(reviewed by He et al. 2014). Therefore given SynGAP’s link to epilepsy, its role in 
AMPA trafficking and its interactions with CaMKII and p38-MAPK it was possible 
that differences in sag would be identified between the rat genotypes.  However, no 
significant differences were found between the Sag in either age group when 
comparing WT and Syngap
+/GAP 
















































































WT shown in black, Syngap+/GAP shown in blue. 
 
(A) Resting membrane potential (analysed by n = animal: WT = -59.73 ± 1.518 mV, n = 6, 
Syngap+/GAP = -60.65 ± 1.113 mV, n = 4, Mann-Whitney test p = 0.6952; analysed by n = cell: 
WT = -59.53 ± 1.174 mV, n = 14, Syngap+/GAP = -60.77 ± 0.7521 mV, n = 15, Unpaired t test p = 
0.3766). 
(B) Input resistance (analysed by n = animal: WT = 111.4 ± 9.203 MΩ, n = 6, Syngap+/GAP = 103.7 ± 
26.26 MΩ , n = 4, Mann-Whitney test p = 0.4476; analysed by n = cell: WT = 106.4 ± 9.421 MΩ 
, n = 14, Syngap+/GAP = 103.5 ± 13.72 MΩ , n = 15, Unpaired t test p = 0.8644).  
(C) Membrane time constant (analysed by n = animal: WT = 15.81 ± 2.427 ms, n = 5, Syngap+/GAP = 
15.81 ± 2.203 ms, n = 3, Mann-Whitney test p = 0.7857; analysed by n = cell: WT = 15.56 ± 
1.479 ms, n = 1,2 Syngap+/GAP = 15.44 ± 0.9356 ms, n = 15, Mann-Whitney test p = 0.9436 ). 
(D) Capacitance (analysed by n = animal: WT = 153.8 ± 20.18 pF, n = 6, Syngap+/GAP = 171.4 ± 27.37 
pF, n = 4, Mann-Whitney test p = 0.7524; analysed by n = cell: WT = 156.1 ± 16.07 pF, n = 12, 
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WT shown in black, Syngap+/GAP shown in blue. 
 
(A) Current step protocol with 25 pA current steps from -100 pA to +400 pA 
(B) Representative traces of WT and Syngap+/GAP recordings.  
 




Figure 22 Legend continued… 
 
(C) Action potential threshold (analysed by n = animal: WT = -43.12 ± 1.89 mV n = 6, Syngap+/GAP  = 
-40.19 ± 1.17 mV n = 4 Mann-Whitney test p = 0.3524; analysed by n = cell: WT = -42.54 ± 
1.446 mV, n = 13, Syngap+/GAP  = -40.50 ± 0.8944 mV, n = 14 Unpaired t test p = 0.2340). 
 
(D) Action potential peak amplitude (analysed by n = animal: WT = 72.35 ± 3.10 mV n = 6, 
Syngap+/GAP = 78.93 ± 4.22 mV n = 4 Mann-Whitney test p = 0.2571; analysed by n = cell: WT 
= 72.59 ± 2.445 mV, n = 13, Syngap+/GAP = 75.17 ± 2.225 mV, n = 4, Unpaired t test p = 0.4411). 
 
(E) Action potential rheobase (analysed by n = animal: WT = 123.10 ± 17.31 pA n = 6, Syngap+/GAP = 
158.60 ± 9.48 pA n = 4, Mann-Whitney test p = 0.1524; analysed by n = cell: WT = 125 ± 12.09 
pA n = 14, Syngap+/GAP  = 160.1 ± 7.674 pA n = 13, Unpaired t test p = 0.0186). 
 
(F) Action potential half-width (analysed by n = animal: WT = 1.48 ± 0.13 ms n = 6, Syngap+/GAP = 
1.24 ± 0.08 ms n = 4, Mann-Whitney test p = 0.3333; analysed by n = cell: WT = 1.462 ±  
0.09969 ms n = 14, Syngap+/GAP  = 1.252 ± 0.07784 ms n = 14, Mann-Whitney test p = 0.1680). 
 
(G) Action potential maximum rise rate (analysed by n = animal: WT = 220.10 ± 21.25 mV / ms n = 
6, Syngap+/GAP = 305.20 ± 42.20 mV / ms n = 4, Mann-Whitney test p = 0.3333; analysed by n = 
cell: WT = 226.7 ± 19.19 mV / ms n = 13 , Syngap+/GAP  =  316.9 ± 25.61 mV / ms n = 14, Mann-
Whitney test p = 0.0124). 
 
(H) Action potential maximum decay rate (analysed by n = animal: WT = -64.97 ± 4.847 mV / ms n = 
6, Syngap+/GAP   = -76.92 ± 2.465 mV / ms n = 4, Mann-Whitney test p = 0.1714; analysed by n = 
cell: WT = -65.49 ± 3.982 mV / ms n = 13, Syngap+/GAP  = -75.17 ± 3.164 mV / ms n = 14, Mann-





























Figure 23 – There is no significant difference in action potential firing rate in Syngap
+/GAP
 rats 
compared to WT rats at P13-15. 
 
WT shown in black, Syngap+/GAP shown in blue. 
(A) Firing rate vs Input with data collated by n = animal (2 way ANOVA with post hoc 
Bonferroni corrections for multiple comparisons, current injection effect: F(16, 128)  =78.1 , p < 
0.0001; genotype effect: F(1, 8) = 1.677, p = 0.2314; current injection x genotype interaction: 
F(16, 128) = 1.479, p = 0.1171). 
 
(B) Firing rate vs Input with data collated by n = cell (2 way ANOVA with post hoc Bonferroni 
corrections for multiple comparisons, current injection effect: F(16, 400)  = 206.2, p < 0.0001; 
genotype effect: F(1, 25) = 2.396, p = 0.1342; current injection x genotype interaction: F(16, 400) 
= 1.521, p = 0.0886). 
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WT shown in black, Syngap+/GAP shown in blue. 
 
(A) Sag -250 pA step protocol applied 6 times for each cell.   
(B) WT (black) and Syngap+/GAP (blue) example traces. 
(C) Sag with n = animal (WT = 6.854 ± 0.5613%, n = 5, Syngap+/GAP = 5.967 ± 0.5479%, n = 3, 
Mann-Whitney test p = 0.3571), sag with n = cell (WT = 6.413 ± 0.4655%, n = 10, Syngap+/GAP = 


























































































WT shown in black, Syngap+/GAP shown in blue. 
(A) Resting membrane potential (analysed by n = animal: WT = -62.81 ± 0.96 mV, n = 8, 
Syngap+/GAP = -61.56 ± 1.68 mV, n = 8, unpaired t test p = 0.6454; analysed by n = cell: WT = -
63.78 ± 0.9171 mV, n = 31, Syngap+/GAP = -62.11 ± 1.102 mV, n = 23, Unpaired t test p = 
0.4447). 
(B) Input resistance (analysed by n = animal: WT = 63.3 ± 5.28 MΩ , n = 8, Syngap+/GAP = 72.70 ± 
6.63 MΩ , n = 7, Mann-Whitney test p = 0.3969; analysed by n = cell: WT = 63.97 ± 4.710 MΩ , 
n = 25, Syngap+/GAP = 73.57 ± 6.215 MΩ , n = 19, unpaired t test p = 0.2583).  
(C) Membrane time constant (analysed by n = animal: WT = 12.31 ± 0.99 ms, n = 8, Syngap+/GAP = 
13.67 ± 0.74 ms, n = 7, Mann-Whitney test p = 0.3357; analysed by n = cell: WT = 12.83 ± 1.03 
ms, n = 24, Syngap+/GAP = 14.29 ± 0.70 ms, n = 18, unpaired t test p = 0.0481). 
(D) Capacitance (analysed by n = animal: WT = 194.2 ± 17.34 pF, n = 8, Syngap+/GAP = 211.7 ± 26.13 
pF, n = 7, Mann-Whitney test p = 0.5358; analysed by n = cell: WT = 207.5 ± 13.75 pF, n = 24, 
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WT shown in black, Syngap+/GAP shown in blue. 
(A) Current step protocol with 25 pA current steps from -100 pA to +400 pA. 
(B) Representative traces of WT (black) and Syngap+/GAP (blue) recordings. 




Figure 26 legend continued… 
 
(C) Action potential threshold (analysed by n = animal: WT = -44.37 ± 1.68 mV n = 8, 
Syngap+/GAP = -44.21 ± 1.60 mV n = 7 Mann-Whitney test p = 0.9551; analysed by n = cell: 
WT = -44.01 ± 1.50 mV n = 25, Syngap+/GAP = -44.31 ± 1.27 mV n = 19 unpaired t test p = 
0.8833). 
 
(D) Action potential peak amplitude (analysed by n = animal: WT = 76.79 ± 2.839 mV n = 8, 
Syngap+/GAP = 78.1 ± 3.2 mV n = 7 Mann-Whitney test p = 0.5358; analysed by n = cell: WT 
= 78.40 ± 2.37 mV n = 25, Syngap+/GAP = 78.7 ± 2.49 mV n = 19 unpaired t test p = 0.9319). 
 
(E) Action potential rheobase (analysed by n = animal: WT = 193.3 ± 15.44 pA n = 8, 
Syngap+/GAP = 201.6 ± 24.43 pA n = 7, Mann-Whitney test p = 0.7983; analysed by n = cell: 
WT = 200.3 ± 11.47 pA n = 25, Syngap+/GAP = 196.1 ± 15.85 pA n = 19, unpaired t test p = 
0.8234). 
 
(F) Action potential half-width (analysed by n = animal: WT = 0.96 ± 0.03 ms n = 8, 
Syngap+/GAP  = 1.09 ± 0.07 ms n = 7, Mann-Whitney test p = 0.0939; analysed by n = cell: 
WT = 0.94 ± 0.04 ms n = 25, Syngap+/GAP  = 1.09 ± 0.05 ms n = 19, unpaired t test p = 
0.0135). 
 
(G) Action potential maximum rise rate (analysed by n = animal: WT = 345.3 ± 24.57 mV / ms n 
= 8, Syngap+/GAP  = 315 ± 34.51 mV / ms n = 7, Mann-Whitney test p = 0.3969; analysed by 
n = cell: WT = 365.20 ± 23.81 mV / ms n = 25, Syngap+/GAP  = 315.2 ± 22.98 mV / ms n = 
19, unpaired t test p = 0.1475). 
 
(H) Action potential maximum decay rate (analysed by n = animal: WT = -104.9 ± 3.84 mV / ms 
n = 8, Syngap+/GAP   = -92.69 ± 8.29 mV / ms n = 7, Mann-Whitney test  p = 0.0721; analysed 
by n = cell: WT = -108.50 ± 4.11 mV / ms n = 25, Syngap
+/GAP 
  = -91.92 ± 4.78 mV / ms n = 





























Figure 27 – There is no significant difference in action potential firing rate in Syngap
+/GAP
 rats 
compared to WT rats at P26-30. 
 
WT shown in black, Syngap+/GAP shown in blue. 
(A) Firing rate vs Input when analysed by n = animal (2 way ANOVA with post hoc Bonferroni 
corrections for multiple comparisons, current injection effect: F(17, 221)  = 95.43 p < 0.0001; 
genotype effect: F(1, 13) = 0.03826,  p = 0.8479 current injection x genotype interaction: F(17, 
221) = 0.1255, p > 0.9999). 
 
(B) Firing rate vs Input when analysed by n = cell (2 way ANOVA with post hoc Bonferroni 
corrections for multiple comparisons, current injection effect: F(17, 731)  = 213.5, p < 0.0001; 
genotype effect: F(1, 43) = 0.01825,  p = 0.8932 current injection x genotype interaction: F(17, 
731) = 0.1062, p > 0.9999). 
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Figure 28 – Current sag is not significantly different between P26-30 WT and Syngap
+/GAP
 rats.  
 
WT shown in black, Syngap+/GAP shown in blue. 
 
(A) Sag -250 pA step protocol applied 6 times for each cell. 
 
(B) WT (black) and Syngap+/GAP (blue) example traces. 
 
(C) Sag (WT = 4.324 ± 0.1974%, n = 5, Syngap+/GAP = 5.641 ± 1.572%, n = 3, Mann-Whitney 
test p = 0.5917), sag (WT = 4.171 ± 0.1914 %, n = 9, Syngap+/GAP = 5.752  ± 1.716%, n = 10, 
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4.3.3 mEPSC recordings in cultured neurons 
Due to the lethality of homozygous SynGAP mutation, the only way to examine 
electrical properties of homozygous neurons was to record from cultured neurons.  
Recordings were made in the presence of TTX (300 nM) and picrotoxin (50 μM) to 
block spontaneous, action potential driven activity in order to unmask the miniature 
events.  As Figure 29 shows, there is no difference in mEPSC amplitude across 
genotypes, which is illustrated by the cumulative distribution plots of the amplitude 
for each genotype as well as the histogram graphs.  The histograms also demonstrate 
the expected positive skew in mEPSC amplitude (Bekkers et al. 1990; McBain & 
Dingledine 1992; Wyllie et al. 1994). 
 





recordings revealed a significant difference when the 
unit of analysis was ‘n = pup’ (WT = 2.54 ± 1.44 Hz, Syngap
+/GAP 
= 0.58 ± 0.09 Hz, 
Syngap
GAP/GAP 
= 1.29 ± 0.21 Hz, Kruskal-Wallis test statistic 6.102, p = 0.0473) and 
also when the unit of analysis was ‘n = cell’ (WT = 2.02 ± 0.91, Syngap
+/GAP 
= 0.78 ± 
0.14 Hz, Syngap
GAP/GAP 
= 2.01 ± 0.51 Hz, Kruskal-Wallis test statistic 7.389, p = 
0.0249).   Dunn’s correction revealed on both analyses that the statistically different 
result on Kruskal-Wallis testing was due to heterozygous recordings having a 
significantly lower event frequency than recordings from homozygotes.  The 
cumulative distribution plots of the inter-event frequencies illustrate this difference 
(Figure 29).  
 
This finding of reduced frequency of mEPSCs in Syngap
+/GAP
 rat recordings which is 
evaluated in more detail in the discussion section below, is unexpected as previously 
an increase in frequency has been seen in Syngap
-/-
 mice (Vazquez et al. 2004; 
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Figure 29 legend: 
 
 (A) There is no significant difference in mEPSC amplitude between genotypes when the unit of 
analysis is ‘pup’ (WT = 15.5 ± 1.88 pA n = 8, Syngap+/GAP = 14.30 ± 0.80 pA n = 15, SyngapGAP/GAP = 
14.59 ± 0.91 pA n = 9, Kruskal Wallis Test with Dunn’s correction for multiple testing; Kruskal-
Wallis statistic 0.2057, p = 0.9023). 
 
 (B) There is a significant difference in mEPSC frequency between genotypes when the unit of 
analysis is ‘pup’ (WT = 2.54 ± 1.44 Hz n = 8, Syngap+/GAP = 0.58 ± 0.09 Hz n = 15, SyngapGAP/GAP = 
1.29 ± 0.21 Hz, n = 9, Kruskal Wallis Test with Dunn’s correction for multiple testing; Kruskal-
Wallis statistic 6.102, p = 0.0473.  Dunn’s testing: WT vs. Syngap+/GAP Mean Rank Difference 5.504, 
not significant; WT vs. SyngapGAP/GAP Mean Rank Difference -4.063, not significant; Syngap+/GAP vs. 
SyngapGAP/GAP Mean Rank Difference -9.567 significant). 
 
(C) There is no significant difference in mEPSC amplitude between genotypes when the unit of 
analysis is ‘cell’ (WT = 15.04 ± 1.34 pA n = 13, Syngap+/GAP = 14.56 ± 0.75 pA n = 24, SyngapGAP/GAP 
= 14.37 ± 0.85 pA n = 14, Kruskal Wallis Test with Dunn’s correction for multiple testing; Kruskal-
Wallis statistic 0.0101, p = 0.9950). 
 
(D) There is a significant difference in mEPSC frequency between genotypes when the unit of 
analysis is ‘cell’ (WT = 2.02 ± 0.91 Hz n = 13, Syngap+/GAP = 0.78 ± 0.14 Hz n = 24, SyngapGAP/GAP = 
2.01 ± 0.51 Hz, n = 14, Kruskal Wallis Test with Dunn’s correction for multiple testing; Kruskal-
Wallis statistic 7.389, p = 0.0249.  Dunn’s testing: WT vs. Syngap+/GAP Mean Rank Difference 5.569, 
not significant; WT vs. SyngapGAP/GAP Mean Rank Difference -8.005, not significant; Syngap+/GAP vs. 
SyngapGAP/GAP Mean Rank Difference -13.57 significant). 
 
(E) mEPSC Amplitude and (F) mEPSC frequency cumulative frequency distributions.  
 
(G) WT, (H) Syngap+/GAP and (I) SyngapGAP/GAP recordings display the typical positively skewed 
distribution that is expected in mEPSC recordings (WT median = 15.05, WT mean = 17.28 pA, 
Syngap+/GAP median = 14.01 pA, Syngap+/GAP mean = 16.20 pA, SyngapGAP/GAP median = 13.79 pA, 






4.3.4 Excitatory and inhibitory recordings in acute hippocampal slices 
To investigate excitatory and inhibitory currents, recordings were made from 
pyramidal cells in acute hippocampal slices at the ages of P13-15 and P26-30.  
Firstly, spontaneous excitatory currents (sEPSCs) were recorded at -70 mV, followed 
by spontaneous inhibitory currents (sIPSCs) at 0 mV.  TTX and PTX were then bath 
applied and further recordings made at -70 mV and 0 mV to capture miniature 
EPSCs (mEPSCs) and miniature IPSCs (mIPSCs).  Example traces for P13-15 and 
P26-30 are shown in Figure 30 and Figure 31. 
 
In a subset of recordings, CNQX was washed on at -70 mV to demonstrate through 
the abolition of events that these currents were AMPAR mediated.  In other 
recordings, picrotoxin was washed on at 0 mV to demonstrate through abolition of 





























Figure 30 – P13-15 example traces from excitatory and inhibitory current recordings. 
 
(A) WT sEPSC, (B) Syngap+/GAP sEPSC, (C) WT sIPSC, (D) Syngap+/GAP sIPSC, (E) WT mEPSC, (F) 












Figure 31 – P26-30 example traces from excitatory and inhibitory current recordings. 
 
(A) WT sEPSC, (B) Syngap+/GAP sEPSC, (C) WT sIPSC, (D) Syngap+/GAP sIPSC, (E) WT mEPSC, (F) 






Figure 32 – The abolition of excitatory currents with CNQX and inhibitory currents with PTX 
in P26-30 recordings demonstrates they are mediated by AMPARs and GABARs respectively. 
 
Application of 10 µM CNQX, abolishes the sEPSC and mEPSC currents demonstrating that they are 
AMPAR mediated (A) sEPSC no drug (B) sEPSC with CNQX, (E) mEPSC with TTX only, (F) 
mEPSC with TTX and CNQX.   
 
Application of 50 μM PTX abolishes the sIPSC and mIPSC currents demonstrating that they are 
GABAR mediated (C) sIPSC no drug (D) sIPSC with PTX, (G) mIPSC with TTX only, (H) mIPSC 




The mean results were similar for the experiments conducted at P13-15 and P26-30, 
namely that there was no significant difference between sEPSC, sIPSC, mEPSC or 
mIPSC mean amplitude nor frequency between WT and Syngap+/GAP rats 
regardless of whether the unit of analysis was ‘animal’ (Figure 33 and Figure 36) or 
‘cell’ (Figure 34 and Figure 37).  The numbers in each group when collated by 
animal were however small and perhaps with larger sample sizes differences in 
sEPSC amplitude and frequency would have been seen between genotypes.  The 
numbers of experimental subjects was low in some of the groups, particularly in WT 
sEPSC recordings at P26-30.  This was due to discarding cells during post-hoc 
analysis as they did not meet the inclusion criteria (e.g. holding current, access 
resistance etc).  This was an unfortunate limitation explored further in the discussion.  
The amplitudes of both genotypes showed the expected positively skewed 
distribution of excitatory (Bekkers et al. 1990; Cormier & Kelly 1996; McBain & 
Dingledine 1992; Wyllie et al. 1994) and inhibitory (Edwards et al. 1990; De Simoni 
et al. 2003) spontaneous and miniature events in both age groups (P13-15: Figure 34 
and Figure 35 and P26-30: Figure 37 and Figure 38).     
Examination of the cumulative frequency distributions of the P13-15 recordings 
revealed that the sEPSCs and mEPSCs from Syngap
+/GAP
 rats tended to be larger 
amplitude and higher frequency events. In contrast, there was little difference in the 
cumulative frequency distributions of sIPSCs and mIPSCs between WT and 
Syngap
+/GAP
 rats (Figure 35).  Therefore the overall effect was of a shift towards 




At P26-30 the cumulative frequency distributions show that the sEPSCs and 
mEPSCs from Syngap
+/GAP
 rats still tended to be of larger amplitude, but tended to 
be slightly less frequent than in WTs (Figure 37). The distributions of sIPSCs and 
mIPSCs between WT and Syngap
+/GAP
 rats showed much smaller differences as they 
had done in the younger animals (Figure 38).  Therefore although it would be less 
marked than at P13-15, the overall effect would still be of a shift towards excitation 
over inhibition in the CA1 pyramidal cells of Syngap
+/GAP
 rats at P26-30 as a change 
in either amplitude or frequency is sufficient to modify synaptic strength (Rumbaugh 




Many authors have published research suggestive of a shift to excitation in models of 
SynGAP haploinsufficiency (Vazquez et al. 2004; Rumbaugh et al. 2006; Clement et 
al. 2012; Clement et al. 2013; Wang 2013; Ozkan et al. 2014; Berryer et al. 2016) so 
whilst the mean data presented here is not necessarily in keeping with the literature, 
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Figure 33 – At P13-15 the amplitude of excitatory and inhibitory currents are not significantly 
different between WT and Syngap
+/GAP
 recordings when the unit of analysis is ‘animal’. 
 
(A) There is no significant difference in the sEPSC or mEPSC amplitude between WT and 
Syngap+/GAP hippocampal brain slices (WT sEPSC = 16.74 ± 1.29 pA n = 7, Syngap+/GAP sEPSC = 
22.62 ± 1.97 pA n = 3, Mann-Whitney test p = 0.0667, WT mEPSC = 16.52 ± 0.42 pA n = 6, 
Syngap+/GAP mEPSC = 16.91 ± 2.07 pA n = 4, Mann-Whitney test p = 0.4762).  
 
(B) There is no significant difference in the sEPSC or mEPSC frequency between WT and 
Syngap+/GAP hippocampal brain slices (WT sEPSC = 1.45 ± 0.21 Hz n = 7, Syngap+/GAP sEPSC = 2.96 
± 0.91 Hz n = 3, Mann-Whitney test p = 0.2667, WT mEPSC = 1.0 ± 0.29 Hz n = 6, Syngap+/GAP 
mEPSC = 2.19 ± 0.83 Hz n = 4, Mann-Whitney test p = 0.1143). 
 
(C) There is no significant difference in sIPSC or mIPSC amplitude between WT and Syngap+/GAP 
hippocampal brain slices (WT sIPSC = 24.27 ± 1.68 pA n = 7, Syngap+/GAP sIPSC = 24.18 ± 3.68 pA 
n = 5, Mann-Whitney test p = 0.5303, WT mIPSC = 19.89 ± 1.34 pA n = 7, Syngap+/GAP mIPSC = 
22.65 ± 1.19 pA n = 4, Mann-Whitney test p = 0.1636).  
 
(D) There is no significant difference in sIPSC or mIPSC frequency between WT and Syngap+/GAP 
hippocampal brain slices (WT IPSC = 5.16 ± 0.80 Hz n = 7, Syngap+/GAP sIPSC = 6.13 ± 1.25 Hz n = 
5, Mann-Whitney test p = 0.5303, WT mIPSC = 4.16 ± 0.72 Hz n = 7, Syngap+/GAP mIPSC = 3.90 ± 
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Figure 34 – At P13-15 there is a shift in the cumulative distributions of both sEPSCs and 
mEPSCs in Syngap
+/GAP








Figure 34 legend: 
 
 (A) There is no significant difference in the mean amplitude of excitatory recordings between WT 
and Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sEPSC = 17.91 ± 
1.07 pA n = 15, Syngap+/GAP sEPSC = 22.62 ± 1.97 pA n = 3, Mann-Whitney test p = 0.1299, WT 
mEPSC = 16.56 ± 0.84 pA n = 15, Syngap+/GAP mEPSC = 16.23 ± 1.91 pA n = 6, Mann-Whitney test 
p = 0.6222).  
 
(B) There is no significant difference in the mean frequency of excitatory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sEPSC = 1.81 ± 0.34 
Hz n = 15, Syngap+/GAP sEPSC = 2.96 ± 0.91 Hz n = 3, Mann-Whitney test p = 0.2034, WT mEPSC = 
1.59 ± 0.37 Hz n = 15, Syngap+/GAP mEPSC = 2.28 ± 0.63 Hz n = 6, Mann-Whitney test p = 0.3023). 
 
 (C), (D), (E) and (F) Cumulative frequency distributions of sEPSC amplitude, mEPSC amplitude, 
sEPSC inter-event interval, and mEPSC inter-event interval respectively. 
 
 (G) The frequency distributions of the pooled sEPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in spontaneous sEPSC recordings (WT median = 14.02, 
WT mean = 18.00 pA, Syngap+/GAP median = 18.33 pA, Syngap+/GAP mean = 23.25 pA). 
 
(H) The frequency distributions of the pooled mEPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in mEPSC recordings (WT median = 13.35, WT mean 
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Figure 35 – At P13-15 the distributions of both sIPSCs and mIPSCs are similar between WT 
and Syngap
+/GAP








Figure 35 legend: 
 
(A) There is no significant difference in the mean amplitude of inhibitory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sIPSC = 24.47 ± 1.97 
pA n = 11, Syngap+/GAP sIPSC = 25.38 ± 3.14 pA n = 9, Mann-Whitney test p = 0.8238, WT mIPSC = 
20.94 ± 1.11 pA n = 12, Syngap+/GAP mIPSC = 22.1 ± 1.76 pA n = 6, Mann-Whitney test p = 0.4936).  
 
(B) There is no significant difference in the mean frequency of inhibitory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sIPSC = 4.93 ± 0.63 
Hz n = 11, Syngap+/GAP sIPSC = 5.92 ± 1.01 Hz n = 9, Mann-Whitney test p = 0.2034, WT mIPSC = 
1.6 ± 0.4 Hz n = 15, Syngap+/GAP mIPSC = 2.3 ± 0.6 Hz n = 6, Unpaired t test p = 0.3967). 
 
 (C), (D), (E) and (F) Cumulative frequency distributions of sIPSC amplitude, mIPSC amplitude, 
sIPSC inter-event interval, and mIPSC inter-event interval respectively. 
 
 (G) The frequency distributions of the pooled sIPSC amplitudes from WT and Syngap+/GAP recordings 
display the positive skew expected in spontaneous IPSC recordings (WT median = 22.36 pA, WT 
mean = 25.51 pA, Syngap+/GAP median = 20.82 pA, Syngap+/GAP mean = 21.8 pA). 
 
(H) The frequency distributions of the pooled mIPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in mIPSC recordings (WT median = 18.73 pA, WT 
mean = 20.89 pA, Syngap+/GAP median = 18.81 pA, Syngap+/GAP mean = 21.32 pA).  The apparent 
difference in numbers of values between genotypes simply reflects the fact that the number of WT 
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Figure 36 - At P26-30 the amplitude of excitatory and inhibitory currents is not significantly 
different between WT and Syngap
+/GAP
 recordings when the unit of analysis is ‘animal’. 
 
 (A) There is no significant difference in the mean amplitude of recordings between WT and 
Syngap+/GAP hippocampal brain slices (WT sEPSC = 13.64 ± 0.52 pA n = 2, Syngap+/GAP sEPSC = 
16.82 ± 1.50 pA n = 6, Mann-Whitney test p = 0.2857, WT mEPSC = 11.64 ± 1.10 pA n = 5, 
Syngap+/GAP mEPSC = 16.42 ± 4.23 pA n = 4, Mann-Whitney test p = 0.4127).  
 
(B) There is no significant difference in the frequency of sEPSC and mEPSC recordings between WT 
and Syngap+/GAP hippocampal brain slices (WT sEPSC = 3.28 ± 0.69 Hz n = 2, Syngap+/GAP sEPSC = 
2.97 ± 0.88 Hz n = 6, Mann-Whitney test p = 0.4286, WT mEPSC = 1.77 ± 0.62 Hz n = 5, 
Syngap+/GAP mEPSC = 0.72 ± 0.17 Hz n = 4, Mann-Whitney test p = 0.1905). 
 
(C) There is no significant difference in the amplitude of sIPSC and mIPSC recordings between WT 
and Syngap+/GAP hippocampal brain slices (WT sIPSC = 30.33 ± 6.31 pA n = 8, Syngap+/GAP sIPSC = 
27.27 ± 3.18 pA n = 5, Mann-Whitney test p = 0.7242, WT mIPSC = 18.91 ± 2.22 pA n = 4, 
Syngap+/GAP mIPSC = 18.45 ± 1.55 pA n = 4, Mann-Whitney test p = 0.6857).  
 
(D) There is no significant difference in the frequency of sIPSC and mIPSC recordings between WT 
and Syngap+/GAP hippocampal brain slices (WT sIPSC = 15.06 ± 1.20 Hz n = 8, Syngap+/GAP sIPSC = 
16.86 ± 2.9 Hz n = 5, Mann-Whitney test p = 0.8329, WT mIPSC = 13.12 ± 4.34 Hz n = 4, 
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Figure 37 – At P26-30 there is a shift in the cumulative distributions of both sEPSCs and 
mEPSCs in Syngap
+/GAP







Figure 37 legend: 
 
(A) There is no significant difference in the mean amplitude of excitatory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sEPSC = 13.64 ± 0.52 
pA n = 2, Syngap+/GAP sEPSC = 17.29 ± 1.81 pA n = 8, Mann-Whitney test p = 0.2667, WT mEPSC = 
12.19 ± 1.07 pA n = 9, Syngap+/GAP mEPSC = 14.57 ± 2.63 pA n = 7, Mann-Whitney test p = 0.4698). 
  
(B) There is no significant difference in the mean frequency of excitatory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sEPSC = 3.28  ± 
0.69 Hz n = 2, Syngap+/GAP sEPSC = 2.95 ± 0.68 Hz n = 8, Mann-Whitney test p = 0.5333, WT 
mEPSC = 1.84 ± 0.43 Hz n = 9, Syngap+/GAP mEPSC = 0.94 ± 0.18 Hz n = 7, Mann-Whitney test p = 
0.2105). 
 
 (C), (D), (E) and (F) Cumulative frequency distributions of sEPSC amplitude, mEPSC amplitude, 
sEPSC inter-event interval, and mEPSC inter-event interval respectively. 
 
 (G) The frequency distributions of the pooled sEPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in spontaneous sEPSC recordings (WT median = 11.70 
pA, WT mean = 13.69 pA, Syngap+/GAP median = 14.29 pA, Syngap+/GAP mean = 18.58 pA). 
 
(H) The frequency distributions of the pooled mEPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in mEPSC recordings (WT median = 10.48 pA, WT 
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Figure 38 - At P26-30 the distributions of both sIPSCs and mIPSCs are similar between WT and 
Syngap
+/GAP








Figure 38 legend: 
 
(A) There is no significant difference in the mean amplitude of inhibitory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sIPSC = 31.05 ± 6.54 
pA n = 10, Syngap+/GAP sIPSC = 26.53 ± 3.56 pA n = 8, unpaired t test p = 0.5806, WT mIPSC = 
18.91 ± 2.22 pA n = 4, Syngap+/GAP mIPSC = 18.69 ± 1.89 pA n = 6, Mann-Whitney test p = 0.7619).  
 
(B) There is no significant difference in the mean frequency of inhibitory recordings between WT and 
Syngap+/GAP hippocampal brain slices when the unit of analysis is n = cell (WT sIPSC = 16.13 ± 1.39 
Hz n = 10, Syngap+/GAP sIPSC = 17.82 ± 2.93 Hz n = 8, unpaired t test p = 0.5861, WT mIPSC = 
13.12 ± 4.34 Hz n = 4, Syngap+/GAP mIPSC = 12.79 ± 3.40 Hz n = 6, unpaired t test p > 0.9999). 
 
 (C), (D), (E) and (F) Cumulative frequency distributions of sIPSC amplitude, mIPSC amplitude, 
sIPSC inter-event interval, and mIPSC inter-event interval respectively. 
 
 (G) The frequency distributions of the pooled sIPSC amplitudes from WT and Syngap+/GAP recordings 
display the positive skew expected in spontaneous sIPSC recordings (WT median = 21.81, WT mean 
= 32.02 pA, Syngap+/GAP median = 23.36 pA, Syngap+/GAP mean = 28.14 pA). 
 
(H) The frequency distributions of the pooled mIPSC amplitudes from WT and Syngap+/GAP 
recordings display the positive skew expected in mIPSC recordings (WT median = 18.14, WT mean = 




4.3.5 GABAR/AMPAR and AMPAR/NMDAR recordings in acute 
hippocampal slices 
 
Measurements of GABAR/AMPAR ratios were made in P26-30 hippocampal brain 
slices from WT and Syngap
+/GAP
 rats by delivering 0.1 Hz current pulses every 6 
seconds to the Schaffer collateral axons and recording 30 consecutive events at the 
chloride reversal potential and the AMPA reversal potential.  Picrotoxin (100 µM) 
was then bath applied to block the GABAAR mediated responses as demonstrated in 
Figure 39, before 30 AMPAR mediated events were recorded at -70 mV and 30 
NMDAR and AMPAR mixed events were recorded at +40 mV. 
 
In a subset of cells the nature of the current at +40 mV was demonstrated by the 
application of 10 μM CNQX and 50 μM D-(-)-2-Amino-5-phosphonopentanoic acid 
(D-AP5), a selective NMDA receptor antagonist.  The current was altered by the 
application of either drug alone and abolished by the application of both together 
showing the current is mediated by both AMPARs and NMDARs.  In a further 
subset of cells, CNQX (10 μM) was applied during recordings at -70 mV in the 
presence of PTX which abolished the current confirming it was AMPAR mediated 
(Figure 39). 
 
No significant differences were found between WT and Syngap
+/GAP
 recordings 
when the GABAR charge transfer was divided by the AMPAR charge transfer to 
give the GABAR / AMPAR ratio.  This was regardless of whether the unit of 
analysis was ‘animal’ or ‘cell’ (Figure 40).  No significant differences were found in 
AMPAR/NMDAR ratio between genotypes either (Figure 40). 
 
Alterations in AMPA  /  NMDA currents in SynGAP haploinsufficiency were 
identified at P14 in the Syngap
+/-
 mouse hippocampus (Clement et al. 2012).  
However, this had resolved by 6 weeks of age.  Given that synaptic transmission and 
mEPSC amplitude and frequency which were also increased at P14 had resolved by 
P21, it may be the case that a difference would’ve been evident in the AMPA/ 




Figure 39 – The pharmacological modification of the currents recorded in GABAR / AMPAR 
and AMPAR / NMDAR experiments demonstrates the receptors that mediate the currents. 
 
(A) Application of 75-100 µM PTX during a recording at the AMPA reversal potential (100 μM PTX 
applied at +14mV in this case) abolishes the current.  This demonstrates that responses recorded at the 
AMPA reversal potential were GABAAR mediated. 
 
(B) Application of 10 μM CNQX to a recording at -70mV in the presence of PTX abolishes the 
current.  This demonstrates responses recorded at -70mV in the presence of PTX are AMPAR 
mediated. 
 
(C) and (D) The current at +40 mV is both AMPAR and NMDAR mediated as demonstrated by the 
application (in the presence of PTX) of 10 μM CNQX and 50 μM D-APV singly and in combination.  
Applying either drug alone in the presence of PTX changes the waveform, but only in the presence of 
both is the current abolished. 
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Figure 40 - There is no difference in AMPA / GABAA and AMPA / NMDA receptor ratios in 
P26-30 rats when the unit of analysis is ‘animal’.  
 
(A) WT (black) and Syngap+/GAP (blue) GABA : AMPA example traces.  
 
(B) WT (black) and Syngap+/GAP (blue) AMPA : NMDA example traces. 
 
(C) AMPA receptor to GABAA receptor ratio was unchanged in Syngap
+/GAP rats compared to WT 
rats when analysed by animal (WT = 0.3271 ± 0.06372 n = 7, Syngap+/GAP = 0.34 ± 0.07806 n = 
10, Mann-Whitney test p = 0.9811) and by cell (WT = 0.7622 ± 0.1886 n = 12, Syngap+/GAP = 
0.7156 ± 0.1199 n = 19, Mann-Whitney test p = 0.9776). 
 
(D) AMPA receptor to NMDA receptor ratio was also unchanged in Syngap+/GAP rats compared to 
WT rats when analysed by animal (WT = 12.18 ± 2.398 n = 8, Syngap+/GAP = 10.44  ± 3.069 n = 
6, Mann-Whitney test p =0.5481) and by cell (WT = 12.51 ± 3.333 n = 11, Syngap+/GAP = 9.920  




4.4  Discussion 
This body of work presents the first comprehensive analysis of cellular and synaptic 
electrophysiological properties in SynGAP_GAP deletion rats.  Somewhat 
surprisingly, the predicted protein synthesis independent exaggeration in 
hippocampal mGluR LTD was not observed despite this being a strong phenotype in 
similar Syngap
+/-
 mouse experiments.  Furthermore, the hypothesis that there would 
be a shift towards excitation in electrophysiological measurements was 
unsubstantiated by mean data, but the cumulative distributions of excitatory and 
inhibitory currents pointed in the direction of excitation as predicted.   
 
On examination of CA1 pyramidal cells, no significance differences were seen 
between WT and Syngap
+/GAP
 recordings of passive cellular properties or action 
potential properties (when analysed by n = animal).  Although dentate gyrus cells 
and Layer 2/3 pyramidal neurons have been shown to be hyperexcitable in Syngap
+/-
 
mice neurons, systematic evaluation of the properties of CA1 pyramidal neurons in 
models of SynGAP have not been presented before.  The current data suggests that in 
this brain region at P13-15 and P26-30, there is no distinct cellular phenotype.  As no 
overt anatomical, developmental or behavioural differences were noted between WT 
and Syngap
+/GAP
 rats, it is perhaps reasonable to expect that any cellular phenotype 
would be relatively mild as gross changes in the functions of individual cells could 
severely and noticeably impact on the functioning of the rat as a whole.  The lack of 
difference between genotypes may also be a function of the age ranges at which 
recordings were made as the previous hyperexcitability identified in the Syngap
+/-
 
hippocampus (albeit in the dentate gyrus) was noted  at P8-9 but had resolved by P14 
(Clement et al. 2012).  The influence of experimental age is discussed in full below. 
 
Although on examination of the synaptic function in these rats no differences were 
seen in GABAR/ AMPAR or AMPAR/ NMDAR ratios or in the mean amplitude or 
frequency of excitatory or inhibitory currents, there was a shift in the cumulative 
distributions of excitatory currents suggestive of an imbalance between excitation 
and inhibition in favour of excitation.  It is possible that with higher experimental 
numbers a difference between genotypes would’ve been delineated.  This is in 
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keeping with evidence in the literature suggestive of increased excitation in SynGAP 
haploinsufficiency (Vazquez et al. 2004; Rumbaugh et al. 2006; Clement et al. 2012; 
Clement et al. 2013; Wang et al. 2013).  However my finding that the frequency of 
mEPSCs from cultured Syngap
+/GAP
 rat CA1 pyramidal neurons was reduced is at 
odds with this. 
  
To explore the validity of the data and consider why certain experiments gave 
unexpected results it is helpful to consider two categories of variable.  The first is 
variables that may be common to every experiment, namely experimental model, 
gender, background rat strain, experimental age and sample size.  The second are the 
factors that are relevant to particular experiments only. 
4.4.1 Common variables 
Experimental model 
The SynGAP rat is different from previous SynGAP mouse studies because the 
mutant allele still results in translation of a truncated form of SynGAP, whereas the 
mutant allele in two of the most extensively studied mouse models is fully knocked 
out resulting in no protein production (initial papers using these models were by 
Vazquez et al. 2004; Rumbaugh et al. 2006).  The mouse designed by Kim and 
colleagues (Kim et al. 2003) does have low levels of SynGAP remaining (as 
described in paragraph 3.2.1), but there are fewer publications pertaining to it.  When 
attempting direct comparison between the current work and previous publications 
this difference in model should therefore be born in mind. 
 
When considering the lack of exaggerated hippocampal mGluR LTD in the 
Syngap
+/GAP
 rats compared to the findings of Barnes et al. 2015, could it be that the 
remaining ‘mutant’ SynGAP in heterozygous rats is sufficient to mediate an 
indistinguishable level of LTD from WT rats?  This seems unlikely as the rats lack 
the portion of the SynGAP gene that codes for the protein’s enzymatic GAP domain 
which is thought to influence LTD by regulating both Ras and Rap (Chen et al. 1998; 
Kim et al. 1998; Krapivinsky et al. 2004; Walkup et al. 2015).  Ras and Rap in turn 
modulate the surface expression of  AMPARs (Zhu et al. 2002; Zhu et al. 2005; 
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Derkach et al. 2007), a reduction in which leads to LTD (Carroll et al. 1999; Lüscher 
et al. 1999; Luthi et al. 1999; Man et al. 2000; Xiao et al. 2001; Snyder et al. 2001).    
Furthermore, the degree of LTD has been shown to correlate with mEPSC amplitude 
and frequency in the hippocampus (Zhang et al. 2005) and increased mEPSC 
amplitude has been shown to be due to enhanced by incorporation of the GluR2- 
lacking type of AMPAR into the cell membrane (Wang et al. 2013).  Therefore the 
results in Syngap
+/GAP
 rats are puzzling as not only would loss of the GAP domain be 
predicted to result in the increased LTD seen by Barnes et al. which isn’t seen in the 
Syngap
+/GAP
 rats, the assumption would be that AMPAR currents would be increased 
as was seen in Syngap
-/-
 mouse mEPSC amplitude (Vazquez et al. 2004) and 
frequency (Vazquez et al. 2004; Rumbaugh et al. 2006).  The decrease in mEPSC 
frequency in Syngap
+/GAP
 rat recordings found in this body of work (Figure 29) is 
more in keeping with overexpression of SynGAP (Rumbaugh et al. 2006) and the 
lack of difference in the mean amplitude and frequency of AMPAR mediated 
sEPSCs, mEPSCs or AMPAR / NMDAR ratios in Syngap
+/GAP
 rat hippocampal 
slices was also not as predicted.  Could this mean that despite the deletion of the 
coding region for the GAP domain, there is somehow sufficient GAP function in the 
SynGAP_GAP deletion rat for SynGAP to fulfil its role as a brake on downstream 
pathways?  This would seem to be highly unlikely and would still not explain the 
reduced frequency of mEPSCs from Syngap
+/GAP
 rats.  A GTPase assay to assess 





 rats.   
Compensatory Mechanisms 
In genetically altered models it is possible that compensatory mechanisms have 
developed to counteract the negative impact of the genetic mutation.  This could in 
theory result in a balancing of function so that for example, electrophysiological 
recordings do not reveal a difference between genotypes.  However, exaggerated 
mGluR LTD and alterations in excitatory and inhibitory currents have been identified 
in mouse models of Syngap haploinsufficiency as described.  There is no obvious 
reason to explain why genetically modified rats would achieve equilibrium in 
function through compensatory mechanisms when genetically modified mice did not.  
Comparing the results found in transgenic animals with models of acute knockdown 
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of SynGAP is one way of exploring compensatory mechanisms further.  When this 
was done in  mice it was found that siRNA disruption of the SynGAP protein after 
synaptogenesis produced the same phenotypes of an increase in mEPSC frequency 
and increased ERK pathway activation as was seen in transgenic Syngap
-/-
  mouse 
cultures (Rumbaugh et al. 2006).  Furthermore, the increase seen in dentate gyrus 
AMPAR / NMDAR ratio in heterozygous SynGAP mice was recapitulated by acute 
knockdown of SynGAP at postnatal day 1 in a Cre LoxP conditional mouse, but not 
in adult mice (Clement et al. 2012).  This suggests these are direct effects of the loss 
of SynGAP and not related to compensatory mechanisms.  Interestingly though, 
significantly lower levels of phosphorylated p38 found in Syngap
-/-
 cultured mouse 
neurons when synaptic activity had been blocked weren’t replicated by siRNA 
knockdown of SynGAP (Rumbaugh et al. 2006).  It is possible that this is due to 
compensatory mechanisms leading to the phenotype in the transgenic mice.  Acute 
knockdown experiments could be planned in the SynGAP_GAP deletion rats to 
investigate the role of compensatory mechanisms further. 
Sex differences 
Both male and female animals were used in the SynGAP_GAP deletion rat 
experiments despite some evidence in the literature of differences in hippocampal 
function between male and female rats.  Most of the reported gender differences have 
been in adult rats (Maren 1995; Yang et al. 2004; Oberlander & Woolley 2016) 
which were not examined in this current body of SynGAP work.  The exception was 
the paper by Maren et al. which found greater perforant path - dentate gyrus LTP and 
burst depolarisation in male rats in adult and pre-pubescent animals (35 days) in 
comparison with younger animals (Maren  et al. 1994).  This was not seen in female 
rats.  This suggests there may be gender specifics differences in hippocampal 
function just a few days later than recordings were made in the current experiments 
(the latest being P30).  However there is no published literature of gender differences 
in hippocampal function at the age ranges used in this thesis (P13-15 and P26-30). 
 
It is reasonable to expect that hormonal changes at puberty might mark the beginning 
of a greater divergence between male and female function and so knowing when 
puberty is in Long-Evans Hooded rats could be important when considering the 
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SynGAP rat data.  Papers use different methods to indicate puberty onset in female 
rats.  Ojeda & Skinner 2006 used first ovulation as a marker which they stated occurs 
in most laboratory rat stocks between P35 and P45.  This time window is in keeping 
with reports using vaginal opening as a marker of puberty onset (Kakeyama et al. 
2008; Hovey et al. 2011).  However there are studies showing earlier vaginal opening 
(Keeley et al. 2015; Stanko et al. 2016) including one with mean vaginal opening at 
30.6 days in Long-Evans rats (Gray et al. 1997). Keeley et al. 2015 showed that 
puberty in Long-Evans male rats was later (between 35 and 40 days).   This data 
suggest it is unlikely that even the older animals in the SynGAP experiments (P26-
30) were pubertal and so subjected to surges in hormones that could potentially 
results in differences between the genders.  Furthermore, when the LTD data was 
analysed by gender there was no significant difference between males and females 
(WT male = 79.0 ± 3.6% n = 10, WT female = 77.2 ± 6.6% n = 2 Syngap
+/GAP
 male 
= 74.4 ± 3.8% n = 15, Syngap
+/GAP
 female = 70.2 ± 7.4% n = 4; Kruskal Wallis test p 
= 0.6960, Dunn’s multiple comparisons test showed no significant differences).  This 
interpretation does require some caution though given small numbers of females.  
The other experimental datasets in this thesis included fewer animals and so the 
validity of sub-dividing the results by gender would have been dubious and so has 
not been done.    
 
It is important to note when considering the current results in the context of 
published research, that the use of both male and female animals has been common 
in the SynGAP electrophysiology research community (Rumbaugh et al. 2006; 
Clement et al. 2012; Clement et al. 2013; Ozkan et al. 2014; Berryer et al. 2016).  
Reassuringly, gender specific data has generally not been presented as the authors 
found no significant difference between males and females.  The exception is a small 
reduction in mEPSC amplitude in parvalbumin positive interneurons found only in 
male mice (Ozkan et al. 2014).  Therefore I do not believe the use of both male and 






Background strain   
Background strain has been recognised as a potential influence in rodent 
hippocampal experiments for many years (Manahan-Vaughan 2000; Nguyen et al. 
2000; Bowden et al. 2012; Kamal et al. 2014).  With regards to rodent LTD in 
particular, certain low frequency stimulation protocols that induce LTD in some 
strains (Wistar and Sprague-Dawley) don’t result in LTD in Lister-Hooded rats 
(Manahan-Vaughan 2000).  When considering this in relation to the current 
Syngap
+/GAP
 WT Long-Evans hooded rat LTD experiments, it is a notable advantage 
to be able to compare the results to the  previously published LTD experiments 
carried out in our laboratory with very similar protocols and equipment (Till et al. 
2015).  The most notable difference between the experiments was the background 
strain of the rats, as those used by Till and colleagues were Sprague-Dawley animals 
rather than the Long-Evans Hooded strain of the SynGAP_GAP deletion rats.   It is 
therefore interesting that Till and colleagues present a mean value of 78.64 ± 3.7% 
for LTD in WT rats which is very similar to the 78.7 ± 3.1% found in the WT 
animals from the SynGAP rat colony.  However Till et al. found that in contrast to 
the SynGAP_GAP Deletion WT rats (but in keeping with Barnes and colleague’s 
Syngap
+/-
 mouse data), LTD was not maintained in WT animals in the presence of 
protein synthesis inhibition by cycloheximide.  This suggests that the protein 
synthesis dependence may somehow relate to the background strain of the rats.  
However, published data has shown the same loss of LTD maintenance in the 
presence of protein synthesis inhibitors in WT Long-Evans Hooded rats at a similar 
age P21-30 (Huber et al. 2000) suggesting background strain is not to blame.    The 
explanation may therefore be specific to the Long-Evans hooded strain of rats used in 
the SynGAP colony as it has been noted that variability can occur within a given 
strain when different breeding practices have been followed (Kacew & Festing 
1996).   
 
Further examination of LTD in different rat strains is therefore warranted before firm 
conclusions can be drawn about the influence of the SynGAP_GAP Deletion 





The age at which some of the experiments in this thesis were conducted may have 
affected the likelihood of revealing certain phenotypes given the pattern of results 
seen in the literature.  WT SynGAP expression in the mouse is known to increase 
from early in life and peak around P7 (Porter et al. 2005) to P14 (Clement et al. 
2012; McMahon et al. 2012) and I have shown in this thesis that levels of SynGAP 
protein also increased during the first month of life in SynGAP_GAP Deletion 
(Figure 15).  This suggests SynGAP may play a particularly critical role during 
development.  Supporting this idea is the fact that many of the electrophysiological 
phenotypes in the Syngap
+/-
 mouse were identified during the first two weeks of life 
and later resolved (Clement et al. 2012; Clement et al. 2013; Ozkan et al. 2014).  For 
example, in the hippocampus the significant differences in heterozygous mice were 
mostly at P14 (increased mEPSC amplitude and frequency, synaptic transmission 
and AMPAR/ NMDAR ratio) and had resolved by P21 (Clement et al. 2012).  In 
keeping with this was the absence of alterations in NMDAR or AMPAR mediated 
currents in 14 – 20 week old Syngap
+/-
 mice (Komiyama et al. 2002).  As noted 
above, acute knockdown experiments have shown mixed results, but interestingly in 
an adult Cre LoxP conditional mouse acute SynGAP knockdown did not show the 
increased AMPAR / NMDAR ratios seen after knockdown at P1 (although did reveal 
increased intrinsic excitability in dentate gyrus neurons) (Clement et al. 2012) and 
induced global haploinsufficiency in mature animals using a conditional knockout 
SynGAP mouse line resulted in no change in mEPSC amplitude or frequency in 
Layer 2/3 pyramidal neurons or in measures of animal behaviour (Ozkan et al. 2014).  
This adds weight to the idea of SynGAP acting mainly during development, but 
some electrophysiological differences have been identified in older Syngap
+/-
 mice.  
These are comprised of  a decrease in adult hippocampal mEPSC amplitude and 
increased frequency following acute SynGAP1 deletion in a Cre LoxP mouse model 
(Muhia et al. 2012), an increase in mPFC mEPSC amplitude and frequency in 
Syngap
+/- 
mice > 9 weeks of age and a decrease in the firing of parvalbumin positive 
cells at 6 weeks of age (Ozkan et al. 2014).   
 
In the present rat work, hippocampal slice experiments were conducted at P13-15 
and P26-30 which should have allowed observations of early phenotypes that then 
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resolve to be made.  The exceptions to this were the LTD experiments (as the age 
range for them was chosen based on the corresponding mouse literature) and the 
GABAR/AMPAR and AMPAR/NMDA ratios.  It would therefore certainly be 
informative to explore the AMPAR/NMDA ratios in particular at the P13-15 in the 
SynGAP_GAP deletion rats with the hypothesis that they would be increased in 
Syngap
+/GAP
 rats.  
 
Sample size and variability 
The size of the final datasets in the SynGAP_GAP deletion rat experiments suffered 
due to the number of recordings that had to be discarded post-hoc for not meeting 
inclusion criteria (e.g. resting membrane potential, holding current etc.) and so being 
potentially indicative of unhealthy or unstable cells/ tissue.  This was compounded at 
times by a lack of available animals due to insufficient pregnancies (despite breeding 
pairs being set up) or maternal cannibalism of litters early in life.   
 
I am aware from personal correspondence with researchers working with SynGAP 
mice and from (Guo et al. 2009) that breeding can be difficult depending on the 
background strain of the animals and so it is possible that this might be a factor in the 
SynGAP rat colony, but cannot be confirmed without a comparable genetic mutation 
on another rat background strain.  It is also possible that for some as yet unidentified 
reason, mutation in the SynGAP protein has an adverse effect on breeding in rats.  
However it did not appear on informal observation that Syngap
+/GAP
 dams had more 
difficulty conceiving, carrying pups to term or levels of cannibalism than their WT 
counterparts.    Over the course of the experiments in this thesis, other animals 
housed with the SynGAP rat colony also went through periods of failing to breed 
well which was suggestive of an unidentified environmental effect within the animal 
house.   
 
These factors have resulted in sample sizes in this thesis that are smaller than would 
be ideal statistically.  As described in the methods section normality tests were used 
in an attempt to standardise the analysis.  However with n ≤ 7, the GraphPad Prism 
Software is unable to perform normality tests and in such cases non-parametric 
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analysis was used to try and prevent over-interpretation of the data.  Furthermore, as 
the Statistics Guide within GraphPad Prism notes, normality tests are less powerful 
with small sample sizes so even though when it was mathematically possible to 
conduct one, it may not have helpful.   
 
On the face of it, this appears to be a limitation, but many of the datasets in this 
thesis were expected to have non-Gaussian distributions e.g. mEPSCs, sEPSCs, 
sIPSCs, mIPSCs etc. so non-parametric analysis could be appropriate.  In this thesis, 
parametric analysis was however used when a normality test was passed which is in 
keeping with the use of parametric analysis in the SynGAP literature (Vazquez et al. 
2004; Rumbaugh et al. 2006; Clement et al. 2012; Clement et al. 2013; Ozkan et al. 
2014).  
 
The variability within samples in the SynGAP_GAP deletion rat experiments 
presented could also be statistically problematic as the standard error of the mean 
(SEM) within each group is often markedly different in a given dataset.  To give just 
one example, the data for the mEPSC recordings from SynGAP rat brain cultures 
shows a difference in SEM of nearly 7 fold (WT SEM = 1.44 Hz, Syngap
GAP/GAP 
= 
SEM 0.21 Hz).  One of the premises of parametric t-tests is that the data points are 
sampled from populations of equal variance.  Furthermore non-parametric Mann-
Whitney test tests determine if the distribution of ranks is different (which it may 
well be if the variance is different), so the unequal variances may make the 
interpretation of results here more difficult.  Larger sample sizes and transformation 
of datasets e.g. log transformation could help to address this in future experiments.   
  
4.4.2 Discussion of the results and variables relevant to specific 
experiments 
 
4.4.2.1 Hippocampal mGluR LTD Experiments 
 
Due to the number and complexity of variables that may have specifically impacted 




The finding of no significant difference in long-term depression between WT and 
Syngap
+/GAP
 rats was somewhat surprising given the robust exaggeration in LTD 
found in Syngap
+/-
 mice by Barnes et al. 2015.  The explanation is unlikely to lie in 
the equipment used as the recordings were made on the same electrophysiological 
rigs (albeit with a change of amplifier) with the same experimental set up and with 
the aid of Dr Adam Jackson who was the third author on the Barnes paper.  There 
was a slight difference in the age of the animals (P25-32 in the mice and P26-30 in 
the rats), but the external and internal solutions used (prior to the addition of drugs) 
were identical and the temperature was very similar (31 ± 1°C in the rat experiments 
vs 30°C with the mice), as was the flow rate (3-5 ml / min in the rat experiments vs 4 
ml / min with the mice).   
 
A higher concentration of DHPG (100 μM vs 50 µM) was used in the rat 
experiments due to personal correspondence from Dr Adam Jackson that this resulted 
in more reliable induction of LTD in other rat LTD recordings.  This is in keeping 
with the known dose response effect of DHPG in rats (Huber et al. 2001).   
 
The use of picrotoxin 
One potentially more significant difference was the fact that Barnes and colleagues 
bathed their slices in 50 µM picrotoxin during their recordings, which was not done 
in the SynGAP rat experiments.  This was because inhibitory blockade was not felt to 
be necessary in the rats to elicit fEPSPs to record from.  Palmer et al. 1997 found that 
DHPG induced hippocampal LTD was facilitated (both the number of successful 
inductions of LTD and the magnitude of the depression) using picrotoxin.  However 
this was not observed when comparing the magnitude of LTD in the WT SynGAP rat 
experiments to that in the WT mice in Barnes’ paper (78.9% in the rat and 77% in 
the mouse), but caution is required when comparing directly across species as other 
authors have reported differences even when experimental protocols are identical 




 Palmer et al. 1997 also found that in the presence of picrotoxin, the NMDA receptor 
antagonist AP5 had little effect on LTD induction or magnitude whereas in 
conditions where the amount of Ca
2+
 entering the cell was more reliant on NMDA 
receptors (e.g. in Mg
2+
 free medium) AP5 significantly reduced LTD.  This therefore 
suggested that in the presence of picrotoxin, a NMDA independent mechanism was 
working.  However, for this to explain the lack of significant difference in LTD 
magnitude in the Syngap
+/GAP
 rat versus mouse experiments, a difference in NMDA 
LTD function would be needed between genotypes and between species.  Carlisle et 
al. 2008 noted reduced NMDA induced LTD in Syngap
+/-
 mice, but only in a high 
calcium solution which doesn’t apply to the current experiments.  Huber et al. 2002 
did find differences in NMDA mediated LTD between species, but her results 
showed a greater LTD magnitude in WT rats over mice which is contrary to the 
SynGAP findings.  Therefore it seems unlikely that the absence of picrotoxin 
resulting in altered LTD mechanism is the explanation for lack of LTD phenotype in 
the rats. 
 
Choice of protein synthesis inhibitor 
Cycloheximide was the drug used to inhibit protein synthesis in the SynGAP rat LTD 
experiments rather than anisomycin which Barnes et al. 2015 used, but the two 
mechanisms of action are very similar as both drugs bind to the large 60S subunit of 
the ribosome and inhibit translation.  Specifically, anisomycin binds to the 60S t-
RNA A-Site and inhibits the binding of the aminoacyl-tRNA molecules (t-RNA 
bound to an amino acid molecule) whereas cycloheximide disrupts the protein 
synthesis further downstream by binding to the 60S t-RNA E-site stalling the 
ribosome during ongoing translation (Garreau De Loubresse et al. 2014; Rodnina & 
Wintermeyer 2016).  There is no obvious reason why this minor difference in action 
would result in a lack of dependence on new protein synthesis in the WT rats. 
 
Sample Size 
Power calculations for the LTD experiments based on the Syngap
+/-
 mouse LTD data 
(Barnes et al. 2015) indicated a group size of 13 would be required for a power of 0.8 
and with a significance level of 0.05.  The data presented here did not quite reach this 
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threshold in both experimental groups (WT n = 19, Syngap
+/GAP
 n = 12) and so the 
experiment was slightly underpowered for the heterozygous animals, but it seems 
unlikely that one extra animal in the Syngap group would have changed the result as 
the LTD for that hypothetical extra animal would’ve had to have been particularly 
exaggerated.  Only 6 animals were needed per genotype to reach statistical 
significance for the protein synthesis experiments.  The data from the SynGAP rats 




Although there are several factors that could potentially have resulted in the 
unexpected LTD and protein synthesis results in the Syngap
+/GAP
 rats in addition to 
the common variables described in section 4.4.1, the background strain of the rats 
appears to be particularly important.  Although it does not obviously explain the lack 
of statistically exaggerated LTD in heterozygotes compared with WT, it would seem 
to be behind the unexpected result in WT rat protein synthesis experiments.  
Therefore if the underlying mechanisms for LTD are somehow mediated differently 
by this particular Long-Evan Hooded rat strain, interpretation of the added effect of a 
SynGAP mutation is extremely difficult.  Further experiments to compare and 
contrast LTD in these rats with LTD in other WT rat strains will be required to 
definitively investigate this. Furthermore, it may be informative to specifically 
quantify new protein synthesis following the application of DHPG as basal protein 
synthesis was shown to be elevated in Syngap
+/- 
mice (Barnes et al. 2015). 
 
4.4.2.2 Intrinsic cell properties and action potential properties 
There is a paucity of published evidence of intrinsic properties in models of SynGAP 
haploinsufficiency.  To date the notable findings in Syngap
+/-
 mice have been greater 
excitability of dentate gyrus neurons compared to WT mice at P8-9, (Clement et al. 
2012) a reduction in layer 2/3 parvalbumin positive interneuron firing at 6 weeks of 
age (Ozkan et al. 2014) and an increase in action potential width in Layer 2/3 
somatostatin positive interneurons in adult  mice (Ozkan et al. 2014).  Therefore it 
isn’t possible to directly compare the parameters measured in the current CA1 




However, when considering the quality of recordings and data obtained, it is helpful 
to compare the WT values with other published data.  Although papers publish 
slightly different parameters, Table 9 and Table 10 enable at least some comparison 
between the WT data from the current experiments with published rat CA1 
pyramidal data.  For some values estimates have by necessity, been taken from 
graphed data as the raw values are not presented.  The variability in some of the 
parameters across the published data is notable and comparison limited by different 
experimental factors (age, background strain etc.), but generally the current data is in 
keeping with the range of values seen in the literature which suggests the cells were 
a) hippocampal pyramidal neurons and b) reasonably healthy.  Membrane time 
constant was the notable exception as it was shorter in the current experiments and 
the reasons for this are unclear as changes in other parameters e.g. action potential 
per current sweep might have been expected to be seen in tandem with a shorter 
membrane time constant.  The method used to define the time constant (single mono-
exponential curve fitting using appropriate software) is a recognised method, but 
identifying the point at which the curve plateaued in order to set the parameters for 
the curve fitting was done by eye.  This could therefore represent an experimenter 
error.  As capacitance was calculated by dividing the membrane time constant by the 
input resistance, it is not surprising that the capacitance values are also low compared 
to the literature.  Changes in capacitance can of course reflect differences in cell size, 
but given the potential methodological difficulties with calculation of capacitance 




Table 9 – WT passive cell properties from the current SynGAP rat experiments is in keeping with published WT rat hippocampal slice data 












WT rats from 
SynGAP colony 
P13-15 both genders, 
HHS 
-59.73 111.4 15.81 6.85 (0.93) 153.8 
WT rats from 
SynGAP colony 
P26-30 both genders, 
HHS 




P25-35, both genders, 
SD, HHS or THS 
-61.7 49.4 30.1 Not given 609.3117 
Staff et al. 2000 
2-9 week old, Wistar, 
THS (gender not given) 
-66.2 119.8 40 (0.79) 333.8898 
Thibault et al. 
2001 
3-5 month old, male, 
Fischer, THS 
-58.7 58.9 Not given Not given  
Gu et al. 2007 
4-7 week old, male, 
Wistar, THS 
-68.2 40.7 Not given Not given  
Kaczorowski et 
al. 2007 
P14-28, male Wistar, 
THS 
-60 72 Not given (0.76)  
Routh & 
Johnston 2009 
5-7 week old , male, SD, 
HHS 






P36, male SD, THS -64.8 100.6 27.9 




P21-28, males from 










SD = Sprague-Dawley, HHS = horizontal hippocampal slices, THS = transverse hippocampal slices RS = regular spiking, BS = burst spiking, ‘Estimated’ = 







Table 10 – WT action potential properties from the current SynGAP rat experiments are in keeping with published WT rat hippocampal slice data 










rate (mV / ms) 
Maximum decay 
rate (mV / ms) 
WT rats from 
SynGAP colony 
P13-15, both genders, HHS -43.12 WT 72.35 WT 123.1 WT 1.48 WT 220.1 WT -64.97 WT 
WT rats from 
SynGAP colony 




P25-35, both genders, SD, 
HHS or THS 
Not given 71.0 
Not 
given 
Not given Not given Not given 
Staff et al. 2000 
2-9 week old, Wistar, THS 
(gender not given) 
-46.3 112 213 0.95 381 -94.8 
Thibault et al. 
2001 
3-5 month, male, Fischer, 
THS 
Not given 83.8 151 Not given Not given Not given 
Kaczorowski et 
al. 2007 
P14-28, male Wistar, THS -53 103 1249 Not given Not given Not given 
Routh & 
Johnston 2009 
5-7 week old, 







0.9 estimated 400 estimated Not given 
Chu et al. 2010 2-3 week old, male SD, THS -39.2 96.3 122 1.2 Not given Not given 
Malik & 
Chattarji 2011 





120.1 700 1.6 420 Not given 
SD = Sprague-Dawley, HHS = horizontal hippocampal slices, THS = transverse hippocampal slices RS = regular spiking, BS = burst spiking, ‘Estimated’ = 




During intrinsic cell property experiments, cells were mistakenly been held at -70 pA 
rather than -70 mV.  Therefore, in order to improve the homogeneity of the data, 
cells with a baseline voltage more positive than -64 mV or more negative than -76 
mV were excluded.  A more strict exclusion limit would have severely reduced the 
number of cells that could be included in the analysis.  Hence the passive and action 
potential property data is acknowledged to come with the caveat that some cells were 
held at a potential 12 mV more negative than others.  The level to which some 
conductances are active or inactive may therefore differ between recordings and so 
potentially influence the data.  Ideally the experiments would therefore be repeated 
with all cells maintained at -70 mV.   
 
4.4.2.3 mEPSC recordings in homozygous SynGAP rat hippocampal cultures 
Vazquez et al showed in 2004 that at DIV 10, mEPSCs in hippocampal neurons had 
significantly larger amplitudes and frequency in Syngap
-/-
 mice, than in WT mice.  In 
2006, Rumbaugh and colleagues compared AMPA mEPSC recordings from WT and 
Syngap
-/-
 mouse forebrain neuronal cultures (between DIV 12-19) and also found a 
significant increase in the frequency of mEPSCs in homozygous mice, but no change 
in amplitude.  In homozygous neurons which had been transfected with GFP tagged 
SynGAP (Cα1 isoform), the mEPSC frequency was rescued to WT levels, whereas 
the amplitude was decreased to lower levels than that seen in WT cultures 
(Rumbaugh et al. 2006). 
 
However, in unpublished work from our laboratory, Aoife McMahon did not find a 
significant difference in mEPSC amplitude or frequency between WT and Syngap
-/-
 
mouse cultured cortical and hippocampal cells at DIV 9-11 and 13-14.  Nor did she 
find any alterations in AMPAR or NMDAR mediated currents. Clearly the finding of 
a decrease in mEPSC frequency in the Syngap
+/GAP
 rat cultures is at odds with these 
previous results.  Presented below is a discussion of the factors which could explain 






The cultured neurons looked healthy when compared informally with other culture 
plates.  Recordings were typically discarded if the holding current dropped below -
100 pA.  Furthermore, portions of each trace during which the access resistance was 
found to have exceeded 30 MΩ or varied by more than 20% were discarded.   Traces 
with less than 4 minutes of recording remaining were also discarded.  These 
measures should therefore have excluded unstable recordings which might indicate 
poor cell health. 
 
Were the currents recorded typical of mEPSCs? 
As Figure 29 shows the mEPSCs recorded were the expected asymmetric shape with 
a positive skew in their amplitude distribution (Bekkers et al. 1990; McBain & 
Dingledine 1992; Wyllie et al. 1994).  The mean amplitude and frequency of WT 
recordings in this thesis (15.5 pA and 2.54 Hz) are in keeping with the published 
literature on mEPSC amplitude (11 -15 pA) and frequency (0.2 – 2.5 Hz) in rat 
culture or slice recordings (Turrigiano et al. 1998; De Simoni et al. 2003; Zhang et 




The protocols for preparation of the cultured Syngap
GAP/GAP
 hippocampal neurons in 
this thesis and the Syngap
-/-
 of Vazquez et al. 2004 and Rumbaugh et al. 2006 (who 
took their method from a previous study - Banker & Cowan 1977) are compared in 




 rat protocol is more similar to that of Vazquez et al. and yet 
despite the methodological differences between Vazquez et al. and Rumbaugh et al. 
(e.g. brain region, age at culture preparation and recording, plating density, and 
solution composition) it is the work of these two published studies that shows the 
same phenotype.  This suggests that the methodological differences across all three 
bodies of work do not explain the different phenotype seen in the Syngap
GAP/GAP




Unlike the SynGAP rat experiments, the other authors did not add AraC (which 
blocks glial cell proliferation) to their cultures.  AraC has been shown to increase 
neuronal damage in the presence of glutamate and kill post-mitotic neurons with an 
EC50 of 50 µm (Martin et al. 1990; Ahlemeyer et al. 2003).  However, no exogenous 
glutamate was added to the cultures in the SynGAP rat experiments and the 
concentration of 1 μM AraC used was not toxic to neurons in the Martin et al. paper.  
Therefore it seems unlikely that the addition of AraC itself would explain the 
difference in phenotype between the SynGAP rat experiments and previous studies.   
Rumbaugh et al. specifically encouraged glial growth with glia conditioned media so 
it could be postulated that the absence of glia was important in their finding of 
increased mEPSC frequency.  However Vazquez et al. published similar results and 
they included  B27 in their culture medium which has been shown to result in near 
absence of glial cells (Brewer  et al. 1993).  Therefore I am confident that the 









 hippocampal culture preparation 







































150 NaCl, 3 KCl, 
10 HEPES, 2.5 CaCl2, 
1.3 MgCl2, 10 Glucose, 
0.05 Glycine, 
0.0005 TTX, 0.05 PTX 
pH 7.3 
130 Cs Gluconate, 
10 CsCl, 10 
HEPES, 0.1 EGTA, 
















200 9-10 No 
145 NaCl, 5 KCl, 
5 HEPES, 2 CaCl2, 
0.5 MgCl2, 10 Glucose 
0.0005 TTX, 0.03 PTX 
pH 7.4 
145 K gluconate, 
10 KCl, 
5 NaCl, 2 MgCl2, 
0.1 CaCl2, 5 EGTA, 
5 HEPES, 2 ATP. 
pH 7.2 
Rumbaugh 










No, fed with 
glia 
conditioned 
media twice a 
week 
150 NaCl, 3.1 KCl, 
10 HEPES, 2 CaCl2, 
1 MgCl2, 0.1 APV, 
0.005 strychnine, 0.1 




10 Hepes, 5 EGTA, 
2 MgCl2,4 Na-ATP, 
0.1 Na-GTP. 
pH 7.2 




4.4.2.4 Excitatory – Inhibitory Balance Experiments 
Although the mean values for spontaneous and miniature excitatory and inhibitory 
currents were not significantly different between genotypes in the SynGAP_GAP 
deletion rat colony, there was a trend towards increased excitation over inhibition 
which is in keeping with published data.   
 
The factors which may have influenced the recordings are inevitably similar to those 
presented for intrinsic cell properties and mEPSCs in culture and so some repetition 
is required when considering why there was no definite shift towards excitation as 
had been hypothesised.  
 
Is the WT data in keeping with the published literature? 
Table 12 presents data from the small number of published studies with spontaneous 
and miniature current data in WT rat hippocampal slices alongside the data recorded 
in WT SynGAP_GAP Deletion colony rats.  The relative lack of studies for 
comparison is problematic especially as they differ in experimental age and 
background strain in particular and not all studies publish the same parameters.  
Furthermore, estimates of mean values are sometimes by necessity, again taken from 
graphed data as the raw values are not presented.  Only two studies documenting 
spontaneous sEPSC amplitude were found and although their values differed widely, 
the current SynGAP data reassuringly fell between the two.  sEPSC frequency was 
also in keeping with the literature.   Only one study with sIPSC amplitude was 
identified which had markedly higher amplitudes than that found in the SynGAP rat 
experiments.  The sIPSC frequency found in the SynGAP rat colony at P13-15 was 
in keeping with published studies, but the frequency at P26-30 was substantially 
higher in the SynGAP rat colony dataset.  mEPSC data and mIPSC amplitude was 
consistent with the wider body of research, but the mIPSC frequencies found in the 
SynGAP rat colony were higher.  None of the published studies made recordings in 
Long-Evans Hooded rats though so it is impossible to delineate whether these 




In the absence of easily comparable literature, is therefore reassuring that the events 
recorded had asymmetric appearances and fast rise times as would be expected.  
Furthermore the cumulative frequency distributions show the expected positive skew 
(Edwards et al. 1990; Bekkers et al. 1990; Cormier & Kelly 1996; McBain & 
Dingledine 1992; Wyllie et al. 1994; De Simoni et al. 2003).   
 
Recording procedure 
Similar to other experiments, recordings were typically excluded if the holding 
potential was > 100 pA, if the access resistance was above >30 MΩ or if it varied by 
more than 30%.  This should have removed unstable recordings that might be 
indicative of poor cell / slice health.  Furthermore, caesium gluconate was included 
in the internal solution to try to maximise the voltage clamp. 
 
The protocol allowed for the sequential recording of sEPSCs, mEPSCs, sIPSCs and 
mIPSCs from each cell, although in practice for any given cell it was rare for the 
recording from all 4 current types to meet the inclusion criteria described above.  It 
was also relatively common for cells to die before reaching the end of mIPSC 
recordings (or earlier).  By the time mIPSC recording was reached, the recording had 
been underway for a considerable time and so it is possible that the health of the cell 
may have been poorer compared to that at the start of the recording.  As described, 
having thresholds for acceptable ranges of access resistance and holding potential 
attempted to mitigate this.   
 
On examination of the variance in recordings (Table 13), the standard error of the 
mean (SEM) for sIPSC and mIPSC recordings was typically higher than that of the 
sEPSCs and mEPSCs.  As the example traces shown in Figure 30 and Figure 31 
illustrate, the inhibitory current recordings were somewhat noisier than their 
excitatory counterparts, particularly at P26-30 where the frequency of inhibitory 
events is higher.  This may have contributed to the variability in the datasets for 
sIPSC and mIPSCs as distinguishing true from erroneous events is more difficult in 
the presence of noise.  This noise is likely due to low level background interference 
from NMDA receptor activity at 0 mV.  If future recordings were to be made, the 
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excitatory and inhibitory currents could be recorded from different slices.  Not only 
would this reduce the length of time a cell was subject to recording procedures (a 
maximum of 29 minutes in the current experiments), it would allow the 
pharmacological isolation of excitatory and inhibitory currents i.e. excitatory 
recordings could be done in the presence of picrotoxin to block GABAAR and 
inhibitory in the presence of CNQX and AP5 to block AMPAR and NMDAR.  This 
would be particularly advantageous for reducing the noise and potentially the 
variability in inhibitory recordings.   
 
Preliminary experiments were conducted to time the wash in of the bath applied 
drugs against the noticeable change in the recording trace that would signify that the 
drug was taking effect.  Hence 4 minutes was chosen as sufficient time for drug wash 
in, but this is a rather crude method, particularly for establishing if spontaneous 
activity has been blocked by TTX.  It is possible that 4 minutes may have been 
insufficient and so this would have meant there was potentially a mix of spontaneous 
and true miniature events in the early stages of mEPSC and mIPSC recordings. 
Making spontaneous and miniature recordings from separate slices so would 
overcome this difficulty as the slices for miniature recordings could be bathed in 
TTX throughout the experiment.  
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SynGAP Rats P13-15 16.74 (1.45) 24.27 (5.16) 16.52 (1.0) 19.89 (4.16) 
SynGAP Rats P26-30 13.64 (3.28) 30.33 (15.06) 11.64 (1.77) 18.91 (15.05) 
Hershkowitz et al. 
1993 
P16-23 SD, THS 11.9 (0.22)  13.2pA (0.33)  
De Simoni et al. 
2003 
Various ages, male SD 
(1.5 at P14) 
(5.6 at P21) 
 
Estimated P14: 8 pA (0.1) 
Estimated P21: 6.5 pA (0.2) 
Estimated P14: 19.5 pA (1) 
Estimated P21:17 pA (2.75) 
Zhang et al. 2005 
2-3 week old Wistar rats, 
coronal HS 
  11.54 (0.093)  
Parfitt & Madison 
1993 
200-300g SD rats, slice 
orientation not given 
  9 pA (range 0.8-5)  
Malik & Chattarji 
2011 
P36, male SD, THS   22.4 (0.28)  
Pitler & Alger 
1992 
200-300g, male SD rats, 
slice orientation not given 
 
Median = 150 
to 200 pA 
range (2.8-8 




Karlsson et al. 
2011 
P14-40, both genders, 
Wistar, THS 
(1.9) (3.5)   
Katchman et al. 
1994 
P21-28 SD rats, THS    22.6 (0.42  estimated) 
Tian et al. 2012 P18-21, male SD, THS 
34.60 pA 
(0.65) 
 25.49 pA (0.77)  
Amp = amplitude (in pA), Freq = frequency (in Hz), SD = Sprague Dawley, THS = transverse hippocampal slice, ‘Estimated’ = estimated from graphed data in the 





Could the lack of shift in mean excitation / inhibition be because the experiment was 
underpowered?  As this is the first exploration of SynGAP mutation in a rat, directly 
comparable data were not available to conduct a power calculation prior to recording.  
When examining the SynGAP _GAP deletion data post-hoc using the power 
calculation and sample size software at http://biomath.info/power/ttest.htm, it was 
possible to assess how small a difference between the means could be identified for 
an significance level of 0.05 and power 0.8.  As Table 13 reveals, only three of the 
observed differences (P13-15 sEPSC amplitude and frequency and P26-30 sEPSC 
amplitude) were larger than the minimum detectable difference between WT and 
Syngap
+/GAP
 means.  There was also a wide range in sample size for different 
recordings from n = 2 to n = 8 due to post-hoc discarding of cells that did not meet 
the inclusion criteria.  It is therefore possible that the present body of work is 
underpowered meaning a larger sample size may have shown a statistical difference 
between the excitatory and inhibitory currents across the two genotypes.  However, 
given the often large differences in standard error of the mean between the WT and 
Syngap
+/GAP
 data and the non-Gaussian distribution of the data, drawing definitive 
conclusions from the use of such calculations is questionable.  This is because 
standard power calculations assume that the data is a) normally distributed and b) 
sampled from populations with similar variance, neither of which is the case in the 
current dataset. The huge variation in the numbers of animals needed per group 
going forward if this current data is used for a power calculation likely reflects this.  
Clearly it is not ethical or practical to be using hundreds or thousands of animals per 
group, but it is possible that future datasets might be less variable for example if 
excitatory and inhibitory currents were recorded separately as discussed above.  
Smaller sample sizes would therefore be needed to achieve a robust level of 
statistical power. 
  
If the variance in the Syngap
+/GAP
 data was consistently in the same direction 
compared to WT rats, this might be informative, but the direction of variation 





 data is more variable.  The variance does not therefore appear to be 
related to the SynGAP mutation.   
 
Finally, it is worthy of note that it had been hoped that a comparison of action 
potential bursts from CA3 could be made between genotypes during the recordings; 
hence CA3 was left intact when the hippocampal slices were prepared.  However, 
bursting only occurred in two WT recordings at P13-15 (one sEPSC and one sIPSC) 
plus three WT recordings (one sEPSC and two sIPSC) and one Syngap
+/GAP
 (sEPSC) 
at P26-30 (Figure 41).  Therefore the very small number of cells in which it was seen 
prevented any formal analysis of this.  This lack of bursting may relate to the extent 
to which the preparation of hippocampal slices damages CA3 cell dendritic arbours 
(Li et al. 1994). The absence of bursting in cells bathed in TTX was reassuring as the 
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Figure 41 - Examples of sEPSC and sIPSC recordings discarded due to recurrent electrical activity 
from CA3. 




Table 13 – Size of detectable difference in excitatory and inhibitory current amplitude and frequency and future sample size calculations based on the 
current SynGAP rat data 
Parameter 







Size of statistically 
detectable difference 
between groups* 
Size of observed 
difference in means 
between groups 
Sample Size (n) required per 
group if current data is used 
for power calculation 
P13-15 sEPSC Amp (pA) 1.29 (7) 1.97 (3) 5.5 5.88 7 
P13-15 sEPSC Freq (Hz) 0.21 (7) 0.91 (3) 0.91 1.51 <6 
P13-15 mEPSC Amp (pA) 0.42 (6) 2.07 (4) 1.8 0.39 111 
P13-15 mEPSC Freq (Hz) 0.29 (6) 0.83 (4) 1.3 1.19 7 
P13-15 sIPSC Amp (pA) 1.68 (7) 3.68 (5) 7.2 0.09 38218 
P13-15 sIPSC Freq (Hz) 0.8 (7) 1.25 (5) 3.4 0.97 77 
P13-15 mIPSC Amp (pA) 1.34 (7) 1.19 (4) 5.7 2.74 28 
P13-15 mIPSC Freq (Hz) 0.72 (7) 1.12 (4) 3.1 0.26 840 
P26-30 sEPSC Amp (pA) 0.52 (2) 1.5 (6) 2.9 3.18* <6 
P26-30 sEPSC Freq (Hz) 0.69 (2) 0.88 (6) 3.9 0.31 158 
P26-30 mEPSC Amp (pA) 1.1 (5) 4.23 (4) 4.9 4.78 6 
P26-30 mEPSC Freq (Hz) 0.62 (5) 0.17 (4) 2.8 1.05 29 
P26-30 sIPSC Amp (pA) 6.31 (8) 3.18 (5) 27 3.06 536 
P26-30 sIPSC Freq (Hz) 1.2 (8) 2.9 (5) 5.1 1.8 57 
P26-30 mIPSC Amp (pA) 2.22 (4) 1.55 (4) 10 0.46 1464 
P26-30 mIPSC Freq (Hz) 3.88 (4) 5.18 (4) 18 0.95 1049 
Amp = amplitude, Freq = frequency, SEM = standard error of the mean, SD = standard deviation 





4.4.2.5 AMPAR / GABAAR and AMPAR / NMDAR data 
AMPAR / GABAAR and AMPAR / NMDAR ratios were calculated from CA1 
pyramidal cells recordings between the ages of P26-30 as a further measure of 
excitatory / inhibition.  As with other datasets, the research protocols were designed 
to ensure only healthy, stable recordings were included by discarding cells if the 
access resistance was >30 MΩ or if it varied by more than 20% during the recording.  
Care was taken to identify clean monosynaptic evoked responses to reduce the 
likelihood of recording a mixed current response.  The relevant reversal potentials 
were carefully identified too so that at the chloride reversal potential all negatively 
deflecting events were AMPAR mediated and at the AMPA reversal potential all 
positively deflecting events were GABAR mediated.   
 
No significant difference was seen in the AMPAR / GABAAR ratio between WT and 
Syngap
+/GAP
 recordings and as there is no published evidence of AMPAR / GABAAR 
ratios in the SynGAP literature this is a novel finding.  Fewer papers have 
investigated inhibitory function in SynGAP models, but as noted in the introduction 
to this chapter,  mice with SynGAP haploinsufficiency specifically in inhibitory cells 
originating from the medial ganglionic eminence [PV+ and Somatostatin+ (SST+) 
cells], have significantly longer mIPSC mean inter-event interval in layer 2-3 
pyramidal cells in the somatosensory cortex and hippocampal CA1 pyramidal cells 
(Berryer et al. 2016).  Furthermore targeted expression of the light sensitive Channel 
rhodopsin-2 via Cre also revealed reduced amplitude of evoked IPSCs in Layer 5 
pyramidal cells.  Both findings are therefore suggestive of a potential reduction in 
GABAergic function which might have revealed itself in the SynGAP _deletion rat 
experiments as a decrease in AMPAR / GABAAR ratio, but given the literature also 
suggests increases in excitatory function, the ratio could have balanced out.   
 
Alternatively, the fact that no such difference was revealed, may once again relate to 
the idea that SynGAP plays a particularly key role during development as evidenced 
by the numerous papers showing phenotypic differences in SynGAP 
haploinsufficiency models in the first two weeks of life which resolve by P21 
(Clement et al. 2012; Clement et al. 2013; Ozkan et al. 2014). 
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In contrast to AMPAR / GABAAR ratios, AMPAR / NMDAR ratios which have 
been more extensively studied previously in SynGAP haploinsufficiency were also 
recorded and no difference between genotypes was observed.  AMPAR / NMDAR 
ratios are increased in younger rats as discussed under ‘Experimental age’ (section 
4.4.1) above (and shown by Clement et al. 2012; Clement et al. 2013), but 
experiments in adult mice have shown no difference in AMPAR / NMDAR ratios 
(Komiyama et al. 2002).  The ratio of AMPAR / NMDAR in the developing brain of 
WT rats has been shown to increase over the first one to two weeks of life (Crair & 
Malenka 1995) and the unsilencing of AMPA receptors has been found to be relevant 
to LTP induction in young animals, but not mature animals (Abrahamsson et al. 
2008; Hanse et al. 2013).  Given SynGAP’s role in AMPAR trafficking via its 
regulation of Ras and Rap (Chen et al. 1998; Kim et al. 1998; Zhu et al. 2002; 
Krapivinsky et al. 2004; Zhu et al. 2005; Derkach et al. 2007; Walkup et al. 2015) it 
makes sense that differences in AMPA / NMDA ratio in WT and Syngap
+/GAP
 rats 
may well be more evident at younger ages; this would need to be verified in future 
experiments.  As with the other experiments presented in this chapter, the 
experimental model and background strain of the rats may have been influential and 
their roles could be better evaluated if future AMPA / NMDA experiments in 
particular are completed at around P14 in future where this is comparable data in the 
literature.   
 
The question of statistical power is again particularly relevant in these experiments.  
Using the calculator at http://biomath.info/power/ttest.htm, the minimum detectable 
difference between WT and Syngap
+/GAP
 when using the current data and considering 
a statistical significance of 0.05 and power of 0.8 is 0.28 for AMPAR / GABAAR 
ratio and 10 for AMPAR / NMDAR ratio (Table 14).  The observed differences 
between the means in this experiment were 0.0129 and 2 respectively, so the 
experiment was technically underpowered.  The standard error of the mean between 
the data groups was much more consistent between groups than in other datasets 
though.  The groups of data with n ≥ 7 (Syngap
+/GAP
 GABAAR/AMPAR and WT 
AMPAR/NMDAR) passed a normality test and so the use of a power calculator 
which relies on the assumption of normally distributed data is more valid.  However, 
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if the collected data is used for a future power calculation, the number of animals 
required per group for AMPAR / GABAAR is 341 and for AMPAR / NMDAR it is 
31, neither of which is ethical or feasible to achieve.   
 
Table 14 – Size of detectable difference in AMPAR / GABAAR and AMPAR / NMDAR ratios 






















Sample Size (n) 
required per 
group if current 
data is used for 
power 
calculation 
GABAAR/AMPAR 0.06372 (7) 0.07806 (10) 0.28 0.0129 341 
AMPAR/NMDAR 2.398 (8) 3.069 (6) 10 2 31 
*calculated using http://biomath.info/power/ttest.htm 
 
This therefore implies that although a difference could potentially be found between 
genotypes if large numbers of animals were used in the future, ethically and 
practically this isn’t possible.  So, it is reasonable to conclude that although the result 
is not statistically powerful, scientifically there was no meaningful difference in 
AMPAR / GABAAR and AMPAR / NMDAR ratios in P26-30 Syngap
+/GAP
 rats. 
4.4.3 Chapter Summary 
This chapter details the first electrophysiological findings in a SynGAP rat model.  
Some of the data is somewhat surprising, particularly the lack of exaggeration in 
mGluR mediated hippocampal LTD in Syngap
+/GAP
 rats and the reduction in 
frequency of mEPSCs from Syngap
+/GAP 
rat cultures.  The lack of mean difference in 
excitatory and inhibitory current data between genotypes is also rather unexpected, 
but the cumulative frequency distributions are perhaps suggestive of a trend in the 
predicted direction of excitation over inhibition.   
As described, the background strain of the rats and variability within samples are 
factors that are likely to have influenced each dataset albeit to varying degree.  
Notwithstanding this, it would appear at the present time that there is little in the way 
of difference between WT and Syngap
+/GAP
 rats in terms of hippocampal LTD, 
passive and active cell properties, excitatory and inhibitory currents and GABAR / 
AMPAR and AMPAR / NMDAR ratios.   
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5 CHAPTER FIVE: SYNGAP ISOFORM 
EXPERIMENTS 
 
5.1 Key Findings 
 Cortical cells co-transfected with Eα1 and eGFP tended to have larger and 
more frequent mEPSCs than in neighbouring control cells 
 Hippocampal cells co-transfected with Eα1 and eGFP tended to have smaller 
and less frequent mEPSCs than in neighbouring control cells 
 Expression of SynGAP Eα1 isoform may result in greater numbers of cortical 
cells completely lacking mEPSCs (‘silent cells’) 
 Multiple problems with SynGAP isoform specific primers precluded 
interpretation of data regarding the existence or abundance of specific 
SynGAP isoforms in mice  
5.2 Introduction 
As described in the main introduction to this thesis, SynGAP is a complex gene with 
several N and C terminal isoforms which have been identified in various papers and 
are recognised by the notation of the isoform’s N terminal followed by its C terminal 
e.g. Aα1, a system adopted in 2001 (Li et al. 2001).   
McMahon et al. showed that different promoter regions exist for SynGAP A, B and 
C and promote the transcription of these isoforms from distinct transcription start 
sites (TSS).  Multiple TSS exist for SynGAP A and SynGAP C, whereas SynGAP B 
has a single TSS (McMahon et al. 2012).  McMahon and colleagues also identified 
high homology in intronic sequences suggestive of functional significance in 
regulating promoter activity.  In contrast to the N terminal isoforms, McMahon noted 
that the C terminal isoforms are the result of alternative splicing. 
5.2.1 Timeline of SynGAP isoform identification 
As Table 15 shows, the first SynGAP paper (Chen et al. 1998) named the newly 
identified protein ‘Synaptic ras GTPase-activating protein p135 SynGAP’ or just 
‘p135 SynGAP’.  The sequence of the protein published in that paper is now 
recognised as SynGAP Aα1.  Chen and colleagues also identified what they believed 
to be two variants of p135 SynGAP, one an N terminal variant now recognised as 
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SynGAP B and the other a C terminal variant now recognised as SynGAP β.   In the 
same year  Kim and colleagues (Kim et al. 1998) identified a SynGAP protein when 
screening a yeast two–hybrid hippocampal cDNA library to find novel proteins that 
interact with the PDZ domains of the PSD 95/SAP90 family.  The SynGAP protein 
they identified was Cα1 and they also found three different variants which they 
named SynGAP-a, SynGAP-b and SynGAP-c.  These are now recognised as Aγ, 
Bα1 and Cα2 respectively. 
 
Li et al. 2001 identified a transcript they named ‘SynGAP-d’.  The C terminal of this 
is now recognised as SynGAP β, but the N terminal was unique and later shown to 
be an artefact by McMahon and colleagues (McMahon et al. 2012, supplementary 
information).  On designing primers to amplify SynGAP-d by RT-PCR, Li and 
colleagues found seven different sequences with minor differences in their C 
terminal sequences.  These they named α1, α2, β (β1, β2, β3, β4) and γ.   
 
Table 15- Timeline of the identification of different SynGAP isoforms 
Study Author’s variant name 
Isoform the 







Chen et al. 1998 ‘Synaptic ras GTPase-activating 
protein p135 SynGAP’ 
or ‘p135 SynGAP’ 
SynGAP Aα1 AF048976.1 
Chen et al. 1998 SynGAP B AF053938.1 
Chen et al. 1998 SynGAP β AF055883.1 
Kim et al. 1998 SynGAP Cα1 AF050183 
Kim et al. 1998 SynGAP-a Aγ AF058789.2 
Kim et al. 1998 SynGAP-b Bα1 AF058790.1 
Kim et al. 1998 SynGAP-c Cα2 AF050183.2 
Li et al. 2001 
C terminal isoforms α1, α2, β (β1, β2, 
β3, β4) and γ 
C terminal 
isoforms α1, α2, β 




5.2.2 Localisation of SynGAP isoforms 
Some differences in the localisation of SynGAP isoforms have been reported which 
may indicate different isoform functions.  C terminals α1, α2, β (β1, β2, β3, β4) and γ 
were found to be expressed in the brain using RT-PCR, but expression of γ was 
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markedly lower than that of α and β (Li et al. 2001).  α and β were also specifically 
identified in the forebrain structures and cerebellum (Li et al. 2001; Moon et al. 
2008), but whilst Li et al. found the expression profiles of α and β to be similar to 
each other in both the forebrain and cerebellum,  Moon et al. noted that α1 was 
stronger in the cerebellar cortex, and β was stronger in the cerebellar medulla.  In the 
dentate gyrus of the hippocampus Moon et al. showed that α1 formed two distinct 
immunoreactive layers in contrast to the homogeneous distribution of β.   
 
Upon labelling hippocampal slices from 6-8 weeks old Wistar rats with fluorescent 
probes Moon et al. found the immunoreactive puncta for both SynGAPα1 and 
SynGAPβ overlapped with PSD-95 puncta.  However the overlap was more intense  
with SynGAP α1 puncta.   They also noted that a substantial fraction of β clusters did 
not co-localise with PSD-95 implying the presence of β in other sites.  However on 
analysis of the synaptic plasma membrane fraction of 6 weeks old Wistar rat 
forebrain Li et al. found that whilst SynGAP α1 and β were both present in the post-
synaptic density, SynGAP α1 alone was also found in other fractions including the 
post-synaptic raft, the synaptic plasma membrane and the synaptosome (Li et al. 
2001).  This discrepancy may reflect the different brain regions being examined.   
 
Moon et al. went on to observe that α1 was predominantly present at excitatory post-
synaptic sites in Sprague-Dawley rat hippocampal cultures whereas SynGAP β was 
present at both excitatory and inhibitory sites (Moon et al. 2008).   Furthermore Li et 
al. reported that in Sprague-Dawley neocortical cultures β was localised in the 
dendrites including spines and also that it co-localised with PSD-95 (Li et al. 2001).  
This is consistent with the finding that PSD-binding motif on SynGAP α1 was not 
required for the localisation of SynGAP in dendritic spines (Vazquez et al. 2004; 
McMahon et al. 2012).    However SynGAP β was also found to co-precipitate with 
CaMKII α sub-unit which the authors proposed as a mechanism for SynGAP β’s 
strong localisation to the PSD in the absence of the QTRV domain by which 
SynGAP is known to interact with PSD-95 (Li et al. 2001).  With regards to other C 
terminal isoforms, Tomoda et al. showed that GFP tagged SynGAP α2 was localised 
to extending axons but the GFP tagged SynGAP α1 was only localised to the cell 
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soma (Tomoda et al. 2004).  In other later experiments, no SynGAP α2 mRNA was 
found on examination of developing thalamic ventral posterior medial nucleus tissue 
where it might have then localised to thalamo-cortical axons (Barnett et al. 2006).    
 
5.2.3 SynGAP isoform abundance 
Barnett and colleagues found on western blotting of homogenates of S1 (barrel) 
cortex, that in contrast to pan-syngap labelling (i.e. labelling of all isoforms) very 
little SynGAP α1 was present in the first week of life. Thereafter both SynGAP α1 
and pan-SynGAP labelling dramatically increased during the second postnatal week.  
As the same authors saw complete failure of cellular segregation into barrels in layer 
4 of the primary somatosensory cortex of Syngap
+/-
 mice at P6/7, the implication is 
that isoforms other than α1 mediate barrel formation. 
 
In an attempt to understand the developmental relevance of different isoforms in WT 
animals, McMahon et al. 2012 used quantitative reverse transcriptase-PCR to study 
their abundance in C57Bl6 mice using RNA isolated from forebrain and stimulated 
neuronal culture lysates.  Primers complementary to Syngap variant-specific 
sequences were designed and total SynGAP levels peaked at P14 and were 
significantly different from the levels at P4 and P21, but the isoforms showed 
different expression profiles.  Although they peaked at P14 the levels of N terminal 
isoform A were not statistically different from P4 to P14 to P21, but SynGAP B did 
show significant differences between its peak at P14 and the following time points 
(P4, P7, P21 and adulthood). Isoform C was expressed only at low levels up to P7 
and then was dramatically up-regulated by P14 and wasn’t significantly down 
regulated in adulthood as B was.   
 
5.2.4 Differential functions of SynGAP isoforms  
In addition to studying isoform abundance, McMahon and colleagues examined the 
impact of neuronal stimulation on SynGAP isoform expression.  They found that the 
application of bicuculline (a GABAAR receptor antagonist) to increase network 
activity correlated with an up-regulation in SynGAP B and C 4 hours later, whereas 
SynGAP A was down-regulated.  Overall the total SynGAP level did not change 
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indicating the changes in B and C offset that of A and which therefore suggested A is 
the most abundant isoform (McMahon et al. 2012). 
 
They were also the first and so far only group to systematically examine the effects 
of different combinations of N and C terminal isoforms (A, B, C, α1 and α2) on cell 
function.  They established that SynGAP α1 negatively regulates synaptic strength by 
increasing the number of silent cells (those that completely lacked mEPSCs during 
their recordings) and reducing the amplitude and frequency of mEPSCs when 
present.  In the case of Aα1 they confirmed this was not due to alterations in 
postsynaptic morphology and found that the extent to which α1 affects synaptic 
strength is modulated by the N terminal isoform it is coupled with; Aα1 had a larger 
effect than Bα1 and Cα1.  In contrast, the α2 isoform was associated with positive 
rather than negative alterations in synaptic strength (McMahon et al. 2012). 
 
As discussed in the introduction to the previous chapter, other researchers have also 
examined the role of certain specific SynGAP isoforms in cultured neurons.  Wang et 
al. (2013) found the knock down of alpha SynGAP in DIV 11-16 cultured cortical 
neurons resulted in increased mEPSC amplitude.   In keeping with McMahon’s 
work, a marked decrease in both amplitude and frequency of AMPAR mediated 
mEPSCs was observed in over-expression studies of GFP-tagged SynGAP 
Cα1isoform (Rumbaugh et al. 2006).  However in the same work, deletion of the C 
terminal portion of SynGAP including the PDZ binding domain and also separate 
mutation of the GAP domain resulted in no difference in amplitude and frequency 
from untransfected neurons.  This therefore implies the need for a functioning GAP 
domain and possibly the ability to interact via its PDZ binding domain for SynGAP 
to influence mEPSC frequency (Rumbaugh et al. 2006). 
5.3 Aims and Hypothesis 
In order to extend the SynGAP isoform work, this chapter details experiments to 
expand on the finding that distinct SynGAP isoforms can have a differential effect on 
synaptic strength (McMahon et al. 2012) by recording mEPSCs from cells 
transfected with the Eα1 isoform.  It also includes experiments to examine the 
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abundance and relative expression of SynGAP isoforms including putative newly 
identified isoforms.   
 
Based on the previous work of McMahon and colleagues (McMahon et al. 2012) it is 
hypothesised that  
 SynGAP Eα1 isoform will be associated with a reduction in mEPSC 
amplitude and frequency  
 SynGAP A will be the most abundant isoform in Syngap+/- mouse neocortex 
 
5.4 Results 
5.4.1 Identification of New SynGAP Isoforms 
 
Owen Dando, Informatician in the Centre for Integrative Physiology, University of 
Edinburgh mapped mRNA-seq read sets to their respective genomes, examined for 
novel splice junctions at the SynGAP locus and thereby identified putative new 
SynGAP 5' variant forms A1 and G in addition to the known N terminal (A, B, C, E) 
and C terminal (α1, α2, β and γ) isoforms (Figure 42 and Figure 43).  Dando also 
confirmed that there are two variants of SynGAP α2 (α2a and α2b).   SynGAP α2a 
only differs from α1 by the addition of an extra ‘G’ nucleic acid and α2b only differs 
from α2a by the addition of an extra valine (coded for by GTG nucleic acid 
sequence).  The extra G was also noted by Li and colleagues in four of their 
independent cDNA clones (Li et al. 2001). 
 
It should be noted that SynGAP A1 is a different isoform to SynGAP A rather that 
being the A1 referred to by McMahon et al. 2012 which was a form of SynGAP A 
that was generated from a different transcription start site from the other A isoform 
they denoted ‘A2’ (McMahon et al. 2012).    
 
Constructs of SynGAP isoforms Aα1, Bα1,Cα1, Eα1, Gα1 and Aα2, Bα2, Cα2, Eα2, 
Gα2 were made and their sequences confirmed by Sanger sequencing using Dando’s 







Figure 42 - Schematic of the SynGAP protein isoforms. 
 
Courtesy of Owen Dando, Centre for Integrative Physiology, University of Edinburgh (personal 
correspondence) There are 6 N terminal isoforms (A, A1, B, C, E and G) and 5 C terminal isoforms (α1, 
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Figure 43 – Mouse SynGAP Coding Sequence. 
 
The unique portions of each N terminal isoform are highlighted in a different colour.  The unique 
portions of the C terminal isoforms are highlighted in purple and the areas of common sequence between 





5.4.2 SynGAP Eα1 Isoform mEPSCs 
Cortical and hippocampal cell cultures were prepared then mEPSC recordings were 
made from neurons co-transfected with SynGAP Eα1 isoform and eGFP or 
untransfected neurons on the same coverslips (controls).  Recordings were also made 
from neurons on separate coverslips that had not been exposed to lipofectamine 
transfection (‘untransfected’ cells).  The recordings were made in the presence of 
tetrodotoxin (300 nM) and picrotoxin (50 µM) to block spontaneous, action potential 
driven activity in order to unmask the miniature events.  On examination of pooled 
data histograms for the recordings, the positive skew typical of mEPSC recordings 
was seen in the untransfected, control and Eα1 recordings in both the cortical and 
hippocampal cultures (Figure 44). 
 
The mean untransfected cell mEPSC amplitude and frequency were 17.68 ± 1.4 pA 
and 0.88 ± 0.18 Hz (n = 38) in the cortical cultures and 21.9 ± 1.5 pA and 0.85 ± 
0.16 Hz (n = 23) in the hippocampal cultures (Figure 45).  As the cumulative 
frequency distributions in Figure 45 show, the mEPSC amplitude in cortical cells co-
transfected with Eα1 and eGFP tended to be larger and the frequency higher than in 
neighbouring control cells.  However, on analysis of mean data collated by n = cell 
(Figure 45), there was no statisitical difference in mEPSC amplitude (Cortex Control
 
= 14.0 ± 2.3 pA n = 9, Cortex SynGAP Eα1
 
= 10.1 ± 2.9 pA n = 11, Mann-Whitney 
test between control and Eα1 p = 0.2905) or frequency (Cortex Control
 
= 0.72 ± 0.37 
Hz n = 9, Cortex SynGAP Eα1
 
= 0.28 ± 0.14 Hz n = 11, Mann-Whitney test between 
control and Eα1 p = 0.1718). 
 
In hippocampal cells co-transfected with Eα1 and eGFP the mEPSC amplitude 
tended to be smaller and the frequency lower than in neighbouring control cells 
(Figure 45).  However, once again there was no mean difference in mEPSC 
amplitude (Figure 45: Hippocampal Control
 
= 23.1 ± 4.9 pA n = 8, Hippocampal 
SynGAP Eα1
 
= 18.3 ± 1.8 pA n = 11, Mann-Whitney test between control and Eα1 p 
= 0.3511) or frequency (Figure 45: Hippocampal Control
 
= 0.87 ± 0.41 Hz n = 8, 
Hippocampal SynGAP Eα1
 
= 0.26 ± 0.07 Hz n = 11, Mann-Whitney test between 




McMahon and colleagues previously found that α1 C terminal SynGAP isoforms 
reduced the amplitude and frequency of mEPSCs in cultured forebrain neurons 
(McMahon et al. 2012).  Therefore the mixed picture from the current separate 
cortical and hippocampal recordings is intriguing and warrants further exploration in 
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Figure 44 – The frequency distributions of mEPSC amplitude from untransfected, control and 
SynGAP Eα1 are positively skewed. 
 
(A to C) The frequency distribution of the pooled mEPSC amplitudes from cortical untransfected (A), 
control (B) and SynGAP Eα1(C) recordings display the typical positively skewed distribution 
expected in mEPSC recordings (untransfected median = 18.46, untransfected mean = 23.12 pA, 
control median = 16.7 pA, control mean =  19.45 pA, SynGAP Eα1 median = 18.56 pA, SynGAP Eα1 
mean = 22.05 pA). 
 
(D to F) The frequency distribution of the pooled mEPSC amplitudes from hippocampal untransfected 
(D), control (E) and SynGAP Eα1 (F) recordings display the typical positively skewed distribution 
expected in mEPSC recordings (untransfected median = 20.31, untransfected mean = 24.97 pA, 
control median = 28.81 pA, control mean =  34.16 pA, SynGAP Eα1 median = 15.97 pA, SynGAP 









Figure 45 – There is no significant difference in the mean mEPSC amplitude or frequency in 
cortical and hippocampal neurons transfected with the SynGAP Eα1 isoform.  
 
(A) There is no significant difference in mEPSC amplitude between  control and SynGAP Eα1 
recordings (Cortex Untransfected = 17.68 ± 1.4 pA n = 38, Cortex Control = 14.0 ± 2.3 pA n = 9, 
Cortex SynGAP Eα1 = 10.1 ± 2.9 pA n = 11, Mann-Whitney test between control and Eα1 p = 0.2905, 
Hippocampal Untransfected = 21.9 ± 1.5 pA n = 23, Hippocampal Control = 23.1 ± 4.9 pA n = 8, 
Hippocampal SynGAP Eα1 = 18.3 ± 1.8 pA n = 11, Mann-Whitney test between control and Eα1 p = 
0.3511). 
 
Legend continued overleaf… 
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Figure 45 legend continued… 
 
(B) There is no significant difference in mEPSC frequency between control and SynGAP Eα1 
recordings (Cortex Untransfected = 0.88 ± 0.18 Hz n = 38, Cortex Control = 0.72 ± 0.37 Hz n = 9, 
Cortex SynGAP Eα1 = 0.28 ± 0.14 Hz n = 11, Mann-Whitney test between control and Eα1 p = 
0.1718, Hippocampal Untransfected = 0.85 ± 0.16 Hz n = 23, Hippocampal Control = 0.87 ± 0.41 Hz 
n = 8, Hippocampal SynGAP Eα1 = 0.26 ± 0.07 Hz n = 11, Mann-Whitney test between control and 
Eα1 p = 0.3950). 
 
(C) mEPSC amplitude cumulative frequency distribution in cortical and (D) hippocampal cell 
cultures. 
 
(E) mEPSC frequency cumulative frequency distribution in cortical and (F) hippocampal cell cultures.  
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The above mEPSC analyses included both cortical and hippocampal cells that had no 
identifiable mEPSCs during the recording period (a minimum of 5 minutes), so 
called ‘silent cells’ (Figure 46). α1 C terminal SynGAP isoforms have previously 
been shown to be specifically associated with higher proportions of silent cells in 
forebrain neuronal cultures  (McMahon et al. 2012).   
 
As Figure 46 shows, in the present experiment none of the untransfected cells were 
silent, whereas four Eα1 co-transfected cells were silent in the cortical cell 
recordings and 1 each of the cortical and hippocampal control recordings were silent 
(Cortex Control; mEPSCs n = 8, silent n = 1, Cortex Eα1; mEPSCs n = 7, silent n = 
4, Hippocampus Control; mEPSCs n = 7, silent n = 1, Hippocampus Eα1: mEPSCs n 
= 11, silent n = 0).  No statistical analysis of these numbers has been conducted due 
to the small numbers involved, but nevertheless it is suggestive of Eα1 having a 
silencing effect in the cortex like other α1 isoforms.  Although further examination of 
the silent cells was not conducted in the present experiments, McMahon found that 
silent cells were viable, able to fire action potentials (in the absence of TTX) and 
didn’t differ from controls in their holding currents or gross morphology (McMahon 
et al. 2012). 
 
There is a risk that including the silent cell data would cause significant skewing of 
the statistical analysis.  Figure 46 therefore presents the mean mEPSC amplitude and 
frequency data after excluding the silent cells.  As with the full dataset, there is no 
significant difference in mean amplitude or frequency (Cortex Untransfected = 17.68 
± 1.4 pA, 0.88 ± 0.18 Hz n = 38, Cortex Control
 
= 15.73 ± 1.7 pA, 0.8 ± 0.40 Hz n = 
8, Cortex SynGAP Eα1
 
= 15.91 ± 2.6 pA, 0.44 ± 0.2 Hz n = 7, Mann-Whitney test 
between control and Eα1 amplitude p = 0.8665, Mann-Whitney test between control 
and Eα1 frequency p = 0.5358; Hippocampal Untransfected = 21.9 ± 1.5 pA, 0.85 ± 
0.16 Hz n = 23, Hippocampal Control
 
= 26.4 ± 4.2 pA, 0.99 ± 0.45 Hz n = 7, 
Hippocampal SynGAP Eα1
 
= 18.3 ± 1.8 pA, 0.26 ± 0.07 Hz n = 11, Mann-Whitney 
test between control and Eα1 amplitude p = 0.1259, Mann-Whitney test between 
control and Eα1 frequency p = 0.1509).  However, one outlier in the cortical control 
data and two in the hippocampal control group have particularly high frequencies of 
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events which skews the data to make the difference between the control and Eα1 
groups apparently more marked than it actually is.  This is also true for the full 
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Figure 46 – There is no significant difference in mEPSC amplitude or frequency in cultures 
transfected with SynGAP Eα1 isoform when silent cells are excluded. 
 
(A) A proportion of control and SynGAP Eα1 cells were ‘silent’ in cortical and hippocampal cultures 
(Cortex Untransfected; mEPSCs n = 38, silent n = 0, Cortex Control; mEPSCs n = 8, silent n = 1, 
Cortex Eα1; mEPSCs n = 7, silent n = 4, Hippocampus Untransfected; mEPSCs n = 23, silent n = 0, 
Hippocampus control; mEPSCs n = 7, silent n = 1, Hippocampus Eα1: mEPSCs n = 11, silent n = 0). 
 
(B) There is no significant difference in mEPSC amplitude between the control and SynGAP Eα1 
recordings in either cortical or hippocampal cultures when the unit of analysis is n = cell and silent 
cells are excluded (Cortex Untransfected = 17.68 ± 1.4 pA n = 38, Cortex Control = 15.73 ± 1.7 pA n 
= 8, Cortex SynGAP Eα1 = 15.91 ± 2.6 pA n = 7, Mann-Whitney test between control and Eα1 p = 
0.8665, Hippocampal Untransfected = 21.9 ± 1.5 pA n = 23, Hippocampal Control = 26.4 ± 4.2 pA n 
= 7, Hippocampal SynGAP Eα1 = 18.3 ± 1.8 pA n = 11, Mann-Whitney test between control and Eα1 
p = 0.1259). 
 
Legend continues overleaf… 
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Figure 46 legend continued… 
 
 (C) There is no significant difference in  mEPSC frequency between the control and SynGAP Eα1 
recordings in cortical and hippocampal cultures when the unit of analysis is n = cell and silent cells 
are removed from the dataset (Cortex Untransfected = 0.88 ± 0.18 Hz n = 38, Cortex Control = 0.8 ± 
0.40 Hz n = 8, Cortex SynGAP Eα1 = 0.44 ± 0.2 Hz n = 7, Mann-Whitney test between control and 
Eα1 p = 0.5358, Hippocampal Untransfected = 0.85 ± 0.16 Hz n = 23, Hippocampal Control = 0.99 ± 
0.45 Hz n = 7, Hippocampal SynGAP Eα1 = 0.26 ± 0.07 Hz n = 11, Mann-Whitney test between 




5.4.3 SynGAP isoform abundance experiments 
5.4.3.1 Primer Validation 
OneStep RT-PCR was carried out and the product was run on an agarose gel to 
ensure the primer pair sets worked and only amplified one product (Figure 47). 
 
 
Figure 47 - Gels showing successful production and amplification of DNA from 1 µg of synthetic 
SynGAP isoform construct using OneStep RT-PCR. 
 
















Conventional two-step RT-PCR was then conducted using 6 ng of RNA for each 
experiment.  The clean melting curves for each primer pair confirmed the 
amplification of just one product (Figure 48).  The amplification plots showed 
similar amplification across the three replicate samples for each primer set except for 
isoforms B and E (Figure 49).   
 
Standard curves were then constructed by conducting RT-PCR with increasing 
amounts of WT mouse neocortical RNA (Figure 50) in order to calculate the R
2
 and 
primer pair efficiencies for each set of primers. Isoforms A, C and E had very good 
R
2
 values (above 0.99), but the values for isoforms A1, B and GAPDH were lower, 
A1 considerably so (efficiency of 59.35%) (Table 16).  The A1 primer pair was 
therefore discarded and will be re-designed. 
 
There was no detectable product for primer pair G when using adult WT mouse 
neocortical tissue; hence no G data is presented with the melting plots amplification 
plots and standard curve data.  In order to evaluate whether this lack of isoform G 
product was due to a physiological lack of G or an inability to amplify physiological 
levels of it using that particular primer pair, 1 μg of synthetic SynGAP G isoform 
construct was added to a OneStep qPCR reaction.  Under these conditions an 
amplicon was generated and the melting curve and amplification plot were clean 
with no suggestion of non-specific target amplification (Figure 51).  The 
amplification and melt plot graphs have a different appearance for the G isoform data 
when compared with the other isoforms as the MJ research DNA Engine Opticon 
PCR machine was used rather than the Applied Biosystems 7500 Real-Time PCR 
system.  However it was later established that the G primer was not viable for 
reasons detailed in paragraph 5.5.2.4.  It is therefore unclear exactly what the G 
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Figure 48 - SynGAP N terminal isoform primer melt plots continued. 
 
Melt plots of each SynGAP isoform specific primer pair with melting temperature (Tm) shown in 
blue.  6 ng of cDNA used for each. 
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Figure 49 – Amplification plots for SynGAP N terminal isoform primers.  
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Figure 49 – Amplification plots for SynGAP N terminal isoform primers continued. 
 
Amplification plots for each of the SynGAP isoform and the GAPDH control primer pair.  
6 ng of cDNA used for each. 
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Figure 50  – Standard curves for SynGAP N terminal isoform and GAPDH control primer sets. 
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When the primer sets were evaluated, it was clear that aside from A1 (now 
discarded) all of them had efficiency values well over 100% (Table 16).  Primer pair 
efficiency is calculated as  10
(-1/slope of standard curve) 
-1 and at 100% the template doubles 
after each thermal cycle during exponential amplification (Life Technologies 2012).   
High efficiencies can be due to the presence of inhibitors in the reactions or too much 
cDNA in the dilution series (BioTechniques 2011).   High efficient values are 
therefore problematic and the potential impact of them on the RT-PCR data is 
explored in the discussion. 
 
Table 16 – SynGAP isoform qPCR primers 







A CGAGTCCAGCCGAAACAAAC GGGACTCAGCAGGGACTC -0.994 126.37 
A1 CGATGTCCTATGCCCCCTTC GGGACTCAGCAGGGACTC -0.986 59.25 
B GCTCTTCTTGCTGCTTTCCG GGGACTCAGCAGGGACTC -0.833 202.05 
C AAGTGCTGACCATGACCG GGGACTCAGCAGGGACTC -0.993 160.89 
E TTCTCGCTGCATCTTCCGAG GGGACTCAGCAGGGACTC -0.991 134.03 
G CGGTGCGAGATGGAGGC GGGACTCAGCAGGGACTC -0.991* 188.28* 
GAPDH 
Control 
GGGTGTGAACCACGAGAAAT CCTTCCACAATGCCAAAGTT -0.989 94.85 
*G primer results were obtained from separate qPCR in which 1 µg of RNA was added to the 







Figure 51 - G primer pair validation data using 1 µg of synthetic SynGAP G isoform construct. 
 
(A) Melt plot. 
(B) Amplification plot. 
(C) Standard curve. 
 
  




















5.4.4 RNA “spike in” experiments 
Prior to conducting experiments to compare the abundance of different SynGAP 
isoforms, so called ‘pan SynGAP’ primers, designed by McMahon and colleagues 
(McMahon et al. 2012) to amplify all known SynGAP isoforms, were used to check 
for the absence of SynGAP in the homozygous mouse neocortex.  The forward 
primer sequence was CGAAGTGCTGACCATGAC and the reverse primer sequence 
was CGGCTGTTGTCCTTGTTG.  As these were not newly designed primers, full 
validation was not conducted although their amplification and melt curve data were 
examined (Figure 52).  Although the quantity was negligible compared to that in WT 
and Syngap
+/-
, some mRNA was amplified in the Syngap
-/-
 mice (Figure 52).  As the 
amplification plot and melt curve show, this doesn’t appear to be due to 
amplification of off target product as both graphs are indicative of a single amplicon.  
This issue is explored further in the discussion.   
 
Thereafter a known amount of RNA was added to (or ‘spiked’ into) qPCR reactions 
using Syngap
-/-
 mouse neocortex.  This was repeated twice more, with different 
quantities of synthetic RNA used each time (Figure 53).  Unfortunately, these 
experiments did not result in a clear pattern of results.  The relative amounts of 
isoforms A and E amplified across the three spike-in experiments reflect the added 
quantities (i.e. more isoform added to the reaction resulted in greater amounts of 
amplicon).  However, the amount of product for isoform C didn’t follow the pattern 
of how much was added in; the highest amount of C was introduced in the third 
experiment but this resulted in the smallest amount of amplicon.  Furthermore 
SynGAP B and G didn’t amplify in any of the three experiments.  It is possible that 
the amounts of B and G added in were too small to be amplified given the validation 
of their primers was conducted with larger amounts of synthetic RNA.  Total or 
partial inhibition by other isoforms could perhaps explain the results for isoforms B, 
C and G which would be physiologically interesting.  However, it may simply be that 
the primer sets and / or the synthetic RNA were not behaving as predicted under 










(A) Total SynGAP mRNA expression levels in WT, Syngap+/- and Syngap-/- mice using pan 
SynGAP primers designed to amplify all isoforms of the protein. 
 
(B) Melting curve for pan SynGAP primers in in Syngap-/- mouse neocortical tissue showing one 
clear peak. 
 
(C) Amplification plot for pan SynGAP primers in Syngap-/- mouse neocortical tissue showing 








Figure 53 – Introducing known quantities of SynGAP isoforms into qPCR reactions did not 
result in a clear pattern of results. 
 
A), B) and C) show the abundance of each SynGAP N terminal isoform following the ‘spiking in’ of 
the quantities of isoform cDNA noted on the graphs. 
 
D) Combined data from panels A, B and C. 
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In addition to spiking in a mix of isoforms in one experiment, each isoform was also 
added to RT-PCR experiments individually in concentrations ranging from 0.1 pg – 
100 pg (Figure 54).  This was in an attempt to determine the physiological levels of 
isoform expression by comparing the Ct value at which each isoform was detected in 
WT mouse tissue with the concentration at which the same Ct value was seen in the 
synthetic “spike in” experiments.  For example if isoform A had a Ct value of 24 in 
mRNA from WT tissue and the spiking in of 25 pg of synthetic SynGAP A resulted 
in a Ct value of 24, it is possible to conclude that there is 25 pg of SynGAP A mRNA 
in the WT tissue. 
 
Unfortunately only isoforms A and E showed the expected change in abundance in 
relation to amount of RNA added to the mix.  Isoform B was not detected at all and 
C did not vary consistently with the quantity introduced into the reaction.  Therefore 
it wasn’t possible to draw comparisons with WT tissue as the primers weren’t 
behaving in a predictable or comparable manner. 
 
Given this discrepancy in primer efficacy when different quantities of RNA were 
added, OneStep RT-PCR was used to evaluate the behaviour of each primer pair at 
different numbers of PCR cycles to see how similar the results were (Figure 54).  
Unfortunately this revealed considerable differences in results under similar 
experimental conditions.  For example very little SynGAP C amplicon was seen 
under any of the experimental conditions, but in contrast, A, B and E were present at 
25, 35 and 50 cycles.  A, B and G clearly increased in abundance as more RNA was 
added at 25 cycles (although G isn’t visible until 1000 pg is present), but this pattern 
is not very clear for E.  Furthermore at 35 and 50 cycles A and E appear saturated 
with even the smallest amount of RNA (0.1 pg) and by 50 cycles B and G also 
appear saturated.  This considerable lack of consistency in primer efficacy 
invalidates any attempt in this chapter to make conclusions between SynGAP 




Figure 54 – The SynGAP isoform N terminal primers are not working in an equivalent manner 
making comparisons between their amplicons extremely difficult.  
 
(A) Varying amounts of SynGAP isoform synthetic RNA were added individually to RT-PCR 
reactions with a view to comparing this data to that from WT mice to establish the physiological 
concentrations of each isoform in vivo.  Only SynGAP A and E showed the expected decrease in 
abundance with reducing amounts of RNA.  Isoform B wasn’t detected and C did not vary with the 
amount of RNA added.  Therefore it wasn’t possible to make comparison with WT data. 
 
(B) OneStep RT-PCR was carried out using increasing amounts of synthetic SynGAP isoform RNA 
(0.1, 1, 10, 100 and 1000 pg for each primer pair) and using three different number RT-PCR cycle 
numbers.  The results show that the primers are not behaving in an equivalent manner to each other 
making comparisons between SynGAP isoforms invalid.  
 
n.b. the gel images for SynGAP A and B at 35 cycles have been horizontally flipped as the 
concentrations RNA were loaded in the opposite order. 
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The data in this chapter explores the role of the multiple SynGAP isoforms.  The first 
part examines the effect on miniature post-synaptic currents of transfecting the 
previously unstudied SynGAP Eα1 isoform into neuronal cultures.  The second 
presents the data from RT-PCR experiments investigating the different SynGAP N 
terminal isoforms.   
5.5.1 SynGAP Eα1 mEPSC recordings 
The data presented here is suggestive of SynGAP Eα1 resulting in more silent cells 
in the cortex (Figure 46).  However in the cells that did have mEPSCs, no mean 
difference in mEPSC amplitude or frequency was seen when comparing cells co-
transfected with SynGAP Eα1 and eGFP with their neighbouring control cells.  This 
is true for both cortical and hippocampal cultures (Figure 45) and also when the 
silent cells are removed from the analysis (Figure 46).  However, there was a 
tendency for cortical cells co-transfected with Eα1 and eGFP to have larger and more 
frequent mEPSCs, whereas hippocampal cells co-transfected with Eα1 and eGFP 
tended to have smaller and less frequent mEPSCs than neighbouring control cells 
(Figure 45).  Discussion of why a lack of overall Eα1 effect was seen in contrast to 
data in other α1 isoforms (McMahon et al. 2012) is warranted.  Given that these 
experiments were similar to mEPSC recordings from cultured neurons presented in 
Chapter 4, some repetition of the relevant factors here is inevitable.  
 
5.5.1.1 Culture health 
Poor culture health could have affected the quality or stability of the recordings, but 
the cultured neurons looked healthy when compared informally with other culture 
plates.  Furthermore the following measures were taken to reduce the likelihood of 
unstable or poor quality recordings: 
 Recordings were typically discarded if the holding current dropped below -100 
pA   
 Portions of each trace during which the access resistance was found to have 
exceeded 30 MΩ or varied by > 20%  
 Portions of each trace with a root mean squared noise of >4 (calculated by 
Minianalysis Version 6 Software (Synaptosoft Inc.) were discarded 
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 Traces with less than 5 minutes of recording remaining thereafter were also 
discarded 
However, it is worth noting that no silent cells were recorded from the completely 
untransfected coverslips.  This is important as it means that silencing of cells in this 
context could be as a result of exposure to the lipofectamine transfection reagents 
rather than related to SynGAP Eα1.   
 
5.5.1.2 Were the currents recorded typical of mEPSCs? 
A lack of significance could be due to heterogeneity in the type of events being 
recorded.  However, reassuringly, the frequency of untransfected recordings in this 
thesis (Cortical cultures 0.88 Hz, Hippocampal cultures 0.85 Hz) is in keeping with 
the published literature 0.2 – 2.5 Hz in rat culture or slice recordings (Turrigiano et 
al. 1998; De Simoni et al. 2003; Zhang et al. 2005; Sutton et al. 2006).  It is 
acknowledged that the amplitudes recorded (Cortical cultures: 17.68 pA, 
Hippocampal cultures: 21.9 pA) are somewhat higher than the 11 – 15 pA in the 
literature though (Turrigiano et al. 1998; De Simoni et al. 2003; Zhang et al. 2005; 
Sutton et al. 2006).   
 
I am however confident that, on balance, true mEPSCs were recorded because events 
were also manually reviewed to ensure they were fast rising and asymmetric and 
their amplitude distributions were found to have the expected positive skew (Figure 
44) seen by other authors (Bekkers et al. 1990; McBain & Dingledine 1992; Wyllie 
et al. 1994).   
 
5.5.1.3 Research protocol 
McMahon and colleagues found that mouse SynGAP α1 C terminal isoforms were 
associated with a reduction in mEPSC amplitude and frequency. However, they 
recorded from mouse forebrain cultures, whereas the current recordings were made 
from separate rat cortical and hippocampal cultures into which mouse SynGAP Eα1 
were transfected.  Therefore, there could be an effect of species and type of cultured 
cell.  SynGAP is highly conserved between species including portions of intronic 
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sequence which may regulate promoter activity (McMahon et al. 2012).  There also 
appears to be conservation of sequence between mouse and rat for the putative new 
isoforms (personal correspondence from Owen Dando, Centre for Integrative 
Physiology, University of Edinburgh).  It therefore seems unlikely that isoform 
specific effects would be drastically different between mice and rats, but it can’t be 
ruled out.   
 
McMahon and colleagues didn’t differentiate between cortical and hippocampal 
recordings.  This is interesting given the opposite trend in mEPSC amplitude and 
frequency found in the two brain areas in the current dataset.  It isn’t appropriate to 
combine the current cortical and hippocampal datasets here to see how they compare 
more directly to McMahon’s work, as slightly different culturing methods were 
employed for the two cell types.  Given that the hippocampal cells co-transfected 
with Eα1 and eGFP tended to have smaller and less frequent mEPSCs than 
neighbouring control cells, it may be that more of McMahon’s recordings were 
derived from hippocampal cells.  Alternatively it is entirely possible that the 
SynGAP Eα1 isoform has differential effects in different brain areas, but this cannot 
be confirmed or refuted with the present dataset.   
 
Aside from this, the research protocol followed in the current work, mirrors 
McMahon’s protocol closely (Table 17).   Both used liposome mediated transfection 
and recorded from cells at the same day in vitro ages using identical external and 
internal recording solutions.  There were minor difference in McMahon’s inclusion 
criteria as she discarded cells with an access resistance > 28 MΩ rather than 30 MΩ, 
but accepted cells with a holding potential as negative as -150 pA (compared with 
the current -100 pA cut off) as long as they were stable.  On balance I think the 





Table 17 – SynGAP isoform mEPSC experimental procedures are similar to those of McMahon  
Parameter SynGAP Eα1 experiments McMahon et al. experiments 
Cell origin Rat Mouse 
Brain region Cortex and hippocampus Forebrain 
Age at culturing  DIV 20.5 DIV 17.5 
Components of 
culture medium 
Cortical cultures (until feeding) 
Neurobasal A, rat serum, Penicillin-
streptomycin, B27 and Glutamine 
 
Hippocampal (and cortical when fed) 
Basal medium eagle, glucose solution, 
sodium pyruvate, N2 supplement, B27 
supplement and penicillin-streptomycin 
solution or antibiotic-antimycotic 





Lipofectamine 16 to 25 hours before 
recording 
Liposome-mediated co-transfection 
with eGFP and SynGAP 16 to 36 hours 
before recording 
Isoforms Mouse Eα1 Mouse Aα1, Bα1,Cα1, Aα2, Bα2, Cα2 
Age at recording DIV 9 - 11 DIV 9 - 11 
Recording solution 
Identical: (in mM) NaCl 150, KCl 3, HEPES 10, CaCl2 2.5, MgCl2 1.3, glucose 
10, glycine 0.05. 0.5 µM TTX, 50 µM picrotoxin 
Internal solution 
Identical: (in mM) Cs gluconate 130, CsCl 10, HEPES 10, EGTA 0.1, glucose 10, 
sodium phosphocreatine 10, Mg ATP 4 and Na3GTP 0.5. 
  
5.5.1.4 Sample size  
Could the lack of difference in mean amplitude or frequency in E α1 recordings be 
because the experiment was underpowered?  As noted in Chapter 2, there was no 
previous published Eα1 research on which to base a power calculation.  McMahon’s 
Aα1 and Cα1 mEPSC amplitude data from her unpublished thesis and her 2012 
Nature Communications paper (McMahon 2010; McMahon et al. 2012) were 
therefore used as proxy measures.  The required group size in order to achieve an 
effect size of 0.05 and power of 0.8 was found to be between 23 and 127 cells in the 
Eα1 experiments depending on whether Aα1 or Cα1 data (Bα1 data fell between the 
two) was used.  Therefore with group sizes of 7 – 11 for Eα1 transfected cells and 
neighbouring non-transfected cells, it is possible that this experiment would’ve 
observed a significant difference if the number of cells recorded from was higher.   
 
When examining the Eα1data (with silent cells excluded) post-hoc using the power 
calculation and sample size software at http://biomath.info/power/ttest.htm, it was 
possible to assess how small a difference between the means could be identified for a 
significance level of 0.05 and power of 0.8.  As Table 18 shows, the present body of 
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work is statistically underpowered as none of the observed mean values are larger 
than the minimum difference that could be detected.   
 
However, the same caveats apply here as to the excitatory and inhibitory current data 
presented in Chapter 4; the use of power calculations is questionable as the data is a) 
not normally distributed and b) sampled from populations with different variances 
(Table 18). 
 
Once again, the huge variation in the numbers of animals needed per group going 
forward if this current data is used for a power calculation, likely reflects the 
limitations of the power analysis and presents difficulties as it is not practical to use 
datasets as large as 156 let alone 22942.  The predicted numbers for the hippocampal 
data are smaller than that for the cortical data though and so perhaps a pragmatic 
approach would be to increase the hippocampal group sizes to the point at which a 
statistical difference could be detected.  A decision based on the experimental 
findings could then be made with regards to whether there was any merit in doing 
more cortical recordings.  Perhaps a more robust hippocampal dataset could be used 
as the basis for a power calculation for cortical recordings as it could be argued that 
using data from other isoforms for power calculations is fundamentally flawed.   
 
Finally it is again worthy of note that if the variance in the Eα1 data was consistently 
in the same direction compared to control, this might be informative, but the 
direction of variation changes between datasets, much like the Chapter 4 excitatory 




Table 18 – Size of detectable difference in SynGAP Eα1 mEPSC data and future sample size 
























per group if 
current data 





1.7 (8) 2.6 (7) 11 pA 0.18 pA 22,942 
Hippocampal 
mEPSC amplitude 
4.2 (7) 1.8 (11) 18 pA 8.1 pA 31 
Cortical mEPSC 
frequency 
0.4 (8) 0.2 (7) 1.7 Hz 0.36 Hz 156 
Hippocampal 
mEPSC frequency 
0.45 (7) 0.07 (11) 1.9 Hz 0.73 Hz 43 
SEM = standard error of the mean, SD = standard deviation  
*calculated using http://biomath.info/power/ttest.htm 
 
5.5.1.5 Statistical analysis 
The statistical measure (Mann-Whitney test) used to compare the Eα1 transfected 
cells with their neighbouring control cells was perhaps somewhat crude as it did not 
take into account the richness of the data with regards to factors such as transfection 
batch and culture batch.  McMahon and colleagues overcame this by using a 
generalised linear mixed model statistical approach which could be considered for 
future Eα1 experiments.  At the present time without employing a more complex 
analysis it is unclear whether this factor has led to a lack of mean statistical 
significance in the current dataset. 
 
5.5.1.6 Control experiments 
The current experiments compared Eα1 and eGFP co-transfected neurons to 
neighbouring neurons on the same coverslips.  Expression of SynGAP Eα1 was 
taken to have occurred if the co-expressed eGFP was evident (i.e. if the neuron 
fluoresced green).  Therefore neighbouring cells that weren’t fluorescing were 
deemed not to have taken up the Eα1, but no objective measure was made of whether 
this assumption was true.  If SynGAP Eα1 and eGFP were not equally expressed by 
cells that had been successfully transfected, this would therefore make the 




Furthermore, although the control cells had been bath exposed to lipofectamine 
transfection reagents, it was assumed that they had not been successfully transfected 
as they weren’t expressing sufficient amounts of eGFP to fluoresce.  It is not possible 
to know if this was because of some hitherto unidentified difference between them 
and successfully transfected cells that could potentially impact on mEPSC properties.  
Therefore for future experiments a β-globin plasmid could be co-transfected with 
GFP to act as a control.  Control cells would then be more similar to experimental 
cells in so far as they would have taken up an external plasmid and they could also be 
positively identified as having undergone successful transfection if they fluoresce.  
Furthermore, samples could be taken from the cells to identify whether the construct 
was indeed being expressed.  For example flow cytometry could be used to evaluate 
the expression of eGFP due to its fluorescent properties, but RT-PCR could be used 
to specifically ensure the gene of interest and not just its eGFP partner was being 
expressed. 
 
5.5.1.7 Summary of Eα1 recording data 
There is a suggestion that the SynGAP Eα1 isoform might, like other SynGAP 
isoforms have an impact on synaptic strength.  However, the methodological issues 
described above make it difficult to draw definitive conclusions on this without 
further experiments. 
 
5.5.2 SynGAP RT-PCR experiments 
The initial OneStep RT-PCR confirmed the primer sets were able to amplify specific 
product (albeit using synthetic RNA), as did the presence of product in the two step 
RT-PCR experiments on WT neocortical tissue, except for SynGAP isoform G.  
However, these experiments could not evaluate the comparative efficacy of the 
primers and it wasn’t until the RNA “spike in” experiments that it became clear that 
they may not be working in a comparable manner under the same experimental 
conditions.  This was confirmed by the later OneStep RT-PCR reactions with varying 
amounts of RNA and numbers of PCR cycles.  Hence drawing any conclusions from 
the RT-PCR experiments became extremely difficult.  The relevant factors are now 
discussed in more detail below. 
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5.5.2.1 Sub-optimal predicted primer pair properties 
Attempts were made to design the new primers to fit the following list of optimal 
parameters suggested by Dr Paul Baxter, Centre for Integrative Physiology, 
University of Edinburgh, based on his extensive RT-PCR experience: 
 Primer length 17 – 23 bp 
 Melting temperature 59 – 62.9°C 
 Difference in melting temperatures of no more than 1°C 
 Primer end is a cytosine or guanine 
 Primers span an exon boundary 
 Product (amplicon) length of 150 -250 bp    
The primer pair properties were evaluated using the Sigma Aldrich OligoEvaluator
TM
 
(http://www.oligoevaluator.com/OligoCalcServlet).  The amplicon length was 
estimated using the NCBI Blast tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
although it wasn’t always possible to find a mouse transcript in which both the 
forward and reverse primer were found.  Therefore for some primer pairs the 
amplicon length was estimated from a different species.  Given that SynGAP is 
highly conserved between species (McMahon et al. 2012), these estimates are likely 
to be very similar to the hypothetical length in a mouse.  Unfortunately no transcript 
with both the forward and reverse primer sites could be found for SynGAP E or G so 
it wasn’t possible to estimate the amplicon length from Ensembl.  For G this was 
because the forward primer was designed to be within the 5’ untranslated region 
(UTR) of the isoform due to the short length of unique sequence available for G 
primer design.  However, it was also later determined that there was a significant 
flaw in the design of the G primer (see paragraph 5.5.2.4). SynGAP E (as well as G) 
is a putative isoform so it is perhaps not surprising that the forward primer for it 
couldn’t be identified in an existing SynGAP transcript.  SynGAP sequence data 
from Owen Dando was therefore used to predict the amplicon length for isoforms E 
and G.   
 
Whether each primer pair crossed an exon boundary was established by identifying 




000067629;r=17:26941253-26972434;t=ENSMUST00000194598.  The longest 
transcript (ENSMUST00000194598.5) was used except for isoform B and C 
(ENSMUST00000081285.8) and GAPDH (ENSMUST00000118875.7).  As no 
transcript containing the E and G isoform forward primers could be identified it 
wasn’t possible to determine whether they crossed an exon boundary, but once again 
this has become irrelevant for G due to the problems with its design (see paragraph 
5.5.2.4). 
 
The amount of unique sequence for some of the SynGAP isoforms is very short or 
non-existent which meant that it wasn’t possible to ensure that all the melting 
temperatures fell in the desired range or that they didn’t differ by more than 1°C.  
1°C is particularly stringent though as commercial advice suggests a difference of 
5°C is an acceptable range (Life Technologies 2012) within which the primers 
should melt and bind to the target sequence simultaneously.  For the most part 
(except SynGAP E primer set) the current primers all fall within this more lenient cut 
off.  Their melting temperatures were often predicted to be higher than was deemed 
optimal for RT-PCR conditions, but the reverse transcriptase enzyme used for the 2 
step RT-PCR can be used to a temperature of 65°C and the enzyme mix for the 
OneStep PCR up to an annealing temperature of 68°C  (Roche Applied Science 
2010; Qiagen 2012).  Furthermore commercial companies suggest a melting 
temperature between 50 and 65°C (BIO-RAD Laboratories 2006).  The annealing 
temperature for the two step RT-PCR reactions was typically 55°C and given the 
advice that this should be 5°C lower than the primer melting temperature, this might 
have been a more important factor as all the SynGAP isoform primers had melting 
temperatures > 60°C.  With an annealing temperature that is too low, primers can 
bind non-specifically to the template, but examination of the melt curves suggests 
this was not a problem as one clear product was amplified. 
 
The amplicon length was considerably longer that the chosen ideal for many of the 
primer sets which was already more generous at its upper limit than the 
commercially suggested range of 50 – 200 bp (BIO-RAD Laboratories 2006; Qiagen 
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2011; Life Technologies 2012).   Longer amplicons do not amplify as well as shorter 
ones which would lead to lower primer pair efficiencies, so given high primer pair 
efficiencies in this set of experiments, amplicon length wasn’t clearly a problem 
unless it was masked by other more influential factors.   
 
GC content of primers is recommended to fall in the range of 50-60% (BIO-RAD 
Laboratories 2006; Life Technologies 2012) although percentages up to 70% can be 
managed with adjustment of the thermocycling conditions (Roche Applied Science 
2010).  Therefore the GAPDH reverse primer’s GC content of 45% is on the low side 
and the SynGAP G isoform forward primer is on the high side (70%).  It is possible 
that this contributed to the lack of consistency of primer sets under the same 
conditions, but high GC content is more likely to lead to secondary structure 
formation and SynGAP G was not predicted to form secondary structures.  It was in 
fact SynGAP E primer pair that was most at risk of this. 
 
Which, if any, of the individual physiological properties adversely affected each 
primer pair is impossible to delineate from the current data.  However, suffice to say 
there was considerable variation in the properties of the different primer sets which 



























A CGAGTCCAGCCGAAACAAAC 20 66.9 55 346 No None No 
A1 CGATGTCCTATGCCCCCTTC 20 67.6 60 523 No None No 
B GCTCTTCTTGCTGCTTTCCG 20 66.3 55 296 No None No 
C AAGTGCTGACCATGACCG 18 62.5 55.6 76 No None No 














GGGACTCAGCAGGGACTC 18 62.6 66.7 - No None No 
GAPDH 
Forward 
GGGTGTGAACCACGAGAAAT 20 63.8 50 
120 
No Weak No 
GAPDH 
Reverse 




CGAAGTGCTGACCATGAC 18 60.5 55.6 
284 
 




CGGCTGTTGTCCTTGTTG 18 63.1 55.6 
Yes 
(between 
exons 7 and 
8) 
None No 
  *This reverse primer was used for all SynGAP isoform specific primer pairs # information derived from Owen Dando’s data
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5.5.2.2 Sub-optimal primer pair validation data 
Ideally a primer pair will have an efficiency of 100% meaning the template doubles 
after each thermal cycle during exponential amplification (Life Technologies 2012). 
The A1 primer pair was discarded due to particularly low primer pair efficiency 
(59.25%) as any amplicon abundance determined using this primer pair may have 
significantly underestimated the amount of A1 isoform present.   
 
SynGAP B isoform primer pair’s standard curve was not straight seemingly due to a 
particularly low first data point and related to this (because primer pair efficiency = 
10
(-1/slope of standard curve) 
-1), it had an unacceptably high primer pair efficiency of 
202.05%.  Efficiencies in the range of 90-110% are reasonable (BIO-RAD 
Laboratories 2006; Life Technologies 2012) so the data for SynGAP B in particular, 
but also the other SynGAP isoforms was outwith this range.  As mentioned above, 
high efficiencies can be due to the presence of inhibitors in the reactions, particularly 
reagents carried over from the reverse transcriptase step.  They can also arise when 
too much cDNA was used in the dilution series for the standard curve 
(BioTechniques 2011).   It might therefore be worth repeating the standard curves 
with lower concentrations and perhaps giving consideration to adding cDNA 
purification steps despite the Transcriptor First Strand cDNA Synthesis Kit 
instructions stating this isn’t required (Roche Applied Science 2010).    
 
In addition to the high efficiency, the B primer pair had a low R
2
 value of 0.833.  
This is the extent to which the experimental data fit the standard curve and generally 
values less than 0.98 are deemed too low (BIO-RAD Laboratories 2006).   The use of 
Isoform B primer pair was therefore questionable and in fact, there is an argument 
that all the SynGAP isoform primer pairs should’ve been re-evaluated to see if they 
could be better designed prior to RNA “spike in” experiments.  
 
5.5.2.3 RNA used for primer validation 
Use of the OneStep RT-PCR kit confirmed that the primers were able to successfully 
amplify their specific targets in synthetic RNA.  However, further primer validation 
was carried out using two step RT-PCR on WT mouse neocortical tissue rather than 
238 
 
using synthetic RNA.  No product was seen for isoform G and so 1 µg of synthetic 
RNA was used to establish if the problem lay with the reaction and primer pairs (i.e. 
the experiment didn’t result in amplification of G isoform that was present) or in the 
RNA substrate (i.e. there was no G isoform present to amplify).  The 1 µg 
experiments successfully generated an amplicon, suggesting there may not be any G 
isoform in the WT tissue.  However, 1 µg is considerably higher than physiological 
levels of RNA so this could also have had a bearing on the results and it is also 
possible that the synthetic G isoform RNA’s physiological properties cause it to 
behave differently under experimental conditions when compared to the WT tissue, 
something that was not evaluated.   
 
5.5.2.4 There was an error in the SynGAP G forward primer design 
Following the above experiments, it was determined that the design of the SynGAP 
G forward primer is flawed.  On cross referencing the primer sequence again with Dr 
Dando’s sequence information it was confirmed that the first part of the G forward 
primer (CGGTGCGAG) lies at the end of the first exon of G and is within the 5’ 
(UTR) of the protein.   However, it then became clear that the rest of the primer 
sequence (ATGGAGGC) is at the start of the coding region in exon 2, rather than at 
the actual start of exon 2 (which is a continuation of the 5' UTR). This means there is 
a gap between the two portions of sequence which is of course incompatible with a 
functioning primer.  This primer will now need to be redesigned with the correct 
sequence information as a guide. 
5.5.2.5 The behaviour of the SynGAP RT-PCR reactions is not consistent under 
similar experimental conditions 
The relative amounts of isoforms A and E across the three “spike-in” experiments 
(Figure 53) reflect the quantity of RNA added (i.e. more synthetic RNA in = greater 
product produced) and they had the best R
2
 and primer pair efficiencies perhaps 
adding weight to the argument that the data for the other isoforms is adversely 
affected by primer properties.  The amount of product for isoform C didn’t follow the 
pattern of how much was added in though and when synthetic SynGAP C RNA was 
introduced to RT-PCR individually at different concentrations, there was no 
appreciable change in the amount of amplicon detected (Figure 54).  In addition to 
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this, SynGAP B was not detected either when probed for in the multi-spike in 
experiments (Figure 53) or when it was added in individually (Figure 54).  
 
In principle these discrepancies in Isoforms B and C could be due to inhibition by 
other isoforms.  However, in the case of C, the expression pattern in the multi-spike 
in experiments doesn’t seem to relate to the abundance of any of the other isoforms.  
In the case of SynGAP B, the complete lack of product could just as easily reflect 
unexpected synthetic RNA or primer pair behaviour making conclusions about 
inhibition by other isoforms impossible.  
 
In order for comparisons between the SynGAP isoforms to be made, the primer pairs 
for each one need to behave similarly under the same conditions.   OneStep RT-PCR 
experiments conducted to better understand the comparability of the data for the 
different SynGAP isoforms made it abundantly clear that there is huge variation in 
the results (Figure 54).  As noted, this could be due to the primer pairs behaving 
differently from one another.  However the physiological properties of the synthetic 
SynGAP RNA constructs (e.g. melting temperature, GC content etc.) have also not 
previously been evaluated.  If such properties vary between the constructs then this 
would also potentially skew the RT-PCR results.  Furthermore, it is possible that due 
to varying levels of common sequence between the SynGAP isoforms, hybridisation 
occurred between PCR products, the primers and the target cDNAs in the RT-PCR 
experiments.   
5.5.2.6 Some SynGAP appeared to be present in RT-PCR of Syngap-/- neocortical 
tissue 
A further problem with the “spike-in” RT-PCR experiments is the possible presence 
of small amounts of SynGAP in Syngap
-/- 
mice.  The abundance is markedly less than 
that in WT and heterozygous mice, so it is possible that the explanation is the 
amplification of non-specific products.  However, the melting curve for the pan 
syngap primer pair is clean suggesting a single amplicon (Figure 52).  Furthermore 
the pan syngap reverse primer crosses an exon boundary (exon 7 to 8) and so 
contamination with genomic DNA is highly unlikely as it wouldn’t be amplified by 
this primer set.   
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The SynGAP mice used in these experiments were those generated by Komiyama 
and colleagues by disrupting the C2 and GAP domains of the Syngap protein 
(Komiyama et al. 2002).  They used Southern blotting to confirm the structure of the 
gene and reassuringly showed a lack of normal SynGAP DNA in the Syngap
-/-
 mice.  
However, they did not probe in any further detail.  The pan syngap primers used in 
the current RT-PCR experiments bind upstream from where Komiyama and 
colleagues inserted their target vector.  Therefore SynGAP promoters may still be 
present in the mouse from which incomplete and likely non-functional SynGAP 
RNA transcripts can be made.  These would serve as templates in the RT-PCR 
experiment and therefore explain the apparent presence of SynGAP amplicon in the 
Syngap
-/- 
mice.  The fact that the amplified levels are low can be explained by these 
non-functional transcripts undergoing nonsense mediated RNA decay, a mechanism 
by which cells can monitor mRNA quality and prevent the synthesis of truncated 
proteins that could have damaging effects such as dominant negative interactions 
(Brogna & Wen 2009).  Nonsense mediated mRNA decay is  triggered by premature 
translation-termination codons which are in abnormal contexts (Brogna & Wen 
2009; Lykke-Andersen & Jensen 2015), something which could certainly have 
occurred following the disruption of the SynGAP DNA in the Syngap
-/-
 mice.   
 
5.5.3 Chapter summary 
This chapter highlights some of the complexities of studying SynGAP isoforms, in 
particular the difficulties in designing successful, valid primers that are isoform 
specific due to the sequence homology between isoforms.  Unfortunately it is 
therefore not possible to even cautiously draw inferences from any of the SynGAP 
isoform RT-PCR data in this chapter as factors related to the expression of different 
SynGAP isoforms cannot be isolated from factors related to the primer design, 
behaviour of the primers or synthetic RNA.  Going forward with the RT-PCR 
experiments, each of the primer pairs needs to be re-designed in an attempt to make 
their intrinsic physiological properties more consistent and an examination of the 
intrinsic properties of the synthetic RNA would also be advantageous.  If problems 
persist even with better primer validity, this may be suggestive of complex 
hybridisation between the different isoforms and their primers due to their common 
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sequence elements.  As this will be impossible to control for or eliminate, it may be 
that RT-PCR will have to be abandoned as the technique to investigate SynGAP 
isoform abundance and other approaches such as RNA sequencing adopted instead. 
 
However, on a more positive note, this chapter also expands on the previous 
systematic examination of the effect of SynGAP isoforms on synaptic strength 
(McMahon et al. 2012) and tentatively suggests that the Eα1 isoform may influence 
mEPSC amplitude and frequency like other isoforms.  This statement is however 
made with caution given the differences seen were in cumulative frequency 
distributions and not mean data and further experiments are needed to come to firm 







6 CHAPTER SIX: CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
6.1 Concluding remarks 
This thesis presents a variety of work which expands on the current knowledge of the 
functions of the SynGAP protein.  This is of value for fundamental neuroscience 
given SynGAP’s regulatory function in the brain, but it also adds to our 
understanding of the effects of altered SynGAP protein expression.  In humans, 
SynGAP mutations are linked to intellectual disability, autism spectrum disorders 
and epilepsy so understanding the function of the SynGAP protein may in time help 
to better delineate the processes involved in these disorders. 
 
Initial characterisation of the SynGAP_GAP deletion rat confirmed that deleting a 
portion of the SynGAP protein in rats would lead to death in homozygotes.  
Furthermore it showed that that there is no gross behavioural or developmental 
difference between WT and heterozygous rats.  Western blot analysis confirmed the 
hypothesis that the mutant SynGAP would be present in various brain regions 
including the hippocampus and would be found to be comprised of multiple SynGAP 
isoforms.  Developmental western blotting indicated a broadly similar pattern of 
SynGAP expression to that in WT mice. 
 
Electrophysiological examination revealed some surprising findings, firstly the 
absence of the predicted exaggeration in hippocampal mGluR mediated LTD. 
Secondly,  a decrease in the frequency of mEPSCs from cultured Syngap
+/GAP
 
neurons with no difference between Syngap
GAP/GAP 
and WT neurons rather than the 
hypothesised increase.  Moreover, no other definite electrophysiological differences 
were found between WT and Syngap
+/GAP
 rats despite the prediction that changes 
indicative of increased excitability would be identified.  This suggests that perhaps 
there is little in the way of cellular or synaptic phenotype in these animals. 
 
The second major theme of this thesis was to expand on previous data indicating 
specific physiological effects of different SynGAP isoforms and to further explore 
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their expression.  Unfortunately the sequence homology between isoforms heavily 
impacted on the primer design for RT-PCR experiments and the primers were shown 
to be functioning differently under comparable experimental conditions precluding 
the drawing of any firm conclusions about SynGAP isoform abundance and 
regulation.  However observations of the impact of SynGAP isoform Eα1 on 
synaptic strength were tentatively more promising with some suggestion that this 
isoform does indeed play a role in synaptic strength regulation as other isoforms have 
previously been shown to do. 
 
It is important however, that the major confounding variables and methodological 
difficulties identified in this thesis be addressed before consideration can be given to 
which future experiments to pursue.   
6.1.1  Addressing confounding variables 
Although various potentially confounding variables were identified in the results 
presented here, I believe the following are the most significant ones to be addressed 
in future research. 
 
6.1.1.1 Difference in SynGAP rodent model 
Comparisons between the current rat data and previous SynGAP mouse data are 
difficult due to the fact that the mouse models are full knock outs of the mutant 
Syngap allele with very little or no SynGAP protein expression whereas the rat 
model is a deletion in which mutant SynGAP is expressed.   
 
Firstly, undertaking a GTPase assay such as those undertaken in early SynGAP 
research (Chen et al. 1998, Kim et al. 1998) to definitively establish the absence of 
GAP domain function in the SynGAP_GAP deletion rats would help to evaluate the 
difference as the GAP domain mediates SynGAP’s enzymatic function.   
Secondly, one could either engineer mice to have the SynGAP_GAP deletion or 
engineer rats to have a mutation resulting in knock out of the affected Syngap allele.  
Either genetic approach would be equally valid, but given the many advantages of 
studying rats over mice in conditions where learning, memory and sociability are of 
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particular interest, I would choose to engineer a knock out rat for comparison with 
the SynGAP_GAP deletion rat. 
6.1.1.2 Background strain 
As discussed in detail in Chapter 4, it has been difficult in this body of work to 
delineate which effects may be due to the alteration in SynGAP from those related to 
the background strain of the SynGAP_GAP deletion rats.  The potential solutions 
would be to  
1. Engineer rats with the same SynGAP mutation on different background 
strains 
2. Conduct the same experiments presented here in groups of wild type rats 
from different background strains 
Engineering a new genetically modified rat model is costly and time consuming so 
exploring the electrophysiological properties in WT rats from different background 
strains would be a pragmatic approach to delineating the role of strain versus Syngap 
mutation.   
6.1.1.3 Developmental compensation 
The work on altered SynGAP levels in rats has to date not been able to explore 
whether developmental compensation has played a role in the phenotypes or the lack 
thereof.  Hence, going forward, repeating the experiments in conditions of acute 
SynGAP knockdown using a cre-loxP or siRNA approach would be of interest. 
 
6.1.2 The challenges of SynGAP isoform specific primers 
Given the similarity in sequence between SynGAP isoforms, primer design proved 
extremely challenging.  It is possible that re-designing the primers again and 
attempting to adhere more closely to the parameters identified as important for good 
primer validity (Paragraph 2.3.4.3) may improve the comparability of primer sets.  
Examination of the intrinsic properties of the synthetic RNA may also be required to 
ensure they have similar melting temperatures, GC content etc. across different 
experimental conditions.  If they don’t have similar properties or if it is not possible 
to re-design the primers well enough, an alternative technique will need to be 
employed to examine SynGAP isoform abundance.  Even if primer pair validity and 
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RNA intrinsic property problems are minimised, there could still be unpredictable 
hybridisation in the RT-PCR reactions due to the similarities between the different 
primers and RNA which would also mean that a different approach would be needed.   
 
RNA sequencing is a potential alternative technique which has the advantage of 
having a high resolution with low background noise and the ability to identify new 
transcripts.   
 
6.2 Future directions 
Assuming the major methodological flaws in the data presented here have at some 
point in the future been addressed, where should SynGAP_GAP rat research proceed 
to next?  SynGAP mouse research highlights many unanswered questions about the 
SynGAP_GAP deletion rat.  Perhaps the most pressing are  
1. Do the rats have a reduced seizure threshold and could they be experiencing 
subclinical seizures? 
2. Do the rats display any behavioural deficits in learning and memory or social 
interaction? 
3. Is there any evidence of altered brain circuitry in these rats? 
 In order to answer these questions and assuming unlimited funds and resources, I 
would plan to do the following 
 EEG monitoring and an audiogenic seizure paradigm – these would both 
identify susceptibility to and presence of seizures, plus EEG may show other 
abnormal electrical rhythms as non-epileptic EEG abnormalities have been 
noted in humans with SYNGAP1 ID (Mignot et al. 2016) 
 A battery of behavioural tests including Morris water maze experiments and 
object-place-context tasks (for learning and memory), elevated plus maze (for 
measuring anxiety) and three chamber tests of social interaction 
 Brain fMRI using a fear-conditioning paradigm developed in Edinburgh 
(Brydges et al. 2013).  Further investigation of fear would be interesting 
given the reduced anxiety seen in various SynGAP mouse behavioural 
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experiments (Guo et al. 2009; Muhia et al. 2010; Clement et al. 2012; Ozkan 
et al. 2014; Berryer et al. 2016) 
6.3 The ultimate goal 
As a clinician, my patients are my primary focus and so my hope would be that 
robust phenotypes or biomarkers are identified in SynGAP rat models so that 
therapeutic options can be explored.  To me the next logical step would be to 
administer drugs to the rats that act on the biochemical pathways that SynGAP 
regulates with a view to ameliorating those phenotypes.  Some of these drugs are 
already licensed for human use including lovastatin which has been shown to reduce 
exaggerated protein synthesis via the ERK1/2 pathway in Syngap
+/-
 mice (Barnes et 
al. 2015).  This makes it more straightforward to progress to trialling them in people 
with SYNGAP1 ID if positive effects are seen pre-clinically.  As with rat research, 
clinical trials could perhaps involve EEG or fMRI as they translate easily to humans 
and can monitor identified biomarkers and so measure the temporal profile of drug 
treatment response.  My ultimate hope is that the drugs tested would fully ameliorate 
the symptoms and difficulties experienced by patients with SYNGAP ID or at least 








Appendix 1  
 
Presented here are the full images from which exerts have been used in the 
construction of figures in the main body of this thesis. 
Genotyping Gels 
Genotyping gel electrophoresis for 13 SynGAP Rat Pups - exert used in Figure 11. 
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P20 hippocampal western blots 
SynGAP A isoform antibody - exert used in Figure 16. 

















Pan SynGAP isoform antibody blot, used for measurement of beta actin bands only.  Exert used 
in Figure 16. 
 
 





































P20 visual cortex western blots 
SynGAP A isoform antibody.  Exert used in Figure 17. 
 
 
















SynGAP alpha1 isoform antibody.  Exert used in Figure 17. 
 
 
















Developmental western blots 
WT developmental western blot.  Not presented in main thesis. 
 


















Initial One Step RT-PCR gel to confirm the primer pairs were amplifying one product.  Image 
cropped for use in Figure 47: 
 
The following gels are from One Step RT-PCR to determine if the primer pairs were 
behaving in a similar manner to one another under varying experimental conditions – 
gels all used in Figure 54.  





25 Cycles, Isoforms A, A1 (to be disregarded) B, C and E: 
35 Cycles, Isoforms A, A1 (to be disregarded) B, C and E: 






Abrahamsson, T., Gustafsson, B. & Hanse, E., 2008. AMPA silencing is a prerequisite for 
developmental long-term potentiation in the hippocampal CA1 region. Journal of 
neurophysiology, 100(5), pp.2605–14. 
Ahlemeyer, B. et al., 2003. Cytosine arabinofuranoside-induced activation of astrocytes 
increases the susceptibility of neurons to glutamate due to the release of soluble factors. 
Neurochemistry International, 42(7), pp.567–581. 
Aldridge, G.M. et al., 2008. The use of total protein stains as loading controls: an alternative 
to high-abundance single protein controls in semi-quantitative immunoblotting. Journal 
of Neuroscience Methods, 172(2), pp.250–254. 
APA, 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM–5) 5th ed., 
American Psychiatric Association. 
Araki, Y. et al., 2016. Phase Transition in Postsynaptic Densities Underlies Formation of 
Synaptic Complexes and Synaptic Article Phase Transition in Postsynaptic Densities 
Underlies Formation of Synaptic Complexes and Synaptic Plasticity. Cell, 166(5), 
p.1163–1175.e12. 
Araki, Y. et al., 2015. Rapid Dispersion of SynGAP from Synaptic Spines Triggers AMPA 
Receptor Insertion and Spine Enlargement during LTP. Neuron, 85(1), pp.173–189. 
Asperger, H. & Frith, U., 1991. Translation and Annotation of “Autistic psychopathy” in 
childhood. In Autism and Asperger syndrome. Cambridge University Press, pp. 37–92. 
Auerbach, B.D., Osterweil, E.K. & Bear, M.F., 2012. Mutations causing syndromic autism 
define an axis of synaptic pathophysiology. , 480(7375), pp.63–68. 
Banker, G.A. & Cowan, W.M., 1977. Rat Hippocampal Neurons in Dipsersed Cell Culture. 
Brain research, 126, pp.397–425. 
Baraban, S.C. & Schwartzkroin, P.A., 1995. Electrophysiology of CA1 pyramidal neurons in 
an animal model of neuronal migration disorders: prenatal methylazoxymethanol 
treatment. Epilepsy Research, 22(2), pp.145–156. 





 Mice. Journal of Neuroscience, 35(45), pp.15073–15081. 
Barnett, M.W. et al., 2006. Synaptic Ras GTPase activating protein regulates pattern 
formation in the trigeminal system of mice. The Journal of neuroscience, 26(5), 
pp.1355–65. 
Bear, M.F., Huber, K.M. & Warren, S.T., 2004. The mGluR theory of fragile X mental 
retardation. Trends in neurosciences, 27(7), pp.370–7. 
262 
 
Bekkers, J.M., Richerson, G.B. & Stevens, C.F., 1990. Origin of variability in quantal size in 
cultured hippocampal neurons and hippocampal slices. Proceedings of the National 
Academy of Sciences of the United States of America, 87(14), pp.5359–5362. 
Benarroch, E.E., 2013. HCN channels Function and clinical implications. Neurology, 80, 
pp.304–310. 
Bernards, A., 2003. GAPs galore! A survey of putative Ras superfamily GTPase activating 
proteins in man and Drosophila. Biochimica et Biophysica Acta (BBA) - Reviews on 
Cancer, 1603(2), pp.47–82. 
Berryer, M.H. et al., 2016. Decrease of SYNGAP1 in GABAergic cells impairs inhibitory 
synapse connectivity, synaptic inhibition and cognitive function. Nature 
communications, 7, p.13340. 
Berryer, M.H. et al., 2013. Mutations in SYNGAP1 cause intellectual disability, autism, and 
a specific form of epilepsy by inducing haploinsufficiency. Human mutation, 34(2), 
pp.385–94. 
Betancur, C., 2011. Etiological heterogeneity in autism spectrum disorders: more than 100 
genetic and genomic disorders and still counting. Brain research, 1380, pp.42–77. 
BIO-RAD Laboratories, 2006. Real-Time PCR Applications Guide, 
BioTechniques, 2011. BioTechniques Molecular Biology Technique Troubleshooting 
Forum. BioTechniques, 51(6), pp.401–402. 
Bowden, J.B., Abraham, W.C. & Harris, K.M., 2012. Differential effects of strain, circadian 
cycle, and stimulation pattern on LTP and concurrent LTD in the dentate gyrus of 
freely moving rats. Hippocampus, 22(6), pp.1363–1370. 
Braun, K. & Segal, M., 2000. FMRP involvement in formation of synapses among cultured 
hippocampal neurons. Cerebral cortex (New York, N.Y. : 1991), 10(10), pp.1045–52. 
Brewer, G.J. et al., 1993. Optimized Survival of Hippocampal-Neurons in B27-
Supplemented Neurobasal
(Tm)
, a New Serum-Free Medium Combination. Journal of 
Neuroscience Research, 35(5), pp.567–576. 
Brogna, S. & Wen, J., 2009. Nonsense-mediated mRNA decay (NMD) mechanisms. Nature 
Structural & Molecular Biology, 16(2), pp.107–113. 
Brugha, T.S. et al., 2016. Epidemiology of autism in adults across age groups and ability 
levels. The British journal of psychiatry : the journal of mental science, 209, pp.498–
503. 
Brydges, N.M. et al., 2013. Imaging Conditioned Fear Circuitry Using Awake Rodent fMRI. 
PloS one, 8(1), pp.4–10. 
Carlisle, H.J. et al., 2008. SynGAP regulates steady-state and activity-dependent 
263 
 
phosphorylation of cofilin. Journal of Neuroscience, 28(50), pp.13673–13683. 
Carroll, R.C. et al., 1999. Rapid redistribution of glutamate receptors contributes to long-
term depression in hippocampal cultures. Nature neuroscience, 2(5), pp.454–60. 
Carvill, G.L. et al., 2013. Targeted resequencing in epileptic encephalopathies identifies de 
novo mutations in CHD2 and SYNGAP1. Nature genetics, 45(7), pp.825–30. 
Chen, H.J. et al., 1998. A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited 
by CaM kinase II. Neuron, 20(5), pp.895–904. 
Chu, H.-Y. et al., 2010. Electrophysiological effects of SKF83959 on hippocampal CA1 
pyramidal neurons: potential mechanisms for the drug’s neuroprotective effects. PloS 
one, 5(10), pp.1–9. 
Clement, J.P. et al., 2012. Pathogenic SYNGAP1 mutations impair cognitive development 
by disrupting maturation of dendritic spine synapses. Cell, 151(4), pp.709–23. 
Clement, J.P. et al., 2013. SYNGAP1 links the maturation rate of excitatory synapses to the 
duration of critical-period synaptic plasticity. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 33(25), pp.10447–52. 
Cooper, S.-A., 1999. The relationship between psychiatric and physical health in elderly 
people with intellectual disability. Journal of Intellectual Disability Research, 43(1), 
p.54. 
Cooper, S.-A. & Smiley, E., 2009. Prevalence of intellectual disabilities and epidemiology of 
mental ill-health in adults with intellectual disabilities. In Oxford textbook of 
psychiatry, volume 1. pp. 825–829. 
Cormier, R.J. & Kelly, P.T., 1996. Glutamate-induced long-term potentiation enhances 
spontaneous EPSC amplitude but not frequency. Journal of neurophysiology, 75(5), 
pp.1909–18. 
Costa-Mattioli, M. & Monteggia, L.M., 2013. mTOR complexes in neurodevelopmental and 
neuropsychiatric disorders. Nature neuroscience, 16(11), pp.1537–43. 
Cotman, C.W. & Nieto Sampedro, M., 1984. Cell biology of synaptic plasticity. Science, 
225(1977), pp.1287–1294. 
Crair, M.C. & Malenka, R.C., 1995. a Critical Period for Long-Term Potentiation At 
Thalamocortical Synapse. Nature, 375, pp.325–328. 
Deacon, R.M.J. & Rawlins, J.N.P., 2006. T-maze alternation in the rodent. Nature Protocols, 
1(1), pp.7–12. 
Derkach, V.A. et al., 2007. Regulatory mechanisms of AMPA receptors in synaptic 
plasticity. Nature Reviews Neuroscience, 8, pp.101–113. 
Dieckmann, F., Giovis, C. & Offergeld, J., 2015. The Life Expectancy of People with 
264 
 
Intellectual Disabilities in Germany. Journal of Applied Research in Intellectual 
Disabilities, (28), pp.373–382. 
Dierssen, M. & Ramakers, G.J.A., 2006. Dendritic pathology in mental retardation: from 
molecular genetics to neurobiology. Genes, brain, and behavior, 5 Suppl 2(April 
2005), pp.48–60. 
Dittmer, A. & Dittmer, J., 2006. β-Actin is not a reliable loading control in Western blot 
analysis. Electrophoresis, 27(14), pp.2844–2845. 
Edwards, F.A., Konnerth, A. & Sakmann, B., 1990. Quantal analysis of inhibitory synaptic 
transmission in the dentate gyrus of rat hippocampal slices: A patch-clamp study. 
Journal of Physiology, 430, pp.213–249. 
Ehlers, M.D., 2000. Reinsertion or Degradation of AMPA Receptors Determined by 
Activity-Dependent Endocytic Sorting. Neuron, 28(2), pp.511–525. 
Ellenbroek, B. & Youn, J., 2016. Rodent models in neuroscience research: is it a rat race? 
Disease Models & Mechanisms, 9(10), pp.1079–1087. 
Emerson, E. & Baines, S., 2010. Health Inequalities & People with Learning Disabilities in 
the UK : 2010. 
Fitzgerald, T.W. et al., 2015. Large-scale discovery of novel genetic causes of 
developmental disorders. Nature, 519(7542), pp.223–228. 
Garreau De Loubresse, N. et al., 2014. Structural basis for the inhibition of the eukaryotic 
ribosome. Nature, 513, pp.517–523. 
Graves, A., 2013. Hippocampal pyramidal neurons comprison two distinct types that are 
countermodulated by metabotropic receptors. Neuron, 76(4), pp.776–789. 
Gray, L.E. et al., 1997. In Utero Exposure to Low Doses of 2,3,7,8-Tetrachlorodibenzo-p-
dioxin Alters Reproductive Development of Female Long Evans Hooded Rat 
Offspring. Toxicology and applied pharmacology, 146(2), pp.237–44. 
Gu, N., Vervaeke, K. & Storm, J.F., 2007. BK potassium channels facilitate high-frequency 
firing and cause early spike frequency adaptation in rat CA1 hippocampal pyramidal 
cells. The Journal of physiology, 580(Pt.3), pp.859–82. 
Guo, X. et al., 2009. Reduced expression of the NMDA receptor-interacting protein SynGAP 
causes behavioral abnormalities that model symptoms of Schizophrenia. 
Neuropsychopharmacology, 34(7), pp.1659–72. 
Hamdan, F.F. et al., 2011. De novo SYNGAP1 mutations in nonsyndromic intellectual 
disability and autism. Biological psychiatry, 69(9), pp.898–901. 
Hamdan, F.F. et al., 2009. Mutations in SYNGAP1 in Autosomal Nonsyndromic Mental 
Retardation. The New England journal of medicine, 360, pp.599–605. 
265 
 
Hanse, E., Seth, H. & Riebe, I., 2013. AMPA-silent synapses in brain development and 
pathology. Nature Reviews Neuroscience, 14(12), pp.839–850. 
He, C. et al., 2014. Neurophysiology of HCN channels : From cellular functions to multiple 
regulations. Progress in Neurobiology, 112, pp.1–23. 
Heffron, D.S. & Mandell, J.W., 2005. Opposing roles of ERK and p38 MAP kinases in 
FGF2-induced astroglial process extension. Molecular and Cellular Neuroscience, 
28(4), pp.779–790. 
Herring, B.E. & Nicoll, R.A., 2016. Long-Term Potentiation: From CaMKII to AMPA 
receptor trafficking. Annual review of physiology, 78(1), pp.351–65. 
Hershkowitz, N., Katchman, A.N. & Veregge, S., 1993. Site of synaptic depression during 
hypoxia: a patch-clamp analysis. Journal of neurophysiology, 69(2), pp.432–41. 
Hovey, R.C. et al., 2011. Quantitative assessment of mammary gland development in female 
long evans rats following in utero exposure to atrazine. Toxicological Sciences, 119(2), 
pp.380–390. 
Huber, K.M. et al., 2002. Altered synaptic plasticity in a mouse model of fragile X mental 
retardation. Proceedings of the National Academy of Sciences of the United States of 
America, 99(11), pp.7746–7750. 
Huber, K.M. et al., 2001. Chemical Induction of mGluR5- and Protein Synthesis − 
Dependent Long-Term Depression in Hippocampal Area CA1 Chemical Induction of 
mGluR5- and Protein Synthesis – Dependent Long-Term Depression in Hippocampal 
Area CA1. Journal of neurophysiology, 86, pp.321–325. 
Huber, K.M., Kayser, M.S. & Bear, M.F., 2000. Role for rapid dendritic protein synthesis in 
hippocampal mGluR-dependent long-term depression. Science, 288(5469), pp.1254–
1257. 
Iannaccone, P.M. & Jacob, H.J., 2009. Rats! Disease Models & Mechanisms, 2(5–6), 
pp.206–210. 
Iossifov, I. et al., 2012. De Novo Gene Disruptions in Children on the Autistic Spectrum. 
Neuron, 74(2), pp.285–299. 
Jeyabalan, N. & Clement, J.P., 2016. SYNGAP1 : Mind the Gap. Frontiers in Cellular 
Neuroscience, 10, pp.1–16. 
Jonckers, E. et al., 2015. The power of using functional fMRI on small rodents to study brain 
pharmacology and disease. Frontiers in Pharmacology, 6, pp.1–19. 
Kacew, S. & Festing, M.F.W., 1996. Role of Rat Strain in the Differential Sensitivity to 
Pharmaceutical Agents and Naturally Occurring Substances. Journal of Toxicology and 
Environmental Health, 47, pp.1–30. 
266 
 
Kaczorowski, C.C., Disterhoft, J. & Spruston, N., 2007. Stability and plasticity of intrinsic 
membrane properties in hippocampal CA1 pyramidal neurons: effects of internal 
anions. The Journal of physiology, 578(Pt 3), pp.799–818. 
Kakeyama, M., Sone, H. & Tohyama, C., 2008. Perinatal exposure of female rats to 2,3,7,8-
tetrachlorodibenzo-p-dioxin induces central precocious puberty in the offspring. 
Journal of Endocrinology, 197(2), pp.351–358. 
Kamal, A. et al., 2014. Social isolation stress reduces hippocampal long-term potentiation: 
Effect of animal strain and involvement of glucocorticoid receptors. Neuroscience, 256, 
pp.262–270. 
Kaneko, T., Li, L. & Li, S.S., 2008. The SH3 domain- a family of versatile peptide- and 
protein-recognition module. Frontiers in Bioscience, (May 1), pp.4938–4952. 
Kanner, L., 1943. Autistic disturbances of affective contact. Nervous Child, 2, pp.217–250. 
Karlsson, A. et al., 2011. Altered spontaneous synaptic inhibition in an animal model of 
cerebral heterotopias. Brain Research, 1383, pp.54–61. 
Katchman, A.N., Vicini, S. & Hershkowitz, N., 1994. Mechanism of early anoxia-induced 
suppression of the GABAA-mediated inhibitory postsynaptic current. Journal of 
neurophysiology, 71(3), pp.1128–1138. 
Keeley, R.J., Trow, J. & McDonald, R.J., 2015. Strain and sex differences in puberty onset 
and the effects of THC administration on weight gain and brain volumes. 
Neuroscience, 305, pp.328–342. 
Kim, D. et al., 2013. TopHat2: accurate alignment of transcriptomes in the presence of 
insertions, deletions and gene fusions. Genome Biology, 14(4), p.R36. 
Kim, J.H. et al., 1998. SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 
protein family. Neuron, 20(4), pp.683–91. 
Kim, J.H. et al., 2003. The role of synaptic GTPase-activating protein in neuronal 
development and synaptic plasticity. The Journal of neuroscience, 23(4), pp.1119–24. 
Kim, M.J. et al., 2005. Differential roles of NR2A- and NR2B-containing NMDA receptors 
in Ras-ERK signaling and AMPA receptor trafficking. Neuron, 46(5), pp.745–60. 
Knuesel, I. et al., 2005. A role for synGAP in regulating neuronal apoptosis. The European 
journal of neuroscience, 21(3), pp.611–21. 
Komiyama, N.H. et al., 2002. SynGAP regulates ERK/MAPK signaling, synaptic plasticity, 
and learning in the complex with postsynaptic density 95 and NMDA receptor. The 
Journal of neuroscience, 22(22), pp.9721–32. 
Krapivinsky, G. et al., 2004. SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 
MAP kinase activity and NMDA receptor-dependent synaptic AMPA receptor 
267 
 
potentiation. Neuron, 43(4), pp.563–74. 
Krepischi, A.C. V et al., 2010. A novel de novo microdeletion spanning the SYNGAP1 gene 
on the short arm of chromosome 6 associated with mental retardation. American 
journal of medical genetics. Part A, 152A(9), pp.2376–8. 
Krumm, N. et al., 2014. A de novo convergence of autism genetics and molecular 
neuroscience. Trends in Neurosciences, 37(2), pp.95–105. 
Kummer, K.K. et al., 2014. Differences in social interaction- vs. cocaine reward in mouse vs. 
rat. Frontiers in behavioral neuroscience, 8(October), p.363. 
Lai, M.-C., Lombardo, M. V & Baron-Cohen, S., 2014. Autism. The Lancet, 383(9920), 
pp.896–910. 
Lazic, S.E., 2010. The problem of pseudoreplication in neuroscientific studies: is it affecting 
your analysis? BMC neuroscience, 11(1), p.5. 
Lemmon, M.A., 2008. Membrane recognition by phospholipid-binding domains. Nature 
reviews: Molecular cell biology, 9(2), pp.99–111. 
Li, R. & Shen, Y., 2013. An old method facing a new challenge: re-visitng housekeeping 
proteins as internal reference control for neuroscience research. Life Sciences, 92(13), 
pp.747–751. 
Li, W. et al., 2001. Characterization of a novel synGAP isoform, synGAP-beta. The Journal 
of biological chemistry, 276(24), pp.21417–24. 
Li, X.G. et al., 1994. The Hippocampal Ca3 Network - An In-Vivo Intracellular Labeling 
Study. Journal of Comparative Neurology, 339(2), pp.181–208. 
Life Technologies, 2012. Realtime PCR Handbook. 
de Ligt, J. et al., 2012. Diagnostic exome sequencing in persons with severe intellectual 
disability. The New England journal of medicine, 367(20), pp.1921–9. 
Lister, R. et al., 2013. Global epigenomic reconfiguration during mammalian brain 
development. Science, 341(6146), p.1237905. 
Lüscher, C. et al., 1999. Role of AMPA Receptor Cycling in Synaptic Transmission and 
Plasticity. Neuron, 24(3), pp.649–658. 
Luthi, A. et al., 1999. Hippocampal LTD Expression Involves a Pool of AMPARs Regulated 
by the NSF – GluR2 Interaction. Neuron, 24, pp.389–399. 
Lykke-Andersen, S. & Jensen, T.H., 2015. Nonsense-mediated mRNA decay: an intricate 
machinery that shapes transcriptomes. Nature Reviews Molecular Cell Biology, 16(11), 
pp.665–677. 
Magiati, I., Tay, X.W. & Howlin, P., 2014. Cognitive, language, social and behavioural 
outcomes in adults with autism spectrum disorders: A systematic review of longitudinal 
268 
 
follow-up studies in adulthood. Clinical Psychology Review, 34(1), pp.78–86. 
Malik, R. & Chattarji, S., 2011. Enhanced intrinsic excitability and EPSP-spike coupling 
accompany enriched environment-induced facilitation of LTP in hippocampal CA1 
pyramidal neurons. Journal of Neurophysiology, 107(5), pp.1366–1378. 
Malinow, R. & Malenka, R.C., 2002. AMPA receptor trafficking and synaptic plasticity. 
Annual review of neuroscience, 25, pp.103–26. 
Man, H. et al., 2000. Regulation of AMPA Receptor – Mediated Synaptic Transmission by 
Clathrin-Dependent Receptor Internalization. Neuron, 25, pp.649–662. 
Manahan-Vaughan, D., 2000. Long-term Depression in Freely Moving Rats is Dependent 
upon Strain Variation, Induction Protocol and Behavioral State. Cerebral Cortex, 
10(5), pp.482–487. 
Maren, S., 1995. Sexually dimorphic perforant path LTD in urethane-anaesthetized rats. 
Neuroscience letters, 196, pp.177–180. 
Maren, S., De Oca, B. & Fanselow, M.S., 1994. Sex differences in hippocampal long-term 
potentiation (LTP) and Pavlovian fear conditioning in rats: positive correlation between 
LTP and contextual learning. Brain Research, 661, pp.25–34. 
Martin, D.P., Wallace, L. & Johnson, M., 1990. Cytosine Arabinoside Kills Postmitotic 
Neurons in a Fashion Resembling Trophic Factor Deprivation: Evidence That a 
Deoxycytidine-Dependent Process May be Required for Nerve Growth Signal 
Transduction. Journal of Neuroscience, 10(1), pp.184–193. 
Matsuzaki, M. et al., 2004. Structure basis of long-term potentiation in single dendritic 
spines. Nature, 429(6993), pp.761–766. 
Maulik, P.K. et al., 2011. Research in Developmental Disabilities Review article Prevalence 
of intellectual disability : A meta-analysis of population-based studies. Research in 
Developmental Disabilities, 32, pp.419–436. 
McBain, C. & Dingledine, R., 1992. Dual-component miniature excitatory synaptic currents 
in rat hippocampal CA3 pyramidal neurons. Journal of neurophysiology, 68(1), pp.16–
27. 
McCormack, S.G., Stornetta, R.L. & Zhu, J.J., 2006. Synaptic AMPA Receptor Exchange 
Maintains Bidirectional Plasticity. Neuron, 50(1), pp.75–88. 
McMahon, A., 2010. An examination of multiple SynGAP isoforms in mammalian central 
neurons. University of Edinburgh. 
McMahon, A.C. et al., 2012. SynGAP isoforms exert opposing effects on synaptic strength. 
Nature communications, 3, p.900. 
Mefford, H.C., Batshaw, M.L. & Hoffman, E.P., 2012. Genomics, Intellectual Disability, 
269 
 
and Autism. New England Journal of Medicine, pp.733–743. 
Mignot, C. et al., 2016. Genetic and neurodevelopmental spectrum of SYNGAP1 -associated 
intellectual disability and epilepsy. Journal of medical genetics, 0, pp.1–12. 
Montesinos, M., 2014. Pharmacological Intervention for Down Syndrome Cognitive 
Deficits : Emerging Drug Targets. CNS & Neurological Disorders, 13(1), pp.6–7. 
Moon, I.S. et al., 2008. Differential distribution of synGAP alpha1 and synGAP beta 
isoforms in rat neurons. Brain research, 1241, pp.62–75. 
Morrison, D.K., 2012. MAP kinase pathways. Cold Spring Harbor Laboratory Press, 4, 
pp.1–5. 
Muhia, M. et al., 2009. Appetitively motivated instrumental learning in SynGAP 
heterozygous knockout mice. Behavioral neuroscience, 123(5), pp.1114–28. 
Muhia, M. et al., 2010. Disruption of hippocampus-regulated behavioural and cognitive 
processes by heterozygous constitutive deletion of SynGAP. The European journal of 
neuroscience, 31(3), pp.529–43. 
Muhia, M. et al., 2012. Molecular and behavioral changes associated with adult 
hippocampus-specific SynGAP1 knockout. Learning & memory (Cold Spring Harbor, 
N.Y.), 19(7), pp.268–81. 
Munir, K.M., 2016. The co-occurrence of mental disorders in children and adolescents with 
intellectual disability/intellectual developmental disorder. Current Opinion in 
Psychiatry, 29(2), pp.95–102. 
Murphy, C. et al., 2016. Autism spectrum disorder in adults: diagnosis, management, and 
health services development. Neuropsychiatric Disease and Treatment, Volume 12, 
pp.1669–1686. 
Nalefski, E.A. & Falke, J.J., 1996. The C2 domain calcium-binding motif: structural and 
functional diversity. Protein Science, 5(12), pp.2375–2390. 
Nguyen, P. V, Duffy, S.N. & Young, J.Z., 2000. Differential maintenance and frequency-
dependent tuning of LTP at hippocampal synapses of specific strains of inbred mice. 
Journal of neurophysiology, 84(5), pp.2484–2493. 
Nosyreva, E.D. et al., 2006. Metabotropic Receptor-Dependent Long-Term Depression 
Persists in the Absence of Protein Synthesis in the Mouse Model of Fragile X 
Syndrome. , 95, pp.3291–3295. 
Oberlander, J.G. & Woolley, C.S., 2016. 17β-Estradiol Acutely Potentiates Glutamatergic 
Synaptic Transmission in the Hippocampus through Distinct Mechanisms in Males and 
Females. The Journal of neuroscience, 36(9), pp.2677–90. 
Oh, C. et al., 2000. Opposing Role of Mitogen-activated in the Regulation of 
270 
 
Chondrogenesis of Mesenchymes Opposing Role of Mitogen-activated Protein Kinase 
Subtypes , Erk-1 / 2 and p38 , in the Regulation of Chondrogenesis of Mesenchymes *. 
The Journal of biological chemistry, 275(8), pp.5613–5619. 
Oh, J.S., Manzerra, P. & Kennedy, M.B., 2004. Regulation of the neuron-specific Ras 
GTPase-activating protein, synGAP, by Ca2+/calmodulin-dependent protein kinase II. 
The Journal of biological chemistry, 279(17), pp.17980–8. 
Ojeda, S.R. & Skinner, M.K., 2006. Puberty in the rat. In Knobil and Neill’s Physiology of 
Reproduction. Elsevier, pp. 2061–2126. 
Opazo, P., Sainlos, M. & Choquet, D., 2012. Regulation of AMPA receptor surface diffusion 
by PSD-95 slots. Current Opinion in Neurobiology, 22(3), pp.453–460. 
Ozkan, E.D. et al., 2014. Reduced cognition in Syngap1 mutants is caused by isolated 
damage within developing forebrain excitatory neurons. Neuron, 82(6), pp.1317–1333. 
Palmer, M.J. et al., 1997. The group I mGlu receptor agonist DHPG induces a novel form of 
LTD in the CA1 region of the hippocampus. Neuropharmacology, 36(11–12), 
pp.1517–1532. 
Parfitt, K.D. & Madison, D. V, 1993. Phorbol esters enhance synaptic transmission by a 
presynaptic, calcium-dependent mechanism in rat hippocampus. Journal of Physiology, 
471, pp.245–268. 
Parker, M.J. et al., 2015. De novo, heterozygous, loss-of-function mutations in SYNGAP1 
cause a syndromic form of intellectual disability. American Journal of Medical 
Genetics, Part A, 167(10), pp.2231–2237. 
Patja, K., Mölsä, P. & Iivanainen, M., 2001. Cause-specific mortality of people with 
intellectual disability in a population-based, 35-year follow-up study. Journal of 
Intellectual Disability Research, 45, pp.30–40. 
Pena, V. et al., 2008. The C2 domain of SynGAP is essential for stimulation of the Rap 
GTPase reaction. EMBO reports, 9(4), pp.350–5. 
Penzes, P. et al., 2011. Dendritic spine pathology in neuropsychiatric disorders. Nature 
neuroscience, 14(3), pp.285–93. 
Penzes, P. et al., 2013. Developmental vulnerability of synapses and circuits associated with 
neuropsychiatric disorders. Journal of Neurochemistry, 126(2), pp.165–182. 
Pinto, D. et al., 2014. Convergence of Genes and Cellular Pathways Dysregulated in Autism 
Spectrum Disorders. The American Journal of Human Genetics, 94, pp.677–694. 
Pinto, D. et al., 2010. Functional Impact of Global Rare Copy Number Variation in Autism 
Spectrum Disorder. Nature, 466(7304), pp.368–372. 
Pitler, T. a. & Alger, B.E., 1992. Postsynaptic spike firing reduces synaptic GABAA 
271 
 
responses in hippocampal pyramidal cells. The Journal of neuroscience, 12, pp.4122–
4132. 
Pláteník, J., Kuramoto, N. & Yoneda, Y., 2000. Molecular mechanisms associated with long-
term consolidation of the NMDA signals. Life Sciences, 67(4), pp.335–364. 
Porter, K. et al., 2005. Differential expression of two NMDA receptor interacting proteins, 
PSD-95 and SynGAP during mouse development. The European journal of 
neuroscience, 21(2), pp.351–62. 
Prchalova, D. et al., 2017. Analysis of 31-year-old patient with SYNGAP1 gene defect 
points to importance of variants in broader splice regions and reveals developmental 
trajectory of SYNGAP1-associated phenotype: case report. BMC Medical Genetics, 
18(1), p.62. 
Qiagen, 2012. Qiagen OneStep RT-PCR Handbook. , (October). 
Qiagen, 2011. QuantiTect® SYBR® Green PCR Handbook. , (July). 
Qiu, J. et al., 2016. Evidence for evolutionary divergence of activity-dependent gene 
expression in developing neurons. eLife, 5, pp.1–15. 
Rauch, A. et al., 2012. Range of genetic mutations associated with severe non-syndromic 
sporadic intellectual disability: an exome sequencing study. Lancet, 380(9854), 
pp.1674–82. 
Redin, C. et al., 2014. Efficient strategy for the molecular diagnosis of intellectual disability 
using targeted high-throughput sequencing. Journal of medical genetics, 51(11), 
pp.724–36. 
Roche Applied Science, 2010. Transcriptor First Strand cDNA Synthesis Kit, version 6. 
Rodnina, M. V. & Wintermeyer, W., 2016. Protein Elongation, Co-translational Folding and 
Targeting. Journal of Molecular Biology, 428(10), pp.2165–2185. 
Ropers, H.-H. & Hamel, B.C.J., 2005. X-linked mental retardation. Nature Reviews 
Genetics, 6(1), pp.46–57. 
Routh, B. & Johnston, D., 2009. Anatomical and electrophysiological comparison of CA1 
pyramidal neurons of the rat and mouse. J Neurophysiol, (102), pp.2288–2302. 
De Rubeis, S. et al., 2014. Synaptic, transcriptional and chromatin genes disrupted in autism. 
Nature, 515(7526), pp.209–215. 
Rubenstein, J.L.R. & Merzenich, M.M., 2003. Model of autism : increased ratio of excitation 
/ inhibition in key neural systems. Genes, brain, and behavior, 2, pp.255–267. 
Rumbaugh, G. et al., 2006. SynGAP regulates synaptic strength and mitogen-activated 
protein kinases in cultured neurons. Proceedings of the National Academy of Sciences 
of the United States of America, 103(12), pp.4344–51. 
272 
 
Sahin, M., 2012. Targeted treatment trials for tuberous sclerosis and autism: No longer a 
dream. Current Opinion in Neurobiology, 22(5), pp.895–901. 
Saksela, K. & Permi, P., 2012. SH3 domain ligand binding: What’s the consensus and 
where’s the specificity? FEBS Letters, 586(17), pp.2609–2614. 
Scheffzek, K. & Ahmadian, M.R., 2005. GTPase activating proteins: Structural and 
functional insights 18 years after discovery. Cellular and Molecular Life Sciences, 
62(24), pp.3014–3038. 
Senter, R.K. et al., 2016. The Role of mGlu Receptors in Hippocampal Plasticity Deficits in 
Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as 
Novel Therapeutic Strategies. Current neuropharmacology, 14(5), pp.455–73. 
Siddiqui, T.J. et al., 2010. LRRTMs and Neuroligins Bind Neurexins with a Differential 
Code to Cooperate in Glutamate Synapse Development. Journal of Neuroscience, 
30(22), pp.7495–7506. 
Sigma Advanced Genetic Engineering (SAGE) Laboratories, 2012. Project Plan for 
Generation of SynGAP1 Knockout Rat Model. , pp.1–8. 
Sikkel, M.B., MacLeod, K.T. & Gordon, F., 2013. Letter regarding article, “Late sodium 
current inhibition reverses electromechanical dysfunction in human hypertrophic 
cardiomyopathy.” Circulation, 128(10). 
De Simoni, A., Griesinger, C.B. & Edwards, F.A., 2003. Development of rat CA1 neurones 
in acute versus organotypic slices: role of experience in synaptic morphology and 
activity. The Journal of physiology, 550(Pt 1), pp.135–47. 
Snyder, E.M. et al., 2001. Internalization of ionotropic glutamate receptors in response to 
mGluR activation. Nat Neurosci, 4(11), pp.1079–1085. 
Sot, B. et al., 2010. Unravelling the mechanism of dual-specificity GAPs. The EMBO 
journal, 29(7), pp.1205–14. 
Staff, N.P. et al., 2000. Resting and active properties of pyramidal neurons in subiculum and 
CA1 of rat hippocampus. Journal of neurophysiology, 84(5), pp.2398–2408. 
Stanko, J.P. et al., 2016. Differences in the Rate of in Situ Mammary Gland Development 
and Other Developmental Endpoints in Three Strains of Female Rat Commonly Used 
in Mammary Carcinogenesis Studies: Implications for Timing of Carcinogen Exposure. 
Toxicologic Pathology, 44(7), pp.1021–1033. 
Stornetta, R.L. & Zhu, J.J., 2011. Ras and Rap Signaling in Synaptic Plasticity and Mental 
Disorders. Neuroscientist, 17(1), pp.54–78. 
Stülpnagel, C. Von et al., 2015. SYNGAP1 Mutation in Focal and Generalized Epilepsy : A 
Literature Overview and A Case Report with Special Aspects of the EEG. 
273 
 
Neuropediatrics, 46, pp.287–291. 
Sutton, M. a et al., 2006. Miniature neurotransmission stabilizes synaptic function via tonic 
suppression of local dendritic protein synthesis. Cell, 125(4), pp.785–99. 
Takeuchi, T., Duszkiewicz, A.J. & Morris, R.G.M., 2014. The synaptic plasticity and 
memory hypothesis: encoding, storage and persistence. Philosophical transactions of 
the Royal Society of London. Series B, Biological sciences, 369(1633), p.20130288. 
Thibault, O., Hadley, R. & Landfield, P.W., 2001. Elevated Postsynaptic [Ca2+]i and L-Type 
Calcium Channel Activity in Aged Hippocampal Neurons: Relationship to Impaired 
Synaptic Plasticity. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 21(24), pp.9744–9756. 
Thomas, G.M. & Huganir, R.L., 2004. MAPK cascade signalling and synaptic plasticity. 
Nature Reviews Neuroscience, 5(3), pp.173–183. 
Tian, Y. et al., 2012. Urethane suppresses hippocampal CA1 neuron excitability via changes 
in presynaptic glutamate release and in potassium channel activity. Brain Research 
Bulletin, 87(4–5), pp.420–426. 
Tidyman, W.E. & Rauen, K.A., 2016. Pathogenetics of the RASopathies. Human Molecular 
Genetics, (916), pp.1–46. 
Till, S.M. et al., 2015. Conserved hippocampal cellular pathophysiology but distinct 
behavioural deficits in a new rat model of FXS. Human Molecular Genetics, 24(21), 
pp.5977–5984. 
Tomita, S. et al., 2005. Bidirectional synaptic plasticity regulated by phosphorylation of 
stargazin-like TARPs. Neuron, 45(2), pp.269–277. 
Tomoda, T. et al., 2004. Role of Unc51.1 and its binding partners in CNS axon outgrowth. 
Genes & development, 18(5), pp.541–58. 
Turrigiano, G.G. et al., 1998. Activity-dependent scaling of quantal amplitude in neocortical 
neurons. Nature, 391(6670), pp.892–896. 
Tyrer, F., Smith, L.K. & Mcgrother, C.W., 2006. Mortality in adults with moderate to 
profound intellectual disability : a population-based study. Journal of Intellectual 
Disability Research, 51, pp.520–527. 
Vazquez, L.E. et al., 2004. SynGAP regulates spine formation. The Journal of neuroscience, 
24(40), pp.8862–72. 
Vetter, I.R. & Wittinghofer, A., 2001. The guanine nucleotide-binding switch in three 
dimensions. Science, 294(5545), pp.1299–1304. 
Vissers, L.E.L.M., Gilissen, C. & Veltman, J.A., 2015. Genetic studies in intellectual 
disability and related disorders. Nature Reviews Genetics, 17(1), pp.9–18. 
274 
 
bare, W.G. et al., 2016. A model for regulation by syngap-α1 of binding of synaptic proteins 
to PDZ-domain “slots” in the postsynaptic density. eLife, 5, pp.1–31. 
Walkup, W.G. et al., 2015. Phosphorylation of synaptic GTPase-activating protein (synGAP) 
by Ca
2+
 /Calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent 
kinase 5 (CDK5) alters the ratio of its GAP activity toward ras and rap GTPases. 
Journal of Biological Chemistry, 290(8), pp.4908–4927. 
Wang, C.-C., Held, R.G. & Hall, B.J., 2013. SynGAP regulates protein synthesis and 
homeostatic synaptic plasticity in developing cortical networks. PloS one, 8(12), pp.1–
15. 
Wang, J., 2013. Age-Dependent Structural Connectivity Effects in Fragile X Premutation. 
Watabe, A.M., Zaki, P.A. & O’Dell, T.J., 2000. Coactivation of β-Adrenergic and 
Cholinergic Receptors Enhances the Induction of Long-Term Potentiation and 
Synergistically Activates Mitogen-Activated Protein Kinase in the Hippocampal CA1 
Region. The Journal of Neuroscience, 20(16), pp.5924–5931. 
Westermarck, J. et al., 2001. p38 Mitogen-Activated Protein Kinase-Dependent Activation 
of Protein Phosphatases 1 and 2A Inhibits MEK1 and Gene Expression p38 Mitogen-
Activated Protein Kinase-Dependent Activation of Protein Phosphatases 1 and 2A 
Inhibits MEK1 and MEK2 Activity and Col. Molecular and cellular biology, 21(7), 
pp.2373–2383. 
Whishaw, I.Q., 1995. A comparison of rats and mice in a swimming pool place task and 
matching to place task: Some surprising differences. Physiology and Behavior, 58(4), 
pp.687–693. 
WHO, 2007. Atlas Global Resource for Persons with Intellectual Disabilities. 
WHO, 1992. International Statistical Classification of Diseases and Related Health Problems 
10th Revision. World Health Organisation. Available at: 
http://apps.who.int/classifications/icd10/browse/2016/en#/F70 [Accessed December 22, 
2016]. 
Wijetunge, L.S. et al., 2013. Fragile X syndrome: From targets to treatments. 
Neuropharmacology, 68, pp.83–96. 
Winder, D.G. et al., 1999. ERK plays a regulatory role in induction of LTP by theta 
frequency stimulation and its modulation by β-adrenergic receptors. Neuron, 24(3), 
pp.715–726. 
Writzl, K. & Knegt, A.C., 2013. 6p21.3 microdeletion involving the SYNGAP1 gene in a 
patient with intellectual disability, seizures, and severe speech impairment. American 
journal of medical genetics. Part A, 161A(7), pp.1682–5. 
275 
 
Wyllie, D.J.A., Manabe, T. & Nicoll, R.A., 1994. A Rise in Postsynaptic Ca2+ Potentiates 
Miniature Excitatory Postsynaptic Currents and AMPA Responses in Hippocampal 
Neurons. Neuron, 12, pp.127–138. 
Xiao, M.Y., Zhou, Q. & Nicoll, R.A., 2001. Metabotropic glutamate receptor activation 
causes a rapid redistribution of AMPA receptors. Neuropharmacology, 41(6), pp.664–
671. 
Yang, D.W. et al., 2004. Sexual dimorphism in the induction of LTP: Critical role of 
tetanizing stimulation. Life Sciences, 75(1), pp.119–127. 
Zhang, J. et al., 2005. Amplitude/frequency of spontaneous mEPSC correlates to the degree 
of long-term depression in the CA1 region of the hippocampal slice. Brain research, 
1050(1–2), pp.110–7. 
Zhu, J.J. et al., 2002. Ras and Rap control AMPA receptor trafficking during synaptic 
plasticity. Cell, 110(4), pp.443–455. 
Zhu, Y. et al., 2005. Rap2-JNK removes synaptic AMPA receptors during depotentiation. 
Neuron, 46(6), pp.905–916. 
Zoghbi, H.Y. & Bear, M.F., 2012. Synaptic dysfunction in neurodevelopmental disorders 
associated with autism and intellectual disabilities. Cold Spring Harbor perspectives in 
biology, 4(3). 
Zollino, M. et al., 2011. Integrated analysis of clinical signs and literature data for the 
diagnosis and therapy of a previously undescribed 6p21.3 deletion syndrome. European 
journal of human genetics, 19(2), pp.239–42. 
Zucker, R.S., 1973. Changes in the Statistics of Transmitter Release During Facilitation. 
Journal of Physiology, 229, pp.787–810. 
 
 
 
 
 
 
 
 
 
